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1.1. GENERAL INTRODUCTION 
 The search for methods focused on obtaining enantiomerically enriched compounds has been 
one of the biggest challenges is organic chemistry in the last decades. The significance of chirality can 
be seen in numerous natural compounds1, 2 and in molecular receptors in biological systems.3 The 
importance of chirality lies in the fact that enantiomers show different physiological and 
pharmacological properties.4 The world became aware of the implications this fact had after the 
famous Thalidomide case.5 Thalidomide (Figure 1.1) came on the market in 1957 in West Germany 
(and got approved in 46 countries) as a sedative and sleeping drug for pregnant women in a racemic 
mixture of (R)- and (S)-thalidomide. Tragically, after a few years, it became clear that the drug, besides 
being efficient for the indications described above, resulted also in malformations in fetuses. While 
the (R)-enantiomer was effective for sleeping problems, the (S)-enantiomer was teratogenic (a 
substance affecting the development of the fetus and causing structural or functional disability). This 
case showed the necessity of the development of procedures for the synthesis of enantiopure 
compounds. 
 
Figure 1.1. The two enantiomers of thalidomide. 
 Traditionally, the focus for getting enantiopure compounds lied on the use of natural sources 
of compounds coming from the so called “chiral-pool” (nature´s “off the shelf” enantiopure 
compounds such as amino acids and carbohydrates) and also the resolution of racemic mixtures (the 
separation of two enantiomers due to its different chemical properties in a reaction with another 
chiral molecule).6 Another method that was frequently used was the one that uses “chiral auxiliaries”.7 
This methodology consists in the attachment of an achiral substrate to a chiral auxiliary which is 
followed by a stereoselective reaction and subsequent removal and recuperation of the chiral 
auxiliary. A chiral reagent, such as a chiral base, which selectively removes a proton out of two 
enantiotopic protons, can also induce enantioselectivity. However, in the modern organic synthesis, 
several new aspects have emerged as important factors, such as the efficiency of the synthesis, the 
consume of chirality or the necessity for more selectivity, which have led to the rise of asymmetric 
catalysis as a new synthetic methodology with a huge potential. The advantage of this method lies in 
obtaining the enantioenriched products with a high purity, with a low consume of chirality and with 
less residuals.  
The asymmetric catalysis can be divided in two groups: asymmetric biocatalysis and 
chemocatalysis.8, 9 Asymmetric biocatalysis is the chemical process in which enzymes or other 
biological catalysts perform asymmetric reactions in organic compounds. However, biocatalysis has 
several drawbacks: the development of biocatalysts is a slow process and does not follow a set of 
rules, the very limited range of stability (temperature, solvent, pH value, etc.) of the catalysts 
(enzymes) and finally the small amount of well characterized enzymes compared to chemical 
catalysts.10 In chemocatalysis on the other hand, chiral molecules are used for inducing chirality in the 
chemical reactions. Asymmetric chemocatalysis can be separated into two sections. The first one is 
the transition metal asymmetric catalysis, in specific with organometallic catalysts. In these catalysts, 
the d-orbital of the transition-metal (Ni, Cu, Zn, Ag, Pd, Au, etc.) can activate substrates and accelerate 
the reaction rate by coordination, ligand exchange, insertion, etc. what results in the cleavage and the 
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formation of C-C bonds (also C-H and H-H bonds). A great advantage of this kind of catalysis is the 
diversity of ligands that can be used to change the reactivity and selectivity of the transition-metal 
catalysts.11 A drawback is the possibility of residual (toxic) metals in the final products. A solution for 
this drawback is offered by the use of chiral organocatalysts. The term of organocatalysis was 
introduced in 2000 by Macmillan,12 and has shown a big development in the last decade. Chiral 
organocatalysts are, in general, small organic molecules (for example chiral amines or thioureas) that 
are able to both coordinate and activate  substrates, in order to catalyze a reaction in an asymmetric 
way, inducing chirality in the final product.13, 14 An advantage of this method is the absence of, 
possible, toxic metals in the reaction mixture and the final product. A drawback is that the 
methodology is still very young and progress has still to be made. Also, the possible toxicity of the 
organocatalysts has not been investigated enough yet. 
 The importance of the asymmetric catalysis in the formation of carbon-carbon bonds lies in 
the possibility of obtaining stereogenic centers in structurally complex compounds, and asymmetric 
catalysis has been used in several reactions such as Friedel-Crafts, Diels-Alder, alkylation and 
alkynylation reactions, Henry reactions etc.15-17 For this reason, this methodology has been used in the 
synthesis of numerous biologically and pharmacologically active compounds. In this context, chiral 
heterocyclic compounds are extremely important for chemical biology, which includes chiral cyclic 
amines. 
 Looking to the FDA database it can be noticed that nearly 60% of unique small-molecule drugs 
contain minimum one nitrogen heterocycle, which proofs the structural significance of the nitrogen 
heterocycle.18 With this idea in mind, various compounds, with biological and pharmaceutical 
applications, can be found bearing a stereocenter (tertiary and quaternary), in the azomethine carbon. 
For example this is the case in compound A,19 a HIV transcriptase, compound B (a derivative of 
Artemisinin),20 which has proven activity against malaria  and compound C,21 a progesterone receptor 
agonist (Figure 1.2). Another drug that contains a stereocenter in the azomethine carbon is 
Flucloxacillin (D), a narrow-spectrum β-lactam antibiotic of the penicillin class. 
 
Figure 1.2. Heterocyclic compounds A-D containing stereocenters in the azomethine carbon. 
  As proven above, chiral heterocyclic amines have an importance in biological and 
pharmaceutical chemistry. One way to obtain this kind of compounds is by enantioselective 
nucleophilic addition of organometallic reagents to cyclic imines. For this reason, our attention in this 
thesis was focused on the development of new catalytic asymmetric additions to cyclic imines, leading 




1.2. GENERAL OBJECTIVES 
 The nucleophile addition to C=N double bonds is one of the most used methods in the 
synthesis of nitrogenated derivatives. In this thesis we focused our attention to the nucleophilic 
enantioselective addition of organometallic reagents to cyclic imines, which is a challenge due to the 
low reactivity of the azomethine carbon. 
 Having this in mind, in this thesis we have proposed the following general objectives: 
• Enantioselective alkynylation of benzo[e][1,2,3]oxathiazine 2,2-dioxides catalyzed by 
complexes of (R)-VAPOL-Zn 
• Enantioselective alkynylation of benzo[e][1,2,3]oxathiazine 2,2-dioxides catalyzed by 
complexes of (S)-diarylprolinol-Zn 
• Enantioselective alkylation of dibenzo[b,f][1,4]oxazepines catalyzed by complexes of (R)-
VAPOL-Zn 
• Catalytic enantioselective aza-Reformatsky reactions of benzo[e][1,2,3]oxathiazine 2,2-
dioxides 
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 Propargylic amines have emerged in the last years as versatile precursors in the synthesis of 
great variety of valuable compounds such as allylamines, pyrrolidines, oxazoles and pyrroles.1 Their 
use has also been proved as building blocks in the synthesis of a wide range of fine chemicals, natural 
products, pharmaceuticals, herbicides and fungicides.2-4 
Moreover, numerous compounds bearing the aminopropargylic structure can be found in the 
field of chemical biology and pharmacy.5 For example, this particular motif is present in inhibitors of 
the enzyme monoamine oxidase B (MAO-B),6 in antagonists of a subtype of the receptor of N-methyl-
D-aspartate (NMDA) (Figure 2.1, A),7 in inhibitors of platelet aggregation,8 in inhibitors of the γ-
aminobutyric acid (GABA) degradation,9 in antibiotics,10 in inhibitors of acetyl-CoA oxidase (Figure 2.1, 
B),11 inhibitors of HIV transcriptase (Figure 2.1, C)12 and in herbicides13 among others. 
 
Figure 2.1. (A) Antagonist of the receptor of N-Methyl-D-aspartate (NMDA) (B) Inhibitor of acetyl-CoA oxidase 
(C) Inhibitor of HIV transcriptase. 
 The importance of the absolute stereochemistry on the biological activity of chiral compounds 
is well known. Due to this importance, the pharmaceutical industry and the synthetic organic chemists 
have focused their attention on developing new synthetic procedures that allow the synthesis of 
optically enriched compounds over the last years . 
 In general, four methodologies are used to obtain chiral propargylic amines. The first one 
consists in the nucleophilic substitution of propargylic alcohols with nitrogen containing nucleophiles 
(approximation a, Scheme 2.1).14 The second method is the reduction of the C=N double bond in α,β-
unsaturated ketimines (approximation b, Scheme 2.1).15 Another way to obtain chiral propargylic 
amines is the 1,2-addition of carbon nucleophiles to imines with an α,β-triple bond (approximation c, 
Scheme 2.1).16 The last methodology consists in the addition of nucleophilic alkynes to imines 
(approximation d, Scheme 2.1).17 In this chapter, we will focus in the fourth approximation to prepare 
chiral propargylic amines. 
Whilst the asymmetric addition of terminal alkynes to carbonyl groups has been subject to 
various investigations, the asymmetric addition of terminal alkynes to imines has been less studied, 
due to the less reactive character of the azomethine carbon compared to the carbonyl of ketones and 
aldehydes. However, the reactivity of the C=N double bond can be increased by the use of nitrones, 
by the generation of iminium ions or by the introduction of electron-withdrawing groups on the 
nitrogen of the imine. The use of these strategies has permitted the synthesis of propargylic amines 





Scheme 2.1. General approximations for the synthesis of propargylic amines. 
2.1.1. Stoichiometric enantioselective alkynylations of imines 
The first example of a non-catalytic enantioselective alkynylation of imines was described by 
Huffman in 1995.12 In this work, they described the formation of an amine on a tertiary carbon in an 
asymmetric manner. The stereogenic center was formed by the addition of a lithium acetylide to a 
cyclic N-acyl ketimine (Scheme 2.2). In order to obtain the product in an enantioenriched way they 
used a quinine lithium alkoxide as a chiral additive (stoichiometric). The utility of this reaction was 
proven by the synthesis of a HIV reverse transcriptase inhibitor.  
 
Scheme 2.2. Enantioselective alkynylation of a cyclic N-acyl ketimine. 
 As can be observed in the previous example, the processes developed for the synthesis of 
chiral propargylic amines require, in general, the deprotonation of the alkyne with strong bases in a 
previous step. On the other hand, the high reactivity of lithium, magnesium or aluminum acetylide 
results in a poor stereocontrol of the reaction, which on its turn influences negatively the 
enantioselectivity. A possible solution to these problems is the generation of acetylenic 
organometallic reagents in situ which allows the direct addition of the alkyne to imines under mild 
conditions compatible with other electrophilic groups. Alkynyl cuprates, boronates and alkynylzinc 
reagents have proven their utility. 
 In 2006, the research group of Wong described the asymmetric synthesis of N-protected 
propargylic amines by the alkynylation of N-acylimines using binaphthol-modified alkynylboronates 
(Scheme 2.3).18 The best enantioselectivities and highest yields were obtained using 3,3’-disubstituted 
binaphthol with different aryl and alkyl alkynes. A restriction of this reaction is that only non-enolizable 
imines can be used. This methodology was used in the synthesis of (-)-N-acetylcolchinol (a selective 




Scheme 2.3. Enantioselective alkynylation of N-acetylaldimines with alkynylboronates. 
2.1.2. Catalytic enantioselective alkynylations of imines 
One way to generate the acetylene organometallic reagent is using dialkylzinc in order to 
deprotonate the alkyne. Dialkylzinc compounds have been extensively used in alkylation reactions of 
imines.19 However, alkynylation reactions with dialkylzinc or alkylalkynylzinc are not that common, 
since the majority of the alkynylation of imines that are described in literature are performed using 
chiral copper complexes.20 Next, a few selected examples of alkynylations with zinc reagents are 
presented. 
In 2003, the group of Hoveyda presented the first catalytic enantioselective addition of 
alkynylzinc reagents to a variety of o-anisidyl imines.21 The reaction was promoted by a chiral amino 
acid type ligand in the presence of Zr(OiPr)4.HOiPr (Scheme 2.4).  
 
Scheme 2.4. Enantioselective addition of alkynylzinc to imines catalyzed by Zr(OiPr)4.HOiPr 
The authors were able to apply this protocol to different substituted o-anisidyl imines 
obtaining optically enriched secondary propargylic amines with enantioselectivities up to 90% ee and 
good yields. However, the presence of an ortho substituent in the aromatic ring, reduces the 
enantioselectivity to 69%. Trimethylsilylacetylene was used in the reaction, which led to terminal 
propargylic amines once eliminated the TMS group. The reaction was also performed with aliphatic 
and aromatic alkynylzinc, leading to moderate to good enantioselectivities. The obtained propargylic 





Scheme 2.5. Oxidative deprotection of the o-anisidyl group 
The same research group also investigated the synthesis of propargylic amines via a three 
component reaction between α,β-unsaturated aldehydes, an ortho-phenoxy substituted primary 
aromatic amine and an alquilzinc reagent in the presence of Zr(OiPr)4.HOiPr and an chiral amino 
alcohol type ligand (Scheme 2.6).22 
 
Scheme 2.6. Enantioselective synthesis of propargylic amines via the addition of dialkylzinc reagents to alkynyl 
imines. 
 In 2004, Jiang and Si described the enantioselective alkynylation of a cyclic N-acyl ketimine 
using a stoichiometric amount of a chiral amino alcohol as ligand.23 The cyclic imine is activated by a 
trifluoromethyl group and the reaction is performed in the presence of zinc triflate and triethylamine 
(Scheme 2.7). This reaction proved to be a key step in the synthesis of DPC-961, an analogue of 
Efavirenz (Sustiva®, Bristol-Myers-Squibb), a pharmaceutical used in the HIV therapy.24 Various 
aromatic, allylic and silyl-substituted acetylenes were applied in the reaction leading to 
enantioselectivities up to 99.5% and yields higher than 63%. 
 
Scheme 2.7. Enantioselective addition of cyclopropyl acetylene to a cyclic trifluoromethylimine. 
 More recently, the research group of Ma published their results on the diynylation of cyclic N-
acyl trifluoromethylimines using an amino alcohol like ligand and Me2Zn (Scheme ).25 The reaction 
tolerates electron-withdrawing and electron-donating groups on the aromatic ring of the imine, as 




 The authors also synthesized the opposite enantiomers of the diynylation products by using 
the chiral ligand shown in the scheme above (Scheme 2.8). They were also able to eliminate the p-
methoxybenzyl group and reduce partially the triple bond without loss of enantioselectivity. 
 
Scheme 2.8. Addition of diynes to N-acylimines catalyzed by an amino alcohol type ligand and Me2Zn. 
In 2007, the group of Bolm described a three component synthesis of propargylic amines using 
Me2Zn with various aldehydes and o-methoxyaniline.26 The efficiency of the methodology was 
improved by concentrating the reaction mixture using as only solvent the toluene of the Me2Zn 
solution. In the same work the researchers developed also the enantioselective version of the 
reaction, using the same methodology, but performing the reaction in the presence of a (1R, 2S)-
norepinephrine derivative as chiral inducer (Scheme 2.9). Aromatic, heteroaromatic and α-substituted 
aliphatic aldehydes, o-methoxyaniline and phenylacetylene were used to obtain the corresponding 
propargylic amines in moderate to good yields and with enantioselectivities between 68 and 97%. 
However, the reaction with aliphatic alkynes and with trimethylsilylacetylene resulted in lower 
enantiomeric excesses (13-53% ee).  
 
Scheme 2.9. One-pot enantioselective synthesis of propargylic amines with an amino alcohol and Me2Zn. 
 Taking in account that electron-withdrawing groups on the nitrogen atom increase the 
reactivity of the azomethine carbon of the C=N double bond, our group proposed the first 
dimethylzinc-mediated catalytic enantioselective alkynylation of N-sulfonyl imines using BINOL type 
ligands (Scheme 2.10).17 As already observed by Bolm,26 a reduction in the volume of the reaction 
resulted in an increase of the enantioselectivity; a reduction of 50% of the volume resulted in a slight 




Scheme 2.10. Enantioselective alkynylation of N-tosylimines promoted by Me2Zn and BINOL type ligands. 
 With different N-tosylaldimines derived from aromatic and heteroaromatic aldehydes high 
enantioselectivities were obtained (up to ≥99% ee). On the other hand, the aliphatic imines showed 
less enantioselectivity (18-38% ee). Aliphatic alkynes were also applied in the reaction under the same 
reaction conditions, showing, depending the alkyne, enantioselectivities up to ≥99% ee. Moreover, 
the elimination of the tosyl group by SmI2 was also carried out leading to free propargylic amines 
Zhang and collaborators also used a similar catalytic system, formed by Me2Zn and a BINOL-
type ligand.27 They applied this catalytic system in the enantioselective alkynylation of α-
trifluoromethyl ketimine esters (Scheme 2.11). Different types of alkynes (aliphatic, aryl and silyl-
substituted) were tested in the reaction, obtaining in all of the cases excellent enantioselectivities (95-
99% ee).     
 
Scheme 2.11. Enantioselective alkynylation of α-trifluoromethyl ketimine esters catalyzed by BINOL-Zn. 
 In 2009 the Wang group published their results on the first asymmetric addition of terminal 
alkynes to N-(diphenylphosphinoyl)imines promoted by a proline derived β-amino alcohol and Et2Zn.28 
With substoichiometric amounts of ligand, they obtained a moderate enantioselectivity (68% ee) and 
only when they raised the ligand loading to a 100%, the alkynylation products were obtained in good 
yields and excellent enantioselectivities up to 95% ee. The same year they also described the 
nucleophilic addition of trimethylsilylacetylene to the same substrates (Scheme 2.12).29 As chiral 
ligands they used different chiral amino alcohols. Different aryl, heteroaryl and alkyl imines were 
tested and moderate to good enantioselectivities (72-95% ee) were obtained. A drawback of this 
report is the amount of ligand needed in the reaction (60 mol %). They also applied the same 
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conditions to various N-(diethoxyphosphoryl)imines, obtaining good results, both in yield as in 
enantioselectivity.  
 
Scheme 2.12. Enantioselective addition of trimethylsilylacetylene to N-(diphenylphosphinoyl)imines promoted 
by Et2Zn and a β-amino alcohol like ligand. 
In 2010, the same group described the design and application of amino alcohol like tridentate 
ligands derived from prolinol (Scheme 2.13).30 These ligands were applied in the enantioselective 
addition of phenylacetylene, 2-thienyl- and 3-thienylacetylene to aromatic N-
(diphenylphosphinoyl)imines resulting in good yields and good enantioselectivities using less amount 
of chiral ligand (35 mol %). 
 
Scheme 2.13. Enantioselective addition of alkynes to N-(diphenylphosphinoyl)imines. 
 In 2012 our research group published their results on the enantioselective addition of terminal 
alkynes to N-(diphenylphosphinoyl)imines (Scheme 2.14).31  The catalytic system formed by Me2Zn 
and a BINOL type ligand, 3,3'-dibromo-[1,1'-binaphthalene]-2,2'-diol, leads to the best 
enantioselectivities. The optimized reaction conditions were applied on one hand on differently 
substituted N-(diphenylphosphinoyl)imines leading to good yields up to 86% and enantioselectivities 
up to 96%, and on the other hand with different aromatic, heteroaromatic and aliphatic alkynes 
obtaining the corresponding products in good yields (up to 93%) and enantioselectivities (up to 93% 




Scheme 2.14. Enantioselective addition of terminal alkynes to N-(diphenylphosphinoyl)imines. 
 One year later, in 2013, our research group developed an enantioselective Zn-BINOL catalyzed 
alkynylation of aldimines generated in situ from α-amido sulfones (Scheme 2.15).32 The advantage of 
using α-amido sulfones lies in the fact that they are stable solids that can be readily obtained in one-
step fashion by condensation of carbamates and sodium aryl sulfinates with the desired aldehydes, 
and form easily N-carbamoyl imines in basic medium by deprotonation of the carbamate and 
elimination of the sulfinate group. The best results were obtained with 3,3'-bis(3,5-
bis(trifluoromethyl)phenyl)- [1,1'-binaphthalene]-2,2'-diol and Et2Zn as catalytic system. Various 
differently substituted aromatic α-amido sulfones were tested in the reaction conditions obtaining 
good yields and enantioselectivities. Different terminal aromatic and aliphatic alkynes were also 
tested leading to good yields and high enantioselectivities. 
 
Scheme 2.15. Enantioselective alkynylation of aldimines generated in situ from α-amido sulfones. 
In the same publication, a possible catalytic cycle was proposed for the reaction (Scheme 
2.16). Deprotonation of the BINOL and acetylene by diethylzinc leads to the formation of the BINOL 
zincate-ethylalkynylzinc complex catalyst I. A reaction between another diethylzinc molecule and the 
α-amido sulfone leads to the formation of the N-Cbz-protected imine, which coordinates to the 
catalyst complex I to give the intermediate II. In a next step, a transfer of the alkynylide from the 
ethylalkynylzinc moiety to the imine takes place. This leads to the release of the reaction product and 
BINOL-zincate III, which after coordination with another ethylalkynylzinc molecule regenerates the 





Scheme 2.16. Proposed catalytic cycle for the enantioselective alkynylation of aldimines generated in situ from 
α-amido sulfones in presence of BINOL-Zn complexes. 
In 2016, an asymmetric alkynylation reaction using N-(diphenylphosphinoyl)imines as 
electrophiles in the presence of Et2Zn and a BINOL type ligand was described by Pu and collaborators 
(Scheme 2.17).33 The researchers used 3,3’-di(1-diphenylmethylpiperazinyl)methyl H8BINOL as chiral 
ligand, in the presence of 1 equivalent Ti(OiPr)4 and 0.3 equivalents of imidazole. The ligand was 
prepared from the Mannich type reaction of (S)-H8BINOL with paraformaldehyde and 1-
(diphenylmethyl)piperazine. The alkynylation  reaction conditions allow the use of different alkyl and 
aryl alkynes, leading to good yields and enantioselectivities, especially for alkyl alkynes, with 
enantioselectivities up to 85% ee.  
 
Scheme 2.17. Asymmetric alkynylation reaction to N-(diphenylphosphinoyl)imines in the presence of Et2Zn and 
a BINOL type ligand. 
2.1.3. Catalytic enantioselective reactions of benzoxathiazine 2,2-dioxides 
In this chapter, we want to explore the use of cyclic imines as electrophiles. More concretely 
benzoxathiazine 2,2-dioxides, which have never been used as electrophiles in enantioselective 
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alkynylation reactions. The use of these cyclic imines in which the protecting group forms part of the 
structure of the compound can be an alternative towards the N-protected imines, due to the lower 
conformational mobility and the impossibility of E/Z isomeration of the double bond of the imine. 
On the other hand, benzoxathiazine 2,2-dioxides are precursors of the sulphamidate 
structure, which can be found in a considerable number of biologically and pharmacologically active 
compounds. This group can be found, for example, in artemisinin analogues, which are used in clinical 
treatment against malaria (Figure 2.2, A),34  in oxazolidinones (Figure 2.2, B)35  or Iβ-methylcarbapenes 
(Figure 2.2, C),36 which are potent antibacterial drugs. The sulphamidates can also be used as building 
blocks in organic synthesis. An example of this use can be found is the synthesis of N,P-ligands, used 
for the asymmetric addition of butyllithium to benzaldehyde.37  
 
Figure 2.2. (A) Analogue of artemisinin, (B) oxazolidinone derivate, (C) Iβ-methylcarbapene derivative. 
As shown before, benzoxathiazine 2,2-dioxides are very interesting cyclic imines and have 
recently attracted considerable attention in organic synthesis and several catalytic enantioselective 
additions of nucleophiles have been described for the synthesis of chiral sulphamidates.  
2.1.3.1. Catalytic enantioselective hydrogenation reactions of benzoxathiazine 2,2-
dioxides 
 In 2008, Zhou and collaborators published their findings on the hydrogenation of cyclic 
cetimines using palladium as catalyst in the synthesis of cyclic sulphamidates (Scheme 2.18).38 
Optimized conditions were obtained and then applied to a series of ketone derived substituted 
benzoxathiazine-2,2-dioxides. The optimized conditions consist in the use of a Pd(CF3CO2)2/(S,S)-f-
binaphane catalyst in trifluoroethanol at room temperature under H2 atmosphere. Excellent results 
were obtained, both in yield (88-99%) as in enantioselectivity (90-99% ee). In general, arylated 
substrates lead to better enantioselectivities (97-99% ee) than alkylated  substrates (90-94% ee) in this 
enantioselective hydrogenation.  
 
Scheme 2.18. Pd catalyzed enantioselective hydrogenation of benzoxathiazine-2,2-dioxides. 
 In 2016, the same research group published their findings on the enantioselective synthesis 
of α-aminophosphonates through Pd catalyzed hydrogenation of cyclic ketimine phosphonates 
(Scheme 2.19).39 In a first stage, the researchers used a N-tosyl α-ketiminephosphonate, from which 
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they carried out an easy synthesis of α-aminophosphonates. The hydrogenation of this kind of imine 
gives the best results under the following reaction conditions: Pd(OCOCF3)2/(R)-DifluorPhos as 
catalyst, trifluoroethanol/dichloromethane in a 2:1 proportion as solvent at 40 °C. These reaction 
conditions were then applied on differently substituted cyclic α-ketiminephosphonates derived from 
benzoxathiazine 2,2-dioxides, leading to excellent results both in yield (85-92%)  as in 
enantioselectivity (94-99% ee). 
 
Scheme 2.19. Enantioselective synthesis of α-aminophosphonates through Pd catalyzed hydrogenation. 
2.1.3.2. Catalytic enantioselective addition reactions of boron organometallic reagents to 
benzoxathiazine 2,2-dioxides 
 In 2012, Lam and collaborators described the first enantioselective Rh-catalyzed additions of 
alkenylboron compounds to cyclic imines (Scheme 2.20).40 This is the first reaction described in which 
benzoxathiazine 2,2-dioxides function acts as electrophile in an asymmetric catalytic enantioselective 
reaction. The authors proved the importance of the constrained Z-geometry of the C=N bond of these 
imines on the enantioselectivity, testing N,N-dimethylsulfamylimine which lead to the resulting 
product with a low enantioselectivity in the reaction with alkenylrhodium. According to the authors, 
this result could be due to the E/Z-isomerization, which they confirmed using a benzoxathiazine 2,2-
dioxide which does not allow the isomerization. With this substrate, they obtained the corresponding 
alkenylated amine with an excellent enantiomeric excess (98%) and with high yield in the presence of 
a diene as chiral ligand. Various alkenyltrifluoroborates with alkyl or aryl substituents were tested, 
resulting all in high yields and excellent enantiomeric excesses (94-99%). They were also able to 
broaden the scope with differently substituted cyclic imines obtaining excellent results both in yield 
as in enantioselectivity (94-99% ee). A cyclic N-sulfonyl ketimine also proved to be an excellent 
substrate providing the corresponding chiral sultam in 68% yield and 90% ee. The utility of the final 
products was proven with various synthetic transformations such as a hydroboration/oxidation 
sequence leading to an alcohol. After treatment with LiAlH4  and Boc protection a carbamate was 
obtained which can easily be transformed to chiral chroman-4-amine, a scaffold present in several 





Scheme 2.20. Enantioselective Rh-catalyzed additions of alkenylboron compounds to cyclic benzoxathiazine 
2,2-dioxides. 
 In the same year, the same research group described an enantioselective rhodium-catalyzed 
nucleophilic allylation of benzoxathiazine 2,2-dioxides with allylboron reagents (Scheme 2.21).41 As 
already proven in the previous work, various acyclic imines did not proof to be useful in the reaction 
due to the low enatioselectivities obtained. However, the use of  benzoxathiazine 2,2-dioxides in the 
reaction with potassium allyltrifluoroborate in the presence of a rhodium complex derived from a 
chiral diene resulted in the final product in a high yield (95%) and excellent enantiomeric excess (93% 
ee). It has to be noted that the use of potassium allyltrifluoroborate was necessary, whilst other 
allylboronic acids do not give satisfactory results. Differently substituted cyclic imines were tested in 
the optimized reaction conditions, as well as some highly substituted potassium allyltrifluoroborates, 
resulting in good yields (45-97%) and excellent diastereoselective ratios (6:1-17:1) and 
enantioselectivities (91-99% ee). In 2013, the same research group published their further findings on 
the addition of highly substituted potassium allyltrifluoroborates on cyclic aldimines, obtaining similar 
results as described before.42  
 
Scheme 2.21. Enantioselective rhodium-catalyzed nucleophilic allylation of benzoxathiazine 2,2-dioxides with 
allylboron reagents 
 In 2016, the Zhao group published their findings on the cobalt-catalyzed enantioselective 
vinylation of activated ketones and imines (Scheme 2.22).43 The investigators used both cyclic and 
acyclic imines in the reaction with 2-phenyl vinylboronic acid, promoted by CoBr2. Only the 
benzoxathiazine 2,2-dioxide aldimines resulted to be optimum substrates, leading to the final product 
in high yield (75%) and excellent enantiomeric ratio (99.5:0.5), using as the chiral ligand a duanphos 
ligand. The optimized reaction conditions were applied on different substituted cyclic imines and 
various vinyl boronic acids. The reactions resulted in good yields (52-85%) and excellent enantiomeric 




Scheme 2.22. Cobalt-catalyzed enantioselective vinylation of benzoxathiazine 2,2-dioxide aldimines. 
In 2013, the Xu group described a Rh-catalyzed highly enantioselective arylation of cyclic 
ketimines leading to the synthesis of tetrasubstituted carbon stereocenters (both sultams and 
sulfamidates) (Scheme 2.23).44 They use sulfur-based olefin ligands to promote the enantioselectivity 
of the reaction. Xu and collaborators examined various new ligands and under optimized reaction 
conditions [Rh(COE)2Cl2 (3 mol %), ligand (3.3 mol %), KF (3.0 equiv) in toluene], the arylboronation 
reaction between p-anisylboronic and benzoxatiazine 2,2-dioxide aldimines and ketimines bearing a 
CF3 leads to the corresponding final products in good yields (35-99%) and excellent enantioselectivities 
(85-99% ee). 
 
Scheme 2.23. Rh-catalyzed highly enantioselective arylation of cyclic imines. 
 In 2013, the same research group published their findings on the rhodium-catalyzed 
enantioselective addition of arylboronic acids to cyclic aldimines, a work in which the authors 
broadened the scope of the arylation of cyclic aldimines discussed before.44, 45 The same reaction 
conditions were used and the products were obtained in excellent yields (96-99%) and 
enantioselectivities (97-99% ee). 
 In 2014, Hayashi and collaborators described an asymmetric arylation of ketimines derived 
from benzoxathiazine 2,2-dioxides using a palladium phosphinooxazoline catalyst (Scheme 2.24).46 
Taking into account the results of Xu and collaborators in 2013,44, 45 which described the arylation of 
N-sulfamidate aldimines and CF3 substituted N-sulfamidate ketimines, Hayashi and coworkers 
proposed a new method for arylation of the less reactive alkyl and aryl N-sulfonyl ketimines. Under 
optimized conditions [PdCl2((S)-iPr-phox) (5 mol %), AgBF4 as additive in dichloroethane at 65-70 °C], 
the reaction between phenylboronic acid and N-sulfonyl aldimines and N-sulfonyl ketimines (methyl) 
led to excellent results both in yield as in enantiomeric excess (99% and 99.5% respectively). These 
optimized reaction conditions were then applied in the reaction between different arylboronic acids 
and N-sulfamidate ketimine (methyl), obtaining the corresponding products in good to high yields (51-
99%) and excellent enantioselectivities (98-99% ee). Both the ethyl and the pentyl N-sulfamidate 
ketimines were used in the reaction with phenylboronic acid leading to the reaction products in good 
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yields and excellent enantioselectivities (99% ee). Finally, they also tested several aryl N-sulfonyl 
ketimines, which are less reactive than the alkyl ketimines, obtaining satisfying results both in yield as 
in enantioselectivity in the presence of a proton sponge. 
 
Scheme 2.24. Asymmetric arylation of cyclic ketimines using a palladium phosphinooxazoline catalyst. 
  A rhodium-catalyzed asymmetric arylation of cyclic alkyl ketimines in the synthesis of highly 
enantioriched tertiary amines was described by Xu in 2015 (Scheme 2.25).47 With the use of the sulfur-
based olefin ligand, already applied in the arylation of cyclic ketimines,44 they were able to obtain α-
aryl α-alkyl disubstituted benzosultams and benzosulfamidates with excellent enantioselectivities. 
After optimizing the reaction conditions in the reaction between five membered N-sulfonyl ketimines 
and arylboronic acids, the researchers focused their attention on the enantioselective arylation of 
benzoxathiazine 2,2-dioxide alkylketimines. With a slight modification of the reaction conditions, they 
obtained, in the reaction between different substituted substrates and different arylboronic acids, 
variable yields (17-96%) and excellent enantioselectivities (≥99% ee). 
 
Scheme 2.25. Rhodium-catalyzed asymmetric arylation of cyclic ketimines. 
 The Zhang group published, in 2015, their findings on the asymmetric addition of arylboronic 
acids to cyclic N-sufamidate ketimine esters (Scheme ).48 The optimized conditions for the reaction 
[methyl (S)-6-(4-(tert-butyl)-4,5-dihydrooxazol-2-yl)nicotinate (7.5 mol %), Pd(TFA)2 (5 mol %) in 
trifluoroethanol] allowed the reaction with phenylboronic acid obtaining the final product in good 
yield (90%) and excellent enantioselectivity (98% ee). The reaction conditions were applied in the 
reaction with various arylboronic acids and differently substituted cyclic N-sufamidate ketimine esters, 
obtaining the α-aminoesters in good yields (52-99%) and excellent enantioselectivities (92-99% ee). 
The researchers also performed a DFT calculation, which shows that both the rate determining step 
and the stereoselectivity determining step is the aryl transfer from the boride to the carbon atom of 




Scheme 2.26. Asymmetric addition of arylboronic acids to cyclic ketimine esters. 
Some months later, Nishimura and Takedi described a rhodium catalyzed asymmetric addition 
of arylboronic acids to similar substrates (cyclic ketimine esters), directed towards the synthesis of 
α,α-diaryl-α-amino acid derivatives (Scheme 2.27).49 The initial study focused on the addition of 
phenylboronic acid to the cyclic ketimine ethyl ester. It was observed that in the presence of 
[Rh(OH)((S,S)-Bn-tfb*)]2 (tfb=tetrafluorobenzobarrelene) the final product was obtained in excellent 
yield (99%) and enantioselectivity (96% ee). The scope of the reaction was extended to a wide variety 
of cyclic ketimine esters and arylboronic acids obtaining the corresponding products in excellent yields 
(84-99%) and enantioselectivities (83-97% ee).  
 
Scheme 2.27. Rhodium catalyzed asymmetric addition of arylboronic acids to cyclic ketimine esters 
 Recently, the Zhou group published their results on the Pd-catalyzed enantioselective 
arylation of cyclic α-ketiminephosphonates with arylboronic acids (Scheme 2.28).50 The investigators 
used a cyclic α-ketiminephosphonate as model substrate in the addition reaction with phenylboronic 
acid. They obtained excellent results both in yield (95%) and enantioselectivity (99% ee) using a 
palladium phosphinooxazoline complex, with only a 1 mol % of ligand, in trifluoroethanol (TFE) as 
solvent. These optimized reaction conditions were used in reactions with differently substituted cyclic 
α-ketiminephosphonates derived from benzoxathiazine-2,2-dioxide and various arylboronic acids, all 
of which led to the corresponding products with good yields (73-97%) and excellent 





Scheme 2.28. Pd-catalyzed enantioselective arylation of cyclic α-ketiminephosphonates with arylboronic acids. 
Very recently, Zhang and collaborators described a Ni(II)-catalyzed asymmetric addition of 
arylboronic acids to benzoxathiazine 2,2-dioxides (Scheme 2.29).51 Under optimized conditions 
(Ni(ClO4)2.6H2O/tropos phosphine-oxazoline biphenyl complex in trifluoroethanol as solvent at 60 °C), 
various arylboronic acids are tested in the reaction with cyclic aldimines, with excellent yields (77-
99%) and enantioselectivities (82-97% ee). Furthermore, the authors amplified the scope by testing 
various aldimines and ester and aryl ketimines, resulting in good yields (55-99%) and excellent 
enantioselectivities (92-99.8% ee). 
 
Scheme 2.29. Ni(II)-catalyzed asymmetric addition of arylboronic acids to benzoxathiazine 2,2-dioxides 
In 2015, the Jarvo group described a silver-catalyzed enantioselective propargylation reaction 
of N-sulfonyl ketimines (Scheme 2.30).52 Upon optimization of the reaction conditions, they were able 
to obtain a homopropargylic amine in a good yield and excellent enantiomeric ratio (99:1) through 
the reaction between allenylboronic acid pinacol ester and a cyclic five membered N-sulfonyl ketimine 
using silver in the presence of a Walphos ligand as catalyst. The same reaction conditions were applied 
on the reaction between allenylboronic acid pinacol ester and different cyclic alkyl ketimines derived 
from benzoxathiazine 2,2-dioxides, which are less reactive, obtaining the corresponding products in 




Scheme 2.30. Silver-catalyzed enantioselective propargylation reaction of N-sulfonyl and sulfamidate 
ketimines. 
2.1.3.3. Catalytic enantioselective Mannich reactions of benzoxathiazine 2,2-dioxides 
 In 2014, Ma and collaborators published their findings on the Cu-catalyzed decarboxylative 
Mannich reaction of β-ketoacids with benzoxathiazine-2,2-dioxides as electrophiles (Scheme 2.31).53 
This decarboxylative Mannich reaction is an alternative pathway to the synthesis of β-aminoketones. 
Upon optimization, the researchers concluded that all Cu(I) salts tested gave good results in 
combination with a bisoxazoline ligand, whereas the Cu(II) salts tested gave lower enantioselectivities. 
They were also able to decrease the ligand loading to a 1 mol % maintaining a good enantioselectivity. 
With the optimized conditions in hand, the researcher extended the scope of the reation to various 
differently substituted benzoxathiazine 2,2-dioxides and various aromatic and aliphatic β-ketoacids, 
led to excellent yields (86-99%) an enantioselectivities (92-99% ee). Through a series of synthetic 
transformations, the obtained products can lead to chroman-4-amines without loss of optical purity. 
 
Scheme 2.31. Cu-catalyzed decarboxylative Mannich reaction of β-ketoacids with benzoxathiazine-2,2-dioxides 
In the same year, Zhang and collaborators described an organocatalytic direct Mannich 
reaction of alkyl methyl ketones with cyclic benzoxathiazine 2,2-dioxides (Scheme 2.32).54 The reaction 
conditions were optimized in the reaction between acetone and benzoxathiazine-2,2-dioxide and the 
best results were obtained when the reaction was catalyzed by a 10 mol % of a Cinchona alkaloid in 
the presence of a 20 mol % of a Brønsted acid (trifluoroacetic acid) in toluene at 10 °C. At first, various 
cyclic aldimines were tested under the reaction conditions with acetone, obtaining the corresponding 
products in high yields (76-99%) and enantioselectivities (91-97% ee). In order to extend the scope of 
the reaction, the researchers applied the same conditions in the reaction between benzoxathiazine-
2,2-dioxide and different alkyl methyl ketones, leading to good results (50-99%, 87-97% ee). However, 
when the alkyl group was voluminous, no reaction was observed, probably due to steric hindrance. In 
2016, the same research group described the organocatalytic enantioselective Mannich reaction of 
aryl methyl ketones with cyclic imines with Cinchona alkaloid based primary amines.55 They used the 
same catalyst that was used in the publication in 2014 (however the reaction was performed in p-
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xylene) in the reaction between differently substituted imines and various aryl methyl ketones leading 
to the corresponding products with good yields (32-99%) and enantioselectivities (89-98% ee).  
 
Scheme 2.32. Organocatalytic Mannich reaction of alkyl methyl ketones with cyclic benzoxathiazine 2,2-
dioxides 
Also in 2016, Ma and collaborators described a catalytic asymmetric decarboxylative Mannich 
reaction of malonic acid half esters with cyclic aldimines derived from benzoxathiazine  2,2-dioxides 
(Scheme 2.33).56 As a model reaction, the authors used the reaction between benzoxathiazine 2,2-
dioxides and a malonic acid half ester. The best result in the addition reaction were obtained in the 
presence of CuTC [copper(I)-thiophene-2-carboxylate] and a bisoxazoline ligand in THF at 15 °C. These 
reaction conditions are applied in the reaction between different cyclic aldimines and various malonic 
acid half esters, leading to an extended scope with good yields (72-91%) and enantioselectivities (87-
96% ee). The reaction can also be carried out with a malonic acid half thioester leading to the 
corresponding product with a moderate yield (58%) and an excellent enantioselectivity (96% ee).  
 
Scheme 2.33. Catalytic asymmetric decarboxylative Mannich reaction of malonic acid half esters with cyclic 
aldimines. 
 In the same year, the same research group described a one-pot enantioselective synthesis of 
fused aziridines, through a decarboxylative Mannich reaction followed by an oxidative C-H amination 
of cyclic imines with β-ketoacids (Scheme 2.34).57 The researchers observed that the reaction between 
cyclic imines derived from benzoxathiazine 2,2-dioxides and β-ketoacids in the presence of KI and 
TBHP (tert-butylhydroperoxide) in THF at room temperature gives rise to the synthesis to racemic 
fused aziridines in moderate to good yields (46-78%). The researchers were able to make this reaction 
also in an enantioselective way, however the treatment of an enantiopure intermediate product 
(reaction between benzoxathiazine 2,2-dioxide and β-ketoacid) with KI and TBHP led to the racemic 
fused aziridine. Strikingly, when the reaction was performed in an one-pot manner, first the 
enantioselective decarboxylative Mannich reaction in the presence of a CuI/Ph-Box complex and then 
addition of KI and TBHP to the same reaction mixture, the final product was obtained in moderate to 




Scheme 2.34. One-pot enantioselective synthesis of fused aziridines. 
Recently, Melchiorre and collaborators have described a light-triggered enantioselective 
organocatalytic Mannich type reaction with cyclic imines derived from benzoxathiazine 2,2-dioxides 
(Scheme 2.35).58 By photochemical reaction of 2-alkylbenzophenones, a hydroxy-o-quinodimethane 
was generated, which would react with cyclic imines in the presence of an organocatalyst to give rise 
to a [4+2] cycloaddition. However, the researchers observed only a Mannich type reaction. The 
presence of a dimeric Cinchona alkaloid derivative (DHQ)2PHAL (after optimization), led to the 
Mannich product in good yield (82%) and enantioselectivity (72% ee). The optimized reaction 
conditions were applied to the reaction between differently substituted cyclic imines and various 2-
alkylbenzophenones leading to the corresponding products in moderate to good yields (38-84%) and 
enantioselectivities (37-77% ee).  
 
Scheme 2.35. Light-triggered enantioselective organocatalytic Mannich type reaction with cyclic imines. 
2.1.3.4. Catalytic enantioselective aza-Friedel-Crafts reactions of benzoxathiazine 2,2-
dioxides 
 In 2014, our research group described an organocatalytic enantioselective aza-Friedel-Crafts 
reaction of 2-naphthols with cyclic imines derived from benzoxathiazine-2,2-dioxides (Scheme 2.36).59 
The optimized conditions of the reaction were the following: addition of 2-naphthols in the presence 
of 10 mol % of an organocatalyst derived from cupreine in dichloroethane at -20 °C and addition of 
the imine via a syringe pump during 12 hours. The authors were able to demonstrate the effectiveness 
of their system in the reaction with various 1-naphthols, 2-naphthol and sesamol to differently 
substituted benzoxathiazine-2,2-dioxides, leading to the corresponding products with good yields (52-




Scheme 2.36. Organocatalytic enantioselective aza-Friedel-Crafts reaction of 2-naphthols with cyclic imines. 
  
2.1.3.5. Catalytic enantioselective [4+2] cycloaddition reactions of benzoxathiazine 2,2- 
dioxides 
 In 2013, Kang and collaborators described the enantioselective [4+2] cycloaddition of cyclic 
imines with acyclic enones or ynones leading to sulfamidate-fused 2,6-disubstituted piperidin-4-ones 
(Scheme 2.37).60 The reaction conditions were optimized in the reaction between benzoxathiazine 
2,2-dioxide and (E)-4-phenylbut-3-en-2-one in the presence of a Cinchona alkaloid derivative (primary 
amine) and o-fluorobenzoic acid in toluene at 20 °C, leading to the cycloaddition product with a yield 
of 80% and an enantioselectivity of 97% ee (dr >19:1). These reaction conditions were then applied to 
the reaction between differently substituted cyclic aldimines and various enones, leading to the [4+2] 
cycloaddition products in good yields (60-85%)  and excellent enantioselectivities (90-97% ee, dr 
>16:1). The same reaction conditions were also applied in the reaction between various cyclic 
aldimines and ynones, leading to 2,6-disubstituted 2,3-dihydropyridin-4(1H)-ones in good yields (60-
80%) and enantioselectivities (87-94% ee). 
 
Scheme 2.37. Enantioselective [4+2] cycloaddition of cyclic imines and acyclic enones or ynones. 
 In the same year, Guo and collaborators described the phosphine catalyzed [4+2] 
cycloaddition of cyclic imines with allenoates (Scheme 2.38).61 In the first part of the publication, the 
researchers focused on the non-enantioselective [4+2] cycloaddition with PPh3 of various α-
substituted allenoates and differently substituted benzoxathiazine 2,2-dioxides, obtaining the 
cycloaddition products in good to excellent yields (45-98%). In the second part, the researchers 
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investigated the enantioselective version of this reaction. They used an amino acid based bifunctional 
chiral phosphine in the presence of 4Å molecular sieves, leading to the corresponding products with 
good yields (72-89%), moderate diastereomeric ratio (3:1-9:1) and good to excellent 
enantioselectivities (66-99% ee).  
 
Scheme 2.38. Phosphine catalyzed [4+2] cycloaddition of cyclic imines with allenoates. 
 In 2016, Kim and collaborators described the stereoselective synthesis of a benzosulfamidate-
fused tetrahidroquinazoline scaffold via an organocatalytic [4+2] cycloaddition of 2-amino-β-
nitrostyrenes with cyclic imines (Scheme 2.39).62 At first , the investigators performed the non-
enantioselective version of the reaction with various cyclic imines, promoted by imidazole, resulting 
in moderate to good yields (27-77%). The enantioselective version of the reaction was then tested 
with a squaramide ligand, leading to the corresponding products in good yields (40-85%), excellent 
diastereomeric ratios (>20:1) and low enatiomeric ratios (53:47-69:31).  
 





 El objetivo general de este capítulo es el desarrollo de un método catalítico y enantioselectivo 
de adición de alquinos terminales a aldiminas cíclicas derivadas de salicilaldehidos (2,2-dióxido 
benzoxatiazinas) que transcurra con buenos rendimientos y excesos enantioméricos.   
 
 En el estudio de este primer proyecto se considerarán los siguientes aspectos:  
1. Influencia de la estructura de diversos ligandos de tipo (R)-BINOL (L1-L6), (R)-VAPOL (L7) y (R)-
VANOL (L8) sobre el rendimiento y la enantioselectividad de la reacción. 
 
2. La influencia de la naturaleza del reactivo de dialquilzinc utilizado (Me2Zn y Et2Zn), número de 
equivalentes de dialquilzinc, disolvente, temperatura de reacción y número de equivalentes de 
alquino. 
3. Evaluación de diversas aldiminas cíclicas del tipo 2,2-dióxido benzoxatiazina con diferente 
naturaleza electrónica y estérica en la reacción de alquinilacion con fenilacetileno.  
 
4. Evaluación de distintas aldiminas cíclicas del tipo 2,2-dióxido benzoxatiazina en la reacción con 
diferentes alquinos terminales que presentan sustituyentes con distinta naturaleza electrónica y 
estérica. 
 
5. Evaluación de distintas transformaciones sintéticas basadas en la reactividad del triple enlace y del 
grupo sulfamidato presente en los productos de alquinilación sin pérdida de pureza óptica.  
6. Determinación de la configuración absoluta del centro estereogénico presente en las aminas 
propargílicas quirales obtenidas. 
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2.3. RESULTADOS Y DISCUSIÓN 
2.3.1. Síntesis de 2,2-dióxido benzoxatiazinas 
Las iminas cíclicas con esqueleto de 2,2-dióxido benzoxatiazina han sido preparadas a partir 
de aldehídos salicílicos comerciales y clorosulfonilamina,  preparada in situ a partir de isocianato de 
clorosulfonilo, a temperatura ambiente utilizando como disolvente N,N-dimetilacetamida (DMA). Los 
resultados se encuentran recogidos en la tabla 1. Este procedimiento fue descrito por el grupo de Lam 
en 2012.40 Como se puede apreciar en la tabla, todas las iminas se obtuvieron con rendimientos 
moderados, excepto la imina 1a la cual se obtuvo con un 85% de rendimiento. Las iminas se pueden 
purificar mediante cromatografía de columna, sin experimentar descomposición por hidrólisis.  
Tabla 2.1. Síntesis de 2,2-dióxido benzoxatiazinas. 
 
Entrada  4 R t (h) 1 R (%)a 
1 4a H 18 1a 85 
2 4b 6-Me 18 1b 41 
3 4c 6-tBu 18 1c 49 
4 4e 6-Br 18 1e 60 
5 4f 8-Me 18 1f 53 
6 4g 8-tBu 18 1g 42 
a Rendimiento tras purificación por cromatografía de columna. 
2.3.2. Optimización de las condiciones de la reacción 
Para abordar el proceso de optimización de la reacción de alquinilación de aldiminas cíclicas 
se escogió la reacción entre la 2,2-dióxido benzoxatiazina (1a) y fenilacetileno (2a). Inicialmente se 
tomaron como referencia las condiciones optimizadas para la alquinilación enantioselectiva de N-
tosiliminas publicada previamente por nuestro grupo.17 Este procedimiento consiste en la adición de 
una disolución de Me2Zn 2 M en tolueno sobre fenilacetileno. Tras una hora de agitación, se adiciona 
una disolución de (R)-BINOL (L1) en tolueno y, transcurridos 15 minutos, se añade la aldimina cíclica 
1a (Procedimiento A, Figura 2.3). No obstante, el producto de alquinilación se obtuvo con rendimiento 
moderado (61%) y prácticamente racémico (4% ee). Por ello, decidimos modificar el procedimiento 
experimental y para ello nos basamos en el procedimiento descrito por nuestro grupo en 2012 para 
la alquinilación enantioselectiva de α-amido sulfonas.32 El nuevo procedimiento (Procedimiento B, 
Figura 2.3) consistía en añadir la disolución de Et2Zn sobre una disolución de fenilacetileno y (R)-BINOL 
(L1) en diclorometano. Tras una hora de agitación se añadía la aldimina cíclica a 0 °C. El producto de 





PROCEDIMIENTO A                                           PROCEDIMIENTO B 
 
Figura 2.3. Procedimientos experimentales A y B. 
 Debido a que la aplicación de este último procedimiento condujo a una enantioselectividad 
más elevada que la obtenida en el procedimiento A, comenzamos el proceso de optimización 
ensayando un conjunto de ligandos en presencia de 3 equivalentes de Et2Zn (1 M en hexano) 
empleando diclorometano como disolvente  a 0 °C (Tabla 2.2).  
Los resultados revelaron que la utilización de ligandos de tipo BINOL con átomos de bromo en 
las posiciones 3,3’ (L2) o 6,6’ (L3), así como los ligandos octahidrogenados L4 y L5 proporcionaron 
enantioselectividades muy bajas (Tabla 2.2, entradas 2-5). Además, un mayor incremento de 
impedimento estérico de los sustituyentes en las posiciones 3,3’ condujo a un exceso enantiomérico 
del 15% (Tabla 2.2, entrada 6). Debido a que la utilización de ligandos de tipo BINOL no condujo a 
resultados satisfactorios, ensayamos la reacción en presencia de un ligando de tipo VAPOL (L7), con el 
cual se obtuvo el correspondiente producto de alquinilación con un rendimiento moderado, pero una 
enantioselectividad del 78% ee (Tabla 2.2, entrada 7). Por último, se evaluó la utilización de (R)-VANOL 
(L8) (Tabla , entrada 8) obteniéndose un rendimiento mayor pero una enantioselectividad inferior 
(Tabla , entrada 8).   
 
  
1h 5 min 
 
15 min 1 h 
 
          PhC≡CH (2a) + Me2Zn 
 
2,2-dióxido benzoxatiazina (1a) 
         PhC≡CH (2a) + (R)-BINOL (L1) 
 
           Et2Zn 
2,2-dióxido benzoxatiazina (1a) 
 
 (R)-BINOL (L1) 
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Tabla 2.2. Adición enantioselectiva de fenilacetileno (2a) a 2,2-dióxido benzoxatiazina (1a) utilizando Et2Zn en 
diclorometano a 0 °C. Evaluación de diferentes ligandos de tipo BINOL.a 
 
 
Entrada Ligando t (h) R (%)b ee (%)c 
1 L1 3 41 30 
2 L2 2 57 3 
3 L3 2 60 6 
4 L4 4 32 4 
5 L5 2 61 3 
6 L6 2 68 15 
7 L7 3 38 -78 
8 L8 2 65 -54 
a 1a (0,090 mmol), 2a (0,650 mmol), 2 M Et2Zn en hexano (0,270 mmol), L1-L8 (0,018 mmol). b Rendimiento tras 
la cromatografía de columna. c Determinado mediante HPLC usando fases estacionarias quirales. 
Una vez identificado el ligando L7 como el que proporcionaba los mejores resultados entre los 
ligandos examinados, continuamos el proceso de optimización ensayando la reacción con diferentes 
reactivos de dialquilzinc y disolventes a varias temperaturas (Tabla 2.3). 
La utilización de Me2Zn en lugar de Et2Zn dio lugar a un valor de exceso enantiomérico similar, 
pero se incrementó el rendimiento de la reacción hasta el 84% (Tabla 2.3, entrada 2). A continuación 
evaluamos el efecto de varios disolventes sobre el rendimiento y la enantioselectividad (Tabla 2.3, 
entrada 2-4). Se observó que la utilización de tolueno como disolvente proporcionó el producto de 
alquinilación con un 73% de rendimiento y 80% de exceso enantiomérico (Tabla 2.3, entrada 3). El uso 
de dicloroetano condujo a los mejores resultados en términos de rendimiento (88%) y 
enantioslectividad (82% ee) (Tabla 2.3, entrada 4). Por ello, continuamos el proceso de optimización 
utilizando dicloroetano como disolvente. 
Cuando redujimos la cantidad de Me2Zn hasta 1,5 equivalentes, observamos un aumento del 
rendimiento de la reacción, pero la enantioselectividad disminuyó notablemente (Tabla 2.3, entrada 
5). Por otra parte, un aumento hasta 4 equivalentes condujo a una ligera mejora de la 
enantioselectividad (Tabla 2.3, entrada 6). Por último, la adición de 6 equivalentes de Me2Zn dio lugar 
a un valor de exceso enantiomérico de 85%; sin embargo, se observó un descenso del rendimiento de 
la reacción (Tabla 2.3, Entrada 7). 
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En cuanto a la temperatura, una disminución a -20 °C resultó en un detrimento del 
rendimiento y la enantioselectividad, mientras que cuando se llevó a cabo la reacción tanto a 10 °C 
como a temperatura ambiente, se observaron resultados comparables a los obtenidos a 0 °C (Tabla 
2.3, entradas 9-10). Así pues, decidimos escoger la temperatura ambiente como temperatura óptima 
de reacción. Finalmente, conseguimos reducir la cantidad de fenilacetileno de 7,2 a 4 equivalentes 
manteniendo tanto el rendimiento como la enantioselectividad de la reacción (Tabla 2.3, Entrada 11). 
Tabla 2.3. Adición enantioselectiva de fenilacetileno (2a) a 2,2-dióxido benzoxatiazina (1a). Evaluación de 
reactivos de dialquilzinc, equivalentes de dialquilzinc, disolvente, temperatura de reacción y equivalentes de 
alquino.a 
 
Entrada R2Zn Equiv Equiv 2a Disolvente t (h) T ( °C) R (%)b ee (%)c 
1 Et2Zn 3 7,2 CH2Cl2 4 0 38 78 
2 Me2Zn 3 7,2 CH2Cl2 2 0 84 75 
3 Me2Zn 3 7,2 Tolueno 3 0 73 80 
4 Me2Zn 3 7,2 ClCH2CH2Cl 2 0 88 82 
5 Me2Zn 1,5 7,2 ClCH2CH2Cl 2 0 95 59 
6 Me2Zn 4 7,2 ClCH2CH2Cl 2 0 84 83 
7 Me2Zn 6 7,2 ClCH2CH2Cl 3 0 62 85 
8 Me2Zn 4 7,2 ClCH2CH2Cl 3 -20 62 77 
9 Me2Zn 4 7,2 ClCH2CH2Cl 2 10 86 83 
10 Me2Zn 4 7,2 ClCH2CH2Cl 2 ta 89 83 
11 Me2Zn 4 4 ClCH2CH2Cl 2 ta 89 82 
a 1a (0,090 mmol), (R)-VAPOL (0,018 mmol). b Rendimiento tras purificación por cromatografía de columna. c 
Determinado mediante HPLC usando fases estacionarias quirales. 
2.3.3. Alcance y limitaciones de la reacción 
En el estudio del alcance y limitaciones de la reacción, se aplicaron las condiciones optimizadas 
para la reacción entre 2,2-dióxido benzoxatiazina (1a) y fenilacetileno (2a) a distintas 2,2-dióxido 
benzoxatiazinas y alquinos terminales.  
2.3.3.1. Evaluación de distintas 2,2-dióxido benzoxatiazinas 
En primer lugar se evaluó la reacción entre varias 2,2-dióxido benzoxatiazinas diferentemente 




Esquema 2.40. Adición enantioselectiva de fenilacetileno (2a) a 2,2-dióxido benzoxatiazinas con (R)-VAPOL y 
Me2Zn. 1 (0,090 mmol), 2a (0,360 mmol), 2 M Me2Zn en tolueno (0,360 mmol), (R)-VAPOL (0,018 mmol). 
Rendimiento tras la cromatografía de columna. Exceso enatiomérico determinado mediante HPLC usando fases 
estacionarias quirales.  
 Como se puede observar en el esquema 2.40, la presencia de un grupo electrón-donante poco 
voluminoso (Me) en la posición 6 de la benzoxatiazina conduce al producto de alquinilación con buen 
rendimiento y una enantioselectividad elevada del 87% ee (3ba). Sin embargo, la presencia del mismo 
grupo en posición 8 del anillo aromático produce una disminución de la enantioselectividad (73% ee, 
3fa). La presencia de un grupo alquilo voluminoso (terc-butilo) en la posición 6 del anillo da lugar al 
producto de alquinilación con un buen rendimiento, pero un moderado exceso enantiomérico del 56% 
(3ca), mientras que la presencia del mismo grupo voluminoso en posición 8 conduce al producto de 
adición con buen rendimiento y con buena enantioselectividad de 81% ee (3ga). Es decir, se observa 
una gran influencia estérica de los sustituyentes situados en la posición 6 del anillo.  
 También se ensayó la reacción de alquinilación con una benzoxatiazina con un grupo electrón-
aceptor en posición 6 (Br), con la que se obtuvo un 59% de rendimiento y 80% ee (3ea) 
2.3.3.2. Evaluación de distintos alquinos terminales  
La aplicabilidad de esta reacción se ensayó también con distintos alquinos aromáticos, 
heteroaromáticos y alifáticos proporcionando buenos rendimientos y excesos enantioméricos 




Esquema 2.41. Adición enantioselectiva de diferentes alquinos terminales 2 a varias 2,2-dióxido benzoxatiazinas 
1 con (R)-VAPOL y Me2Zn. 1 (0,090 mmol), 2 (0,360 mmol), 2 M Me2Zn en tolueno (0,360 mmol), (R)-VAPOL 
(0,018 mmol). Rendimiento tras la cromatografía de columna. Determinado mediante HPLC usando fases 
estacionarias quirales. a Exceso enatiomérico tras cristalización. 
 Se examinaron diferentes alquinos aromáticos terminales con sustituyentes electrón-
donantes y aceptores (Esquema 2.41). La presencia de grupos electrón-donantes (MeO) da lugar a los 
productos de alquinilación con rendimientos elevados al torno al 90%. Se puede observar que la 
presencia del grupo MeO en las posiciones para (3ab y 3bb) o meta (3ad, 3bd y 3ed) del anillo 
aromático del alquino conduce  a los productos resultantes con buenas enantioselectividades (80-82% 
ee). Sin embargo, la presencia del mismo grupo en orto (3ac y 3bc) provoca una disminución de la 
enantioselectividad (65-68% ee). También se ensayó un alquino con un grupo electrón-aceptor (Cl) en 
la posición para del anillo aromático, obteniéndose los productos correspondientes (3ae y 3be) con 
buenos rendimientos (72-75%) y buenas enantioselectividades (82-86% ee). 
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 Cuando se llevó a cabo la reacción utilizando un alquino heteroaromático, se obtuvieron los 
productos de alquinilación (3ag y 3bg) con buenas enantioselectividades (79-86% ee) y buenos 
rendimientos (64-91%). 
 Por último, se evaluaron tres alquinos alifáticos (2i, 2k, 2l). La adición de un alquino unido a 
carbono primario dio lugar a los correspondientes productos de alquinilación con 
enantioselectividades moderadas (60-66% ee). La adición de ciclopropilacetileno condujo a una 
enantioselectividad superior (74-78% ee) y, finalmente, la reacción con 3,3-dimetil-1-butino dio lugar 
a los correspondientes productos de alquinilación (3ak, 3bk) con excesos enantioméricos del 79% ee 
y del 86% ee respectivamente. 
2.3.4. Transformaciones sintéticas  
Con el producto de alquinilación 3aa llevamos a cabo distintas transformaciones sintéticas. En 
primer lugar se llevó a cabo una hidrogenación del triple enlace con Pd/CaCO3 obteniéndose el 
producto 6 con un buen rendimiento de 93% y con mantenimiento de la pureza óptica (Esquema 2.42). 
Además tratamos el producto 6 con LiAlH4 seguido de una protección en forma de Boc (terc-
butiloxicarbonilo), lo cual nos permitió obtener el producto 7 con un buen rendimiento y sin pérdida 
de pureza óptica.42  
 
Esquema 2.42. Transformaciones sintéticas del producto de alquinilación 3aa. 
2.3.5. Determinación de la configuración absoluta 
Por cristalización del compuesto 3ed pudimos obtener una muestra adecuada para el estudio 
por difracción de Rayos X de monocristal, lo cual nos permitió determinar su configuración absoluta. 
El carbono esterogénico presenta configuración (S) (parámetro de Flack: 0.010(8)) (Figura 2.4). La 
configuración de los productos restantes se ha asignado admitiendo el mismo mecanismo de reacción 
para todos los sustratos. 
             




2.3.6. Propuesta mecanística para la alquinilación de 2,2-dióxido 
benzoxatiazinas catalizada por complejos de (R)-VAPOL-Zn 
El esquema 2.43 muestra un posible mecanismo para la reacción de alquinilación de 2,2-
dióxido benzoxatiazinas catalizada por complejos de (R)-VAPOL-Zn. En primer se produce la 
desprotonación del ligando VAPOL y del acetileno por parte del dimetilzinc, lo cual da lugar al complejo 
A (VAPOL zincato-metilalquinilzinc). Este complejo A se coordina con la imina cíclica (2,2-dióxido 
benzoxatiazina) formando el complejo B. En este complejo tiene lugar la transferencia del alquiniluro 
desde el metilalquinilzinc al carbono azometínico la imina, lo cual libera el producto de reacción y el 
VAPOL-zincato C. Se completa el ciclo catalítico tras la coordinación de una nueva molecula de 
metilalquinilzinc al complejo C, generando el complejo A.32    
 
Esquema 2.43. Propuesta mecanística para la alquinilación de 2,2-dioxido benzoxatiazinas catalizada por 




1. Se ha diseñado un método enantioselectivo de adición de alquinos terminales a aldiminas 
cíclicas de tipo 2,2-dióxido benzoxatiazina catalizada por un sistema formado por (R)-VAPOL 
y Me2Zn a temperatura ambiente utilizando ClCH2CH2Cl como disolvente.  
2. Se ha estudiado la reacción con diferentes ligandos de tipo BINOL, obteniéndose los productos 
de alquinilación con enantioselectividades muy bajas. La reacción con (R)-VANOL condujo a 
un buen exceso enantiomérico, pero la reacción transcurrió con mejor enantioselectividad 
cuando se utilizó (R)-VAPOL.  
3. Los sustituyentes sobre el anillo aromático de la aldimina cíclica afectan a la 
enantioselectividad y al rendimiento de la reacción con fenilacetileno. La presencia de un 
grupo electrón-donante o electrón-aceptor poco voluminoso en la posición 6 de la imina 
conduce a enantioselectividades mayores, mientras que un grupo electrón-donante 
voluminoso en esta posición disminuye la enantioselectividad de la reacción. Benzoxatiazinas 
sustituidas con un grupo electrón-donante en la posición 8 dan lugar a buenas 
enantioselectividades. 
4. Se han ensayado seis alquinos aromáticos con grupos electrón-donantes y electrón-aceptores 
en la reacción con diferentes 2,2-dióxido benzoxatiazinas con rendimientos y 
enantioselectividades elevadas. La presencia de sustituyentes en la posición orto del anillo 
aromático del alquino disminuye la enantioselectividad. La reacción con alquinos 
heteroaromáticos y alifáticos  dio lugar a los correspondientes productos de alquinilación con 
enantioselectividades de moderadas a buenas.   
5. Se ha podido realizar la hidrogenación del triple enlace del alquino y la reduci’on del 
sulfamidato con LiAlH4 seguido por protección en forma de Boc dando lugar a la amina 
protegida 7 sin pérdida de pureza óptica. 
6. Se ha podido determinar la configuración absoluta del carbono estereogénico (S) del 
compuesto 3fd mediante difracción de Rayos X. Al resto de productos se les asignó la misma 
configuración absoluta asumiendo que la reacción sigue el mismo curso estereoquímico. 
7. Se ha propuesto un posible mecanismo para la alquinilación de 2,2-dióxido benzoxatiazinas 





2.5. EXPERIMENTAL SECTION 
2.5.1. General experimental methods 
Reactions were carried out under nitrogen in test tubes or round bottom flasks oven-dried 
overnight at 120 °C. Dicloromethane, 1,2-dichloroethane and toluene were distilled from CaH2. THF 
was distilled from sodium benzophenone ketyl. Reactions were monitored by TLC analysis using Merck 
Silica Gel 60 F-254 thin layer plates. Flash column chromatography was performed on Merck silica gel 
60, 0.040-0.063 mm. Melting points were determined in capillary tubes. NMR spectra were run at 300 
MHz for 1H and at 75 MHz for 13C NMR using residual non-deuterated solvent  as internal standard 
(CHCl3: δ  7.26 and 77.0 ppm). Chemical shifts are given in ppm. The carbon type was determined by 
DEPT experiments. High resolution mass spectra (ESI) were recorded on a AB SCIEX Triple TOFTM 
spectrometer equipped with an electrospray source with a capillary voltage of 4.5 kV(ESI). Optical 
rotations were measured using sodium light (D line 589 nm). Chiral HPLC analyses were performed in 
a chromatograph equipped with a UV diode-array detector using chiral stationary columns from 
Daicel. Commercially available alkynes were used as received. 
2.5.2. General synthetic procedure and characterization data for compounds 1 
  Formic acid (20 mmol) was carefully added (dropwise) to chlorosulfonylisocyanate (20 mmol) 
at 0 °C. The mixture was stirred for 2 hours at room temperature to form 5. After 2 hours, the reaction 
was placed at 0 °C and diluted with DMA (15 mL). This solution was then added dropwise to a solution 
of salicylaldehyde 4 (10 mmol) in DMA (15 mL) at 0 °C. After addition, the reaction was placed at room 
temperature and stirred for 18 h. After, the reaction was quenched with 100 mL ice cold water. The 
solution was then extracted with 3 x 50 mL dichloromethane, washed with 3 x 50 mL water and brine 
(50 mL). The organic layer was dried with MgSO4 and concentrated in vacuo. The residue was purified 
by flash chromatography obtaining product 1. The products previously described in literature, are only 
characterized with 1H and 13C NMR. 
Benzo[e][1,2,3]oxathiazine 2,2-dioxide (1a)40, 41 
White solid; 92-94 °C; 1H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 7.76 (ddd, J = 8.3, 7.5, 1.7 Hz, 
1H), 7.69 (dd, J = 7.7, 1.4 Hz, 1H), 7.43 (td, J = 7.6, 1.0 Hz, 1H), 7.32 – 7.27 (m, 1H) ppm. 13C 
NMR (75 MHz, CDCl3) δ 167.6 (CH), 154.3 (C), 137.6 (CH), 130.7 (CH), 126.1 (CH), 118.6 (CH), 
115.4 (C) ppm. 
6-Methylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (1b)40, 41 
White solid; 73-74 °C; 1H NMR (300 MHz, CDCl3) δ 8.61 (d, J = 0.4 Hz, 1H), 7.58 – 7.52 (m, 
1H), 7.46 (dd, J = 1.5, 0.6 Hz, 1H), 7.17 (dd, J = 8.7, 0.3 Hz, 1H), 2.44 (s, 3H) ppm. 13C NMR 
(75 MHz, CDCl3) δ 167.8 (CH), 152.2 (C), 138.4 (CH), 136.4 (C), 130.6 (CH), 118.3 (CH), 115.1 






6-(tert-Butyl)benzo[e][1,2,3]oxathiazine 2,2-dioxide (1c)40, 41 
White solid; 56-58 °C; 1H NMR (300 MHz, CDCl3) δ 8.66 (d, J = 0.6 Hz, 1H), 7.78 (dd, J = 8.7, 
2.4 Hz, 1H), 7.64 (d, J = 2.5 Hz, 1H), 7.26 – 7.21 (m, 1H), 1.36 (s, 9H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 168.2 (CH), 152.0 (C), 149.7 (C), 135.2 (CH), 127.3 (CH), 118.0 (CH), 114.8 (C), 34.7 
(C), 31.0 (CH3) ppm 
 
6-Bromobenzo[e][1,2,3]oxathiazine 2,2-dioxide (1e)40, 41 
White solid; 131-133 °C; 1H NMR (300 MHz, CDCl3) δ 8.62 (s, 1H), 7.85 (dd, J = 8.7, 2.4 Hz, 
1H), 7.82 (d, J = 1.9 Hz, 1H), 7.24 – 7.20 (m, 1H) ppm. 13C NMR (75 MHz, CDCl3) δ 166.2 (CH), 
153.2 (C), 140.2 (CH), 132.9 (CH), 120.5 (CH), 118.7 (C), 116.5 (C) ppm. 
 
8-Methylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (1f)40, 41 
White solid; 89-91 °C; 1H NMR (300 MHz, CDCl3) δ 8.60 (s, 1H), 7.54 (ddd, J = 7.6, 1.6, 
0.8 Hz, 1H), 7.49 (ddd, J = 7.7, 1.6, 0.5 Hz, 1H), 7.26 (t, J = 7.6 Hz, 1H), 2.30 (s, 3H).13C 
NMR (75 MHz, CDCl3) δ 168.2 (CH), 152.1 (C), 139.1 (CH), 128.6 (CH), 128.0 (C), 125.5 
(CH), 114.9 (C), 14.2 (CH3) ppm.  
8-(tert-Butyl)benzo[e][1,2,3]oxathiazine 2,2-dioxide (1g)40, 41 
White solid; 70-72 °C; 1H NMR (300 MHz, CDCl3) δ 8.65 (s, 1H), 7.75 (dd, J = 7.9, 1.6 Hz, 
1H), 7.55 (dd, J = 7.6, 1.6 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 1.44 (s, 9H). 13C NMR (75 MHz, 
CDCl3) δ 168.7 (C), 153.0 (C), 140.2 (C), 135.3 (CH), 129.2 (CH), 125.9 (CH), 116.0 (C), 
34.8 (C), 29.5 (CH3). 
2.5.3. General synthetic procedures and characterization data for compounds 3 
General procedure for the enantioselective alkynylation reaction: A 2 M Me2Zn solution in 
toluene (0.18 mL, 0.36 mmol) was added dropwise on a solution of L7 (9.7 mg, 0.018 mmol) and alkyne 
2 (0.36 mmol) in dichloroethane (0.3 mL) at room temperature under nitrogen. After stirring 1 hour, 
a solution of benzoxathiazine 2,2-dioxide 1 (0.09 mmol) in dichloroethane (1.0 mL) was added via 
syringe. The reaction was stirred until the reaction was complete (TLC). The reaction mixture was 
quenched with NH4Cl (10 mL), extracted with dichloromethane (3x15 mL), washed with brine (10 mL), 
dried over MgSO4 and dried under reduced pressure. Purification by flash chromatography on silica 
gel afforded compound 3. 
General procedure for the non-enantioselective alkynylation reaction: A 1 M Et2Zn solution 
in hexane (0.30 mL, 0.30 mmol) was added dropwise on a solution of racemic BINOL (5.7 mg, 0.02 
mmol) and alkyne 2 (0.72 mmol) in dichloroethane (0.4 mL) at room temperature under nitrogen. 
After stirring 1 hour, a solution of benzoxathiazine 2,2-dioxide 1 (0.10 mmol) in dichloroethane (1.0 
mL) was added via syringe. The reaction was stirred until the reaction was complete (TLC). The reaction 
mixture was quenched with NH4Cl (10 mL), extracted with dichloromethane (3x15 mL), washed with 
brine (10 mL), dried over MgSO4 and dried under reduced pressure. Purification by flash 




(S)-4-(Phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3aa)  
The enantiomeric excess (82%) was determined by chiral HPLC (Chiralpak ODH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 15.82 min, minor 
enantiomer tr = 13.68 min. 
Oil; []D20 = -32.6 (c 1.0, CHCl3, 82% ee); 1H NMR  (300 MHz, CDCl3) δ 7.61 (ddd, J 
= 7.8, 1.6, 1.1 Hz, 1H), 7.50 (dd, J = 7.8, 1.8 Hz, 2H), 7.44-7.33 (m, 4H), 7.28 (dd, J 
= 7.6, 1.3 Hz, 1H), 7.05 (dd, J = 8.2, 1.3 Hz,1H), 5.94 (d, J = 10.0 Hz, 1H), 4.93 (d, J = 9.6 Hz, 1H); 13C NMR 
(75.5 MHz, CDCl3) δ 150.6 (C), 132 (CH), 130.4 (CH), 129.5 (CH), 128.5 (CH), 127.6 (CH), 125.6 (CH), 
121.1 (C), 119.6 (C), 118.7 (CH), 87.7 (C), 82.3 (C), 50.3 (CH); HRMS (ESI) m/z: 284.0376 [M - H]-, 
C15H10NO3S requires 284.0381.  
(S)-6-Methyl-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ba)  
The enantiomeric excess (87%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 16.46 min, minor 
enantiomer tr = 25.98 min. 
Oil; []D20 = -76.73 (c 1.0, CHCl3, 87% ee); 1H NMR  (300 MHz, CDCl3) δ 7.52-7.49 
(m, 2H), 7.41-7.33 (m, 4H), 7.19-7.15 (m, 1H), 6.94 (d, J = 8.4 Hz, 1H), 5.90 (d, J = 9.9 Hz, 1H), 4.88 (d, J 
= 9.9 Hz, 1H), 2.39 (s, 3H); 13C NMR (75.5 MHz, CDCl3) δ 148.5 (C), 135.5 (C), 132.0 (CH), 130.9 (CH), 
129.5 (CH), 128.52 (CH), 127.7 (CH), 121.1 (C), 119.1 (C), 118.5 (CH), 87.6 (C), 82.5 (C), 50.3 (CH), 20.8 
(CH3); HRMS (ESI) m/z: 298.0532 [M - H]-, C16H12NO3S requires 298.0538.  
(S)-6-(tert-Butyl)-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ca) 
The enantiomeric excess (56%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 8.16 min, minor 
enantiomer tr = 9.15 min. 
 Oil; []D20 = -77.26 (c 1.0, CHCl3, 56% ee); 1H NMR  (300 MHz, CDCl3) δ 7.61 (dd, J 
= 2.4, 1.1, 1H), 7.55-7.45 (m, 2H), 7.43-7.30 (m, 4H), 6.98 (d, J = 8.7 Hz, 1H), 5.93 (d, J = 10 Hz, 1H), 4.83 
(d, J = 10,0 Hz, 1H), 1.34 (s, 9H); 13C NMR (75.5 MHz, CDCl3) δ 148.8 (C), 148.3 (C), 131.9 (CH), 129.4 
(CH), 128.6 (CH), 127.4 (CH), 124.3 (CH), 121.2 (C), 118.7 (C), 118.1 (CH), 87.7 (C), 82.7 (C), 50.51 (CH), 
34.6 (C), 31.3 (CH3); HRMS (ESI) m/z: 340.1007 [M - H]-, C19H18NO3S requires 340.1007.  
(S)-6-bromo-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ea) 
The enantiomeric excess (80%) was determined by chiral HPLC (Chiralpak AD-H), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 10.63 min, minor 
enantiomer tr = 12.47 min. 
Oil; []D20 = -114.82 (c 1.0, CHCl3, 80% ee); 1H NMR  (300 MHz, CDCl3) δ 7.73 (dd, 
J = 2.4, 1.1 Hz, 1H), 7.58-7.46 (m, 3H), 7.45-7.33 (m, 3H), 6.94 (d, J = 8.8Hz, 1H), 
5.91 (d, J = 10.0 Hz, 1H), 4.94 (d, J = 10.0 Hz, 1H); 13C NMR (75.5 MHz, CDCl3) δ 149.6 (C), 133.4 (CH), 
132.1 (CH), 130.4 (CH), 129.7 (CH), 128.6 (CH), 121.5 (C), 120.7 (C), 120.4 (CH), 118.3 (C), 88.4 (C), 81.4 






(S)-8-Methyl-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3fa) 
The enantiomeric excess (73%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 12.22 min, minor 
enantiomer tr = 21.42 min. 
Oil; []D20 = -6.00 (c 1.0, CHCl3, 73% ee); 1H NMR  (300 MHz, CDCl3) δ 7.51 – 
7.48 (m, 2H), 7.48 – 7.42 (m, 1H), 7.41 – 7.32 (m, 3H), 7.26 – 7.22 (m, 1H), 
7.15 (t, J = 7.6 Hz, 1H), 5.92 (d, J = 10.2 Hz, 1H), 4.84 (d, J = 10.0 Hz, 1H), 3.30 (s, 3H); 13C NMR (75.5 
MHz, CDCl3) δ 149.1 (C), 131.9 (CH), 131.8 (C), 129.4 (CH), 128.5 (CH), 128.1 (C), 125.0 (CH), 121.1 (C), 
119.5 (CH), 87.8 (C), 82.6 (C), 50.3 (CH), 15.4 (CH3); HRMS (ESI) m/z: 298.0545 [M - H]-, C16H12NO3S 
requires 298.0538.  
(S)-8-(tert-Butyl)-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ga) 
The enantiomeric excess (81%) was determined by chiral HPLC (Chiralpak OD-
H), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 10.08 min, minor 
enantiomer tr = 8.42 min. 
Solid; mp 118-119 °C; []D20 = +8.08 (c 1.0, CHCl3, 81% ee); 1H NMR (300 MHz, 
CDCl3) δ 7.52-7.48 (m, 3H), 7.42-7.34 (m, 4H), 7.20 (t, J = 7.8Hz, 1H), 5.90 (d, J = 10.1Hz, 1H), 4.86 (d, J 
= 10.1Hz, 1H), 1.44 (s, 9H); 13C NMR (75.5 MHz, CDCl3) δ  149,9 (C), 140.1 (C), 131.9 (CH), 129.4 (CH), 
128.5 (CH), 128.0 (CH), 125.4 (CH), 125.1 (CH), 121.3 (C), 121.2 (C), 87.8 (C), 82.6 (C), 50.1 (CH), 35.0 
(C), 30.0 (CH3); HRMS (ESI) m/z: 342.1159 [M + H]+, C19H20NO3S requires 342.1164. 
 (S)-4-((4-Methoxyphenyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ab) 
The enantiomeric excess (83%) was determined by chiral HPLC (Chiralpak 
IC), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 23.85 min, minor 
enantiomer tr = 32.73 min. 
Oil; []D20 = -26.13 (c 1.0, CHCl3, 83% ee); 1H NMR  (300 MHz, CDCl3) δ  7.61 
(dt, J = 7.9, 1.4 Hz, 1H), 7.48 – 7.37 (m, 2H), 7.37 (ddd, J = 8.3, 1.7, 0.8Hz, 1H), 7.31 (td, J = 7.5, 1.2 Hz, 
1H), 7.05 (dd, J = 8.2, 1.2 Hz, 1H), 6.87 (dt, J = 9.2, 2.7 Hz, 2H), 5.92 (d, J = 10.0 Hz, 1H), 4.85 (d, J = 10.0 
Hz, 1H), 3.83 (s, 3H); 13C NMR (75.5 MHz, CDCl3) δ 160.5 (C), 150.6 (C), 133.5 (CH), 130.3 (CH), 127.6 
(CH), 125.6 (CH), 119.9 (C), 118.7 (CH), 114.2 (CH), 113.0 (C), 87.9 (C), 81.1 (C), 55.35 (CH), 50.40 (CH3); 
HRMS (ESI) m/z: 316.0638 [M + H]+, C16H14NO4S requires 316.0644. 
(S)-4-((4-Methoxyphenyl)ethynyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide 
(3bb) 
The enantiomeric excess (87%) was determined by chiral HPLC (Chiralpak 
IC), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 29.96 min, minor 
enantiomer tr = 40.36 min. 
Oil; []D20 = -47.60 (c 1.0, CHCl3, 87% ee); 1H NMR  (300 MHz, CDCl3) δ  7.47 
– 7.39 (m, 2H), 7.36 (dt, J = 2.1, 0.9 Hz, 1H), 7.17 (ddt, J = 8.4, 2.2, 0.8 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 
6.92 – 6.83 (m, 1H), 5.88 (d, J = 9.9 Hz, 1H), 4.78 (d, J = 9.9 Hz, 1H), 3.83 (s, 3H), 2.37 (s, 3H); 13C NMR 
(75.5 MHz, CDCl3) δ 160.5 (C), 148.5 (C), 135.5 (C), 133.6 (CH), 130.9 (CH), 127.7 (CH), 119.3 (C), 118.4 
(CH), 114.2 (CH), 113.1 (C), 87.6 (C), 81.3 (C), 55.4 (CH3), 50.4 (CH), 20.8 (CH3); HRMS (ESI) m/z: 




(S)-4-((2-Methoxyphenyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ac) 
The enantiomeric excess (65%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 19.21 min, minor 
enantiomer tr = 28.89 min.  
Solid; mp 103-105 °C; []D20 = -25.47 (c 1.0, CHCl3, 65% ee); 1H NMR  (300 MHz, 
CDCl3) δ  7.69 (dt, J = 7.7, 1.5 Hz, 1H), 7.43 (dd, J = 7.5, 1.7 Hz, 1H), 7.42 – 7.34 (m, 2H), 7.26 (td, J = 
7.5, 1.2 Hz, 1H), 7.04 (dd, J = 8.2, 1.2 Hz, 1H), 6.96 – 6.90 (m, 2H), 5.99 (d, J = 10.1 Hz, 1H), 4.91 (d, J = 
10.1 Hz, 1 H), 3.89 (s, 3H); 13C NMR (75.5 MHz, CDCl3) δ 160.5 (C), 150.6 (C), 133.7 (CH), 130.9 (CH), 
130.2 (CH), 127.8 (CH), 125.5 (CH), 120.5 (CH), 119.8 (C), 118.5 (CH), 110.8 (CH), 110.3 (C), 86.2 (C), 
84.2 (C), 55.7 (CH3), 50.5 (CH); HRMS (ESI) m/z: 316.0638 [M + H]+, C16H14NO4S requires 316.0644. 
(S)-4-((2-Methoxyphenyl)ethynyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide 
(3bc) 
The enantiomeric excess (68%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 25.23 min, minor 
enantiomer tr = 41.05 min.  
Solid; mp 157-159 °C; []D20 = -58.26 (c 1.0, CHCl3, 68% ee); 1H NMR  (300 MHz, 
CDCl3) δ 7.48 – 7.43 (m, 2H), 7.40 – 7.32 (m, 1H), 7.19 – 7.15 (m, 1H), 6.98 – 6.88 (m, 3H), 5.94 (d, J = 
10.2 Hz, 1H), 4.85 (d, J = 10.0 Hz, 1H), 3.90 (s, 3H), 2.37 (s, 3H); 13C NMR (75.5 MHz, CDCl3) δ 160.6 (C), 
148.5 (C), 135.5 (C), 133.7 (CH), 130.9 (CH), 130.8 (CH), 129.0 (CH), 120.5 (CH), 119.4 (C), 118.3 (CH), 
110.7 (CH), 110.4 (C), 86.3 (C), 84.2 (C), 55.7 (CH3), 50.5 (CH), 20.9 (CH3); HRMS (ESI) m/z: 330.0804 
[M + H]+, C17H16NO4S requires 330.0800. 
(S)-4-((3,5-Dimethoxyphenyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ad) 
The enantiomeric excess (80%) was determined by chiral HPLC (Chiralpak 
ADH), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 12.32 min, 
minor enantiomer tr = 19.33 min. 
Solid; mp 126-128 °C; []D20 = -25.50 (c 1.0, CHCl3, 80% ee); 1H NMR  (300 
MHz, CDCl3) δ 7.61 – 7.57 (m, 1H), 7.42 – 7.36 (m, 1H), 7.27 (td, J = 7.6, 1.3 
Hz, 1H), 7.05 (dd, J = 8.1, 1.3 Hz, 1H), 6.63 (d, J = 2.3 Hz, 2H), 6.48 (dt, J = 10.1, 2.3 Hz, 1H), 5.92 (d, J = 
9.87 Hz, 1H), 4.96 (d, J = 9.9 Hz, 1H), 3.79 (s, 6H); 13C NMR (75.5 MHz, CDCl3) δ 160.6 (C), 150.5 (C), 
130.4 (CH), 127.6 (CH), 125.6 (CH), 122.3 (C), 119.5 (C), 118.7 (CH), 109.8 (CH), 102.6 (CH), 87.6 (C), 
81.8 (C), 55.5 (CH3), 50.2 (CH); HRMS (ESI) m/z: 346.0757 [M + H]+, C17H16NO5S requires 346.0749. 
(S)-4-((3,5-Dimethoxyphenyl)ethynyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]-oxathiazine 2,2-dioxide 
(3bd) 
The enantiomeric excess (82%) was determined by chiral HPLC (Chiralpak 
ADH), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr =12.10 min, 
minor enantiomer tr = 19.93 min. 
Solid; mp 135-136 °C; []D20 = -65.18 (c 1.0, CHCl3, 82% ee); 1H NMR  (300 
MHz, CDCl3) δ 7.36 – 7.34 (m, 1H), 7.20 – 7.15 (m, 1H), 6.93 (d, J = 8.4 Hz, 
1H), 6.64 (d, J = 2.3 Hz, 2H), 6.50 (t, J = 2.3 Hz, 1H), 5.87 (d, J = 10.0 Hz, 1H), 4.91 (d, J = 9.9 Hz, 1H), 
3.79 (s, 6H), 2.37 (s, 3H); 13C NMR (75.5 MHz, CDCl3) δ 160.6 (C), 148.4 (C), 135.5 (C), 130.9 (C), 127.6 
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(CH), 122.4 (C), 119.0 (C), 118.4 (CH), 109.8 (CH), 102.6 (CH), 87.4 (C), 82.0 (C), 55.5 (CH3), 50.2 (CH), 
20.8 (CH3); HRMS (ESI) m/z: 360.0905 [M + H]+, C18 h18NO5S requires 360.0906. 
(S)-6-Bromo-4-((3,5-dimethoxyphenyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]-oxathiazine 2,2-dioxide 
(3ed) 
The enantiomeric excess (82%) (96% ee after crystalization) was determined 
by chiral HPLC (Chiralpak ODH), hexane-iPrOH 90:10, 1 mL/min, major 
enantiomer tr = 22.01 min, minor enantiomer tr = 39.14 min. 
Oil; []D20 = -109.36 (c 1.0, CHCl3, 82% ee);  NMR 1H (300 MHz, CDCl3) δ 7.71 
(dd, J = 2.5, 1.2 Hz, 1H), 7.49 (dd, J = 8.8, 2.4 Hz, 1H), 6.93 (d, J = 9.1 Hz, 1H), 
6.64 (d, J = 2.2 Hz, 2H), 6.51 (t, J = 2.3 Hz, 1H), 5.88 (d, J = 7.0 Hz, 1H), 4.97 (d, J = 8.0 Hz, 1H), 3.80 (s, 
6H); 13C (75,5 MHz, CDCl3) δ 160.6 (C), 149.6 (C), 133.4 (CH), 130.4 (CH), 121.9 (C), 121.4 (C), 120.4 
(CH), 118.3 (C), 109.9 (CH), 102.8 (CH), 88.3 (C), 81.0 (C), 55.5 (CH3), 49.9 (CH); HRMS (ESI) m/z: 
423.9851 [M + H]+, C17H15BrNO5S requires 422.9854. 
(S)-4-((4-Chlorophenyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ae) 
The enantiomeric excess (81%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 11.95 min, minor 
enantiomer tr = 19.02 min. 
 Solid; mp 93-95 °C; []D20 = -26.41 (c 1.0, CHCl3, 81% ee); 1H NMR  (300 MHz, 
CDCl3) δ 7.57 (dt, J = 7.8, 1.2 Hz, 1H), 7.45 – 7.39 (m, 3H), 7.37 – 7.32 (m, 2H), 
7.27 (td, J = 7.8, 1.5 Hz, 1H), 7.05 (dd, J = 8.2, 1.2 Hz, 1H), 5.93 (d, J = 9.9 Hz, 1H), 4.98 (d, J = 9.9 Hz, 
1H); 13C NMR (75.5 MHz, CDCl3) δ 150.5 (C), 135.7 (C), 133.2 (CH), 130.4 (CH), 128.9 (CH), 127.5 (CH), 
125.6 (CH), 119.5 (C), 119.4 (C), 118.8 (CH), 86.5 (C), 83.4 (C), 50.2 (CH); HRMS (ESI) m/z: 317.9993 [M 
- H]-, C15H9ClNO3S requires 317.9992. 
(S)-4-((4-Chlorophenyl)ethynyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3be) 
The enantiomeric excess (86%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 14.06 min, minor 
enantiomer tr = 20.77 min. 
Oil; []D20 = -46.06 (c 1.0, CHCl3, 86% ee); 1H NMR  (300 MHz, CDCl3) δ  7.46 – 
7.41 (m, 2H), 7.36 – 7.33 (m, 3H), 7.20 – 7.16 (m, 1H), 6.94 (d, J = 8.4 Hz, 1H), 5.88 (d, J = 9.6 Hz, 1H), 
4.82 (d, J = 9.8 Hz, 1H), 2.37 (s, 3H); 13C NMR (75.5 MHz, CDCl3) δ 148.4 (C), 135.7 (C), 135.6 (C), 133.2 
(CH), 131.0 (CH), 128.9 (CH), 127.6 (CH), 119.6 (C), 118.9 (C), 118.6 (CH), 86.4 (C), 83.6 (C), 50.2 (CH), 
20.9 (C); HRMS (ESI) m/z: 332.0141 [M - H]-, C16H11ClNO3S requires 332.0148. 
(S)-4-(Thiophen-2-ylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ag) 
The enantiomeric excess (79%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 8.82 min, minor 
enantiomer tr = 11.89 min.  
Oil; []D20 = -13.4  (c 1.0, CHCl3, 79% ee); 1H NMR (300 MHz, CDCl3) δ 7.58 (dt, J = 
7.8, 1.4 Hz, 1H), 7.46 – 7.34 (m, 1H), 7.35 (dd, J = 5.2, 1.2 Hz, 1H), 7.32 (dd, J = 3.6, 1.2 Hz, 1H), 7.27 
(td, J = 7.6, 1.3 Hz, 1H), 7.06 (dd, J = 8.2, 1.3 Hz, 1H), 7.02 (dd, J = 5.1, 3.7 Hz, 1H), 5.96 (d, J = 9.8 Hz, 
1H), 4.93 (d, J = 9.9 Hz, 1H); 13C NMR (75.5 MHz, CDCl3) δ 150.5 (C), 133.7 (CH), 130.4 (CH), 128.7 (CH), 
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127.6 (CH), 127.2 (C), 125.7 (CH), 120.7 (C), 119.3 (C), 118.8 (CH), 86.2 (C), 81.2 (C), 50.5 (CH); HRMS 
(ESI) m/z: 289.9946 [M - H]-, C13H8NO3S2 requires 289.9946. 
(S)-6-Methyl-4-(thiophen-2-ylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3bg) 
The enantiomeric excess (86%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 17.86  min, minor 
enantiomer tr = 24.74 min. 
Oil; []D20 = -24.1 (c 1.0, CHCl3, 86% ee); 1H NMR  (300 MHz, CDCl3) δ 7.36 (dd, J = 
5.1, 1.2 Hz, 1H), 7.33 (dt, J = 3.7, 1.2 Hz, 1H), 7.20 – 7.16 (m, 1H), 7.03 (dd, J = 5.1, 3.7 Hz, 1H), 6.94 (d, 
J = 8.4 Hz, 1H), 5.91 (Br s, 1H), 4.84 (br s, 1H), 2.37 (s, 3H); 13C NMR (75.5 MHz, CDCl3) δ 148.4 (C), 
135.6 (C), 133.7 (CH), 131.0 (CH), 128.6 (CH), 127.6 (CH), 127.2 (CH), 120.9 (C), 118.8 (C), 118.5 (CH), 
86.4 (C), 81.0 (C), 50.4 (CH), 20.8 (CH3); HRMS (ESI) m/z: 304.0107 [M - H]-, C14H10NO3S2 requires 
304.0102. 
(S)-4-(4-Phenylbut-1-yn-1-yl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ai) 
The enantiomeric excess (60%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 14.04 min, minor 
enantiomer tr = 16.72 min. 
Oil; []D20 = -30.34 (c 1.0, CHCl3, 60% ee); 1H NMR (300 MHz, CDCl3) δ 7.37 – 
7.27 (m, 4H), 7.24 – 7.15 (m, 4H), 7.00 (dd, J = 8.2, 1.1 Hz, 1H), 5.64 (d, J = 8.2 Hz, 1H), 4.64 (d, 8.3 Hz, 
1H), 2.88 (t, J = 7.3 Hz, 2H), 2.61 (td, J = 7.2, 2.2 Hz, 2H); 13C NMR (75.5 MHz, CDCl3) δ 150.4 (C), 139.9 
(C), 130.1 (C), 128.5 (CH), 127.6 (CH), 126.6 (CH), 125.4 (CH), 119.9 (C), 118.5 (CH), 88.1 (C), 74.9 (C), 
49.9 (CH), 34.4 (CH2), 20.7 (CH2) HRMS (ESI) m/z: 312.0689 [M - H]-, C17H14NO3S requires 312.0694. 
(S)-6-Methyl-4-(4-phenylbut-1-yn-1-yl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3bi) 
The enantiomeric excess (65%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 16.53 min, minor 
enantiomer tr = 19.80 min. 
Solid; mp 83-85 °C; []D20 = -55.94 (c 1.0, CHCl3, 65% ee); 1H NMR  (300 MHz, 
CDCl3) δ 7.35 – 7.29 (m, 2H), 7.27 – 7.21 (m, 3H), 7.15 – 7.11 (m, 2H), 6.89 (d, J = 9 Hz, 1H), 5.60 (d, J = 
9.9 Hz, 1H), 4.57 (d, J = 10 Hz, 1H), 2.88 (t, J = 7.3 Hz, 2H), 2.61 (dt, J = 6.9, 2.4 Hz, 2H), 2.32 (s, 3H); 13C 
NMR (75.5 MHz, CDCl3) δ 148.3 (C), 140.0 (C), 135.3 (C), 130.7 (CH), 128.5 (CH), 127.7 (CH), 126.6 (CH), 
119.4 (C), 118.3 (C), 87.9 (C), 75.0 (C), 49.9 (CH), 34.4 (CH2), 20.81 (CH2), 20.8 (C); HRMS (ESI) m/z: 
345.1262 [M + NH4]+, C18 h21N2O3S requires 345.1273. 
(S)-4-(3,3-Dimethylbut-1-yn-1-yl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ak) 
The enantiomeric excess (79%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 4.98 min, minor enantiomer 
tr = 5.31 min.  
Oil; []D20 = -58.46 (c 1.0, CHCl3, 79% ee); 1H NMR  (300 MHz, CDCl3) δ 7.49 (dt, J = 
7.7, 1.6 Hz, 1H), 7.39 – 7.33 (m, 1H), 7.24 (dt, J = 7.5, 1.4 Hz, 1H), 7.01 (dd, J = 8.2, 1.2 Hz, 1H), 5.68 (d, 
J = 10.2 Hz, 1H), 4.67 (d, J = 10.1 Hz, 1H), 1.28 (s, 9H); 13C NMR (75.5 MHz, CDCl3) δ 150.5 (C), 130.1 
(CH), 127.5 (CH), 125.5 (CH), 120.3 (C), 118.5 (CH), 97.2 (C), 72.4 (C), 49.9 (CH), 30.6 (CH3), 27.6 (C); 
HRMS (ESI) m/z: 264.0693 [M - H]-, C13H15NO3S requires 264.0694. 
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(S)-4-(3,3-Dimethylbut-1-yn-1-yl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3bk) 
The enantiomeric excess (86%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 4.70 min, minor enantiomer 
tr = 5.33 min. 
Solid; mp 103-105 °C; []D20 = -93.85 (c 1.0, CHCl3, 86% ee); 1H NMR  (300 MHz, 
CDCl3) δ 7.27 – 7.25 (m, 1H), 7.14 – 7.12 (m, 1H), 6.90 (d, J = 8.4 Hz, 1H), 5.63 (d, J = 10.2 Hz, 1H), 4.81 
(d, J = 10.2 Hz, 1H), 2.36 (s, 3H), 1.28 (s, 9H); 13C NMR (75.5 MHz, CDCl3) δ 148.4 (C), 135.3 (C), 130.7 
(CH), 127.9 (CH), 119.8 (C), 118.2 (CH), 97.0 (C), 72.6 (C), 49.8 (CH), 30.6 (CH3), 27.6 (C), 20.9 (CH3); 
HRMS (ESI) m/z: 278.0842 [M - H]-, C14H16NO3S requires 278.0851. 
(S)-4-(Cyclopropylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3al) 
The enantiomeric excess (74%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 9.49 min, minor enantiomer 
tr = 11.12min. 
Solid; mp 84-86 °C; []D20 = -57.19 (c 1.0, CHCl3, 74% ee); 1H NMR  (300 MHz, CDCl3) 
δ 7.50 (dt, J = 7.7, 1.2 Hz, 1H), 7.38 – 7.32 (m, 1H), 7.23 (td, J = 7.6, 1.4 Hz, 1H), 5.64 (d, J = 10.0 Hz, 
1H), 4.70 (d, J = 9.9 Hz, 1H), 1.36 – 1.28 (m, 1H), 0.90 – 0.83 (m, 2H), 0.79 – 0.74 (m, 2H); 13C NMR (75.5 
MHz, CDCl3) δ 150.5 (C), 130.1 (CH), 127.6 (CH), 125.4 (CH), 120.1 (C), 118.5 (CH), 92.1 (C), 68.9 (C), 
50.0 (CH), 8.5 (CH2), 8.4 (CH2), 0.7 (CH); HRMS (ESI) m/z: 248.0374 [M - H]-, C12H10NO3S requires 
248.0381. 
(S)-4-(Cyclopropylethynyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3bl) 
The enantiomeric excess (78%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 10.76 min, minor enantiomer 
tr = 9.49 min. 
Oil; []D20 = -83.56 (c 1.0, CHCl3, 78% ee). 1H NMR  (300 MHz, CDCl3) δ 7.26 (br s, 
1H), 7.15 – 7.12 (m, 1H), 6.89 (d, J = 8.4 Hz, 1H), 5.59 (d, J = 9.9 Hz, 1H), 4.65 (d, J = 
9.0 Hz, 1H), 2.36 (s, 3H), 1.36 – 1.31 (m, 1H), 0.90-0.8 (m, 2H), 0.80 - 0.74 (m, 2H); 13C NMR (75.5 MHz, 
CDCl3) δ 148.4 (C), 135.3 (C), 130.7 (CH), 127.7 (CH), 119.6 (C), 118.3 (CH), 91.9 (C), 69.1 (C), 50.0 (CH), 
20.81 (CH3), 8.5 (CH2), 8.4 (CH2), 0.6 (CH); HRMS (ESI) m/z: 262.0523 [M - H]-, C13H12NO3S requires 
262.0538. 
2.5.4. Synthetic procedures and characterization data for compounds 6 and 7 
(S)-4-Phenethyl-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (6) 
A solution of 3aa (23.1 mg, 0.081 mmol) in absolute EtOH (7.5 mL) was stirred under H2 in the 
presence of Pd/CaCO3 (5%) (10.5 mg) during 1 h. Afterwards, the mixture was filtered over silica gel 
using EtOAc as eluent, and the solvent was removed under reduced pressure. Purification by flash 
chromatography on silica gel afforded compound 6 (23 mg, 98%).  
The enantiomeric excess (80%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 10.55 min, minor 
enantiomer tr = 9.01 min. 
Oil; []D20 = –33.7 (c 1.0, CHCl3, 80% ee); 1H NMR (300 MHz, CDCl3) δ 7.36 (m, 3H), 
7.26-7.23 (m, 3H), 7.18-7.16 (m, 2H), 7.02-6.99 (m, 1H), 4.73-4.64 (m, 2H), 2.97 (ddd, J = 13.5, 7.6, 5.7 
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Hz, 1H), 2.81 (dt, J = 13.9, 8.3 Hz, 1H), 2.42-2.34 (m, 2H); 13C NMR (75,5 MHz, CDCl3) δ 151.18 (C), 140.3 
(C), 129.4 (CH), 128.8 (CH), 128.5 (CH), 126.5 (CH), 126.3 (CH), 125.3 (CH), 122.5 (C), 118.9 (CH), 56.6 
(CH), 35.6 (CH), 31.3 (CH); HRMS (ESI) m/z: 307.1113 [M + NH4]+, C15H19N2O3S requires 307.1116. 
tert-Butyl (S)-(1-(2-hydroxyphenyl)-3-phenylpropyl)carbamate (7) 
To a solution of the cyclic sulfamidate 6 (0.08 mmol, 23 mg) in THF (1 mL), LiAlH4 (1.0 M in 
THF, 3.3 equivalents, 0.264 mmol, 0.26 mL) was added dropwise at rt over 4 min.42 The mixture was 
heated to 60 °C for 2.5 hours, allowed to cool down to rt, and then cooled with an ice bath. The 
reaction was quenched with EtOAc (1 mL), followed by the addition of EtOH (1 mL) and H2O (1 mL). To 
the resulting turbid mixture Boc2O (3 equivalents, 52 mg, 0.24 mmol) was added in one portion and 
the resulting mixture was stirred at rt for 1 hour. The mixture was diluted with EtOAc (15 mL) and 
acidified with aqueous 2 M HCl until the aqueous layer became clear. The aqueous layer was then 
separated and extracted with EtOAc (2 x 15 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by flash chromatography afforded 
compound 7. 
The enantiomeric excess (80%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 8.11 min, minor 
enantiomer tr = 10.23 min. 
Solid; mp 111-113 °C []D20 = –31.7 (c 1.0, CHCl3, 80% ee); 1H NMR (300 MHz, CDCl3) δ 8.38 (s, 1H), 
7.31 – 7.25 (m, 2H), 7.20 (t, J = 7.3 Hz, 1H), 7.20 – 7.13 (m, 4H), 6.95 – 6.91 (m, 1H), 6.88 (td, J = 7.5, 
1.3 Hz, 1H), 5.02 (s, 1H), 4.81 (s, 1H), 2.77 – 2.60 (m, 2H), 2.26 – 2.16 (m, 2H), 1.44 (s, 9H); 13C NMR 
(75,5 MHz, CDCl3) δ 157.4 8 (C), 156.1 (C), 141.1 (C), 128.9 (CH), 128.5 (CH), 128.4 (CH), 126.1 (C), 120.3 
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In the previoius chapter we described the enantioselctive addition of terminal alkynes to cyclic 
imines derived from benzoxathiazine 2,2-dioxide using (R)-VAPOL as ligand and Me2Zn. Good results 
were obtained in terms of enantiomeric excesses. However, VAPOL is a very expensive ligand and the 
enantiomeric excesses show still room for improvement. With this in mind, we decided to focus our 
attention on the development of a superior methodology for the synthesis of chiral propargylic 
sulfamidates, using aminoalcohols as ligands in the addition reaction of terminal alkynes to these cyclic 
imines.  
Chiral aminolalcohols have aready been used as ligands in various enantioselective 
alkynylation reactions of aldehydes. For example, in 2011 Guo and collaborators described the 
enantioselective addition of trimethylsilylacetylene to aldehydes catalyzed by zinc and a prolinol 
derivative.1 The researchers synthesized a series of ligands, obtained by the introduction of (S)- or (R)-
prolinol in the side chain of a chiral cyclopropane backbone. To induce more steric effect, the hydroxyl 
group in prolinol was protected with a voluminous group (tert-butyldimethylsilyl). Excellent results 
were obtained, both in yield (40-88%) and in enantiomeric excess (63-97%), in the enantioselective 
addition of trimethylsilylacetylene to various aromatic and alkyl aldehydes (only 10 mol % of ligand 
was needed in the reaction with aromatic aldehydes) (Scheme 3.1).  
 
Scheme 3.1. Enantioselective addition of trimethylsilylacetylene to aldehydes catalyzed by zinc and a prolinol 
derivative. 
Another example of the use of chiral aminoalcohols as ligands in the enantioselective 
alkynylation of aldehydes was described in 2011 by Kojima and collaborators as they performed an 
enantioselective addition of ethyl propiolate to different aromatic and alkyl aldehydes (Scheme 3.2).2 
The researchers used a diarylprolinol (30 mol %), derivated from L-prolinol, and Et2Zn to form the 
catalytic system. The corresponding products were obtained with low to good yields (32-84%) and 




Scheme 3.2. Enantioselective addition of ethyl propiolate to different aromatic and alkyl aldehydes. 
Chiral aminoalchols have been used as well in the enantioselective alkynylation of ketones, as 
for example in the work of Jiang and collaborators.3 The researchers report the use of a chiral 
aminoalcohol in the enantioselective addition of zinc alkynylide to α-ketoesters for the synthesis of α-
hydroxy-β-ynyl esters (Scheme 3.3). The reaction is catalyzed by a chiral aminoalcohol (0.22 mol %) 
and Zn(OTf)2 (0.2 equiv). The corresponding α-hydroxy-β-ynyl esters (derived from both aromatic and 
alkyl ketones) were obtained with low to good yields (11-95%) and good to excellent 
enantioselectivities (73-94% ee). 
 
Scheme 3.3. Enantioselective addition of zinc alkynylide to α-ketoesters. 
 In 2013, Malek and collaborators described another exemple of the use of chiral 
aminoalcohols in the alkynylation of ketones. They described an enantioselective alkynylation of acyl 
silanes, promoted by a ProPhenol type ligand and Et2Zn.4 The corresponding products were obtained 
with good yields (70-90%) and enantiomeric ratios (98:02 er) (Scheme 3.4). The obtained products 
undergo in a one-pot process a later Brook type rearrangement and an ene-allene cyclization, leading 





Scheme 3.4. Enantioselective alkynylation of acyl silanes, promoted by a ProPhenol type ligand and Et2Zn. 
 Finally, there are also examples of the use of chiral aminoalcohols in the enantioselective 
alkynylation of imines. In 2007, Bolm and and collaborators described a three component synthesis of 
propargylic amines using Me2Zn with various aldehydes and o-methoxyaniline.5 The researchers 
develop the enantioselective version of the reaction, using a (1R, 2S)-norepinephrine derivative as 
chiral inducer (Scheme 3.5). Aromatic, heteroaromatic and α-substituted aliphatic aldehydes, o-
methoxyaniline and phenylacetylene were used to obtain the corresponding propargylic amines in 
moderate to good yields and with enantioselectivities between 68 and 97%.  
 
Scheme 3.5. One-pot enantioselective synthesis of propargylic amines using a (1R, 2S)-norepinephrine 
derivative as chiral inducer. 
A last example of the use of chiral aminoalcohols in the enantioselective alkynylation of imines 
is given by Wang and collaborators.6 They described the enantioselective nucleophilic addition of 
trimethylsilylacetylene to N-phosphinoylimines promoted by a proline derived β-amino alcohol. 
Different aryl, heteroaryl and alkyl imines were tested and moderate to good yields (66-92%) and 





Scheme 3.6. Enantioselective addition of trimethylsilylacetylene to N-(diphenylphosphinoyl)imines promoted 
by a proline derived β-amino alcohol ligand.  
As demonstrated, chiral aminoalcohols have proven to be good chiral inducers in alkynylation 
reactions. However, to our knowledge, they have never been used in the enantioselective alkynylation 
of benzoxathiazine 2,2-dioxides. In this chapter we opted for the use of diarylprolinols in the 
enantioselective alkynylation reaction we have developed in the previous chapter, because this kind 






El objetivo general de este capítulo es el desarrollo de una metodología superior para la 
adición de alquinos terminales a aldiminas cíclicas derivadas de salicilaldehidos (2,2-dióxido 
benzoxatiazinas) que transcurra con mejores excesos enantiomericos.   
 
En el estudio de este segundo proyecto se considerarán los siguientes aspectos:  
1. Influencia de la estructura de diversos ligandos de tipo diarilprolinol (L9–L12) sobre el rendimiento 
y la enantioselectividad de la reacción.  
 
2. Influencia de la naturaleza del reactivo de dialquilzinc utilizado (Me2Zn y Et2Zn), número de 
equivalentes de dialquilzinc, disolvente y temperatura de reacción.  
3. Evaluación de diversas aldiminas cíclicas del tipo 2,2-dióxido benzoxatiazina con diferente 
naturaleza electrónica y estérica en la reacción de alquinilación con fenilacetileno.  
 
4. Evaluación de la aldimina cíclica base del tipo 2,2-dióxido benzoxatiazina en la reacción con 







3.3. RESULTADOS Y DISCUSIÓN  
3.3.1. Síntesis de 2,2-dióxido benzoxatiazinas 
 Con la idea de ampliar el estudio sobre el alcance y limitaciones de la reacción con relación al 
trabajo anterior, se sintetizaron algunas iminas más (Tabla 3.1). Estas iminas se sintetizaron utilizando 
el mismo procedimiento descrito anteriormente (apartado 2.3.1).  
Tabla 3.1. Síntesis de 2,2-dióxido benzoxatiazinas. 
 
Entrada 4 R t (h) 1 R (%)a 
1 4d 6-OMe 18 1d 67 
2 4h 5-OMe 18 1h 59 
3 4i 6,8-tBu 18 1i 71 
4 4j 2-naftil 18 1j 57 
5 4k 6-NO2 18 1k 9 
a Rendimiento después de purificación por cromatografía de columna. 
 Además, se sintetizaron tres tipos de cetiminas con el esqueleto de 2,2-dióxido 
benzoxatiazina. La primera cetimina de tipo 2,2-dióxido benzoxatiazina que se sintetizó fue una 
cetimina con un grupo metilo 9 (R = H) (Esquema 3.7). La imina se sintetizó a partir de 2-
hidroxiacetofenona 8 (R = H) y clorosulfonilamina  5, preparada in situ a partir de isocianato de 
clorosulfonilo, a temperatura elevada (70 °C) en presencia de hidruro sódico utilizando como 
disolvente DMA.   
 
Esquema 3.7. Síntesis de una cetimina de tipo 2,2-dióxido benzoxatiazina con un grupo metilo. 
Tambien se sintetizaron dos cetiminas activadas con grupos electrón-atrayentes. El primer 
producto que se sintetizó de este tipo fue una cetimina activada con un grupo éster etílico (12, R = H) 
(Esquema 3.8). El primer paso de la síntesis consiste en la reacción entre fenol y clorooxoacetato de 
etilo en la presencia de tetracloruro de titanio a -5 °C, obteniendo el correspondiente producto de 
acilación en orto (11, R = H). Este producto se hizo reaccionar con clorosulfonilamina 5 (preparada in 
situ a partir de isocianato de clorosulfonilo) dando como resultado el producto 12 (R = H) con un 




Esquema 3.8. Síntesis de una cetimina de tipo 2,2-dióxido benzoxatiazina con un grupo éster etílico. 
Además se sintetizó una cetimina con un grupo trifluorometil la cual se obtuvo a partir de 2-
bromofenol (10, R = 2-Br), siguiendo las etapas descritas en el esquema 3.9. Primero se protegió el 
bromofenol con MOMCl, obteniendo el compuesto 13. Mediante un tratamiento con butil-litio, por 
intercambio halógeno-litio, se generó el correspondiente compuesto organolítico que se hizo 
reaccionar con trifluoroacetato de etilo. Por tratamiento ácido del producto resultante se obtuvo el 
compuesto 14. Por último, se hizo reaccionar el compuesto 14 con clorosulfonilamina, preparada in 
situ a partir de isocianato de clorosulfonilo, a temperatura ambiente en DMA, obteniéndose el 
producto 15 con un rendimiento global de 12%. 
 
Esquema 3.9. Síntesis de una cetimina de tipo 2,2-dióxido benzoxatiazina con un grupo trifluorometilo. 
3.3.2. Optimización de las condiciones de la reacción 
  Como referencia para empezar el proceso de optimización de la reacción se elegieron las 
condiciones descritas anteriormente para la alquinilación de las 2,2-dióxido benzoxatiazinas con (R)-
VAPOL. Este procedimiento consiste en la adición de cuatro equivalentes de Me2Zn sobre una 
disolución de ligando (20 mol %), y siete equivalentes de fenilacetileno 2a en tolueno a temperatura 
ambiente. Tras agitar media hora, se añade una disolución de la imina cíclica 1a (1 equiv) en tolueno. 
El producto de alquinilación 3aa se obtuvo con un buen rendimiento (80%) y una enantioselectividad 
moderada de 53% ee cuando se utilizó el ligando L9 [(S)-difenil(pirrolidin-2-il)metanol)]. Con este 
resultado empezamos el proceso de optimización ensayando un conjunto de ligandos de tipo (S)-




Tabla 3.2. Adición enantioselectiva de fenilacetileno (2a) a 2,2-dióxido benzoxatiazina (1a). Evaluación de 
ligandos, reactivos de dialquilzinc, número de equivalentes de dialquilzinc, disolvente, temperatura de reacción 
y número de equivalentes de alquino.a 
 
 
Entrada  Ligando (x mol %) Disolvente T ( °C) R (%)b 3aa:16c ee (%)d 
1 L9 (20) Tolueno ta 80 1:0 53 
2 L10 (20) Tolueno ta 85 1:0 57 
3 L11 (20) Tolueno ta 90 1:0.05 93 
4 L12 (20) Tolueno ta 86 1:0 59 
5 L11 (20) CH2Cl2 ta 84 1:0 87 
6 L11 (20) DCE ta 90 1:0.03 83 
7 L11 (20) Et2O ta 57 1:0.01 93 
8 L11 (20) MTBE ta 70 1:0.08 91 
9e L11 (20) Tolueno ta 72 1:0.3f 87 
10g L11 (20) Tolueno ta 96 1:0.02 93 
11g L11 (20) Tolueno 0 98 1:0.03 96 
12h L11 (20) Tolueno 0 96 1:0.01 97 
13h,i L11 (20) Tolueno 0 97 1:0.03 95 
14h L11 (10) Tolueno 0 87 1:0.05 86 
a 1a (0,100 mmol), 2a (0,700 mmol) Ligando L (x mmol) y 1,2 M Me2Zn en tolueno (0,400 mmol). b Rendimiento 
tras la cromatografía de columna. c Determinado mediante 1H RMN. d Determinado mediante HPLC usando fases 
estacionarias quirales. e Se usó 1 M Et2Zn en hexanos (0,4 mmol).f Se observó el producto de etilación. g Complejo 
de Zn quiral formado a 70 °C durante 0,5 h. h Complejo de Zn quiral formado a 70 °C durante 1 h. i 0,3 mmol de 
Me2Zn. 
 Usando los ligandos L10 o L12 se obtuvo el producto de alquinilación con buen rendimiento, 
pero con un exceso enantiomérico moderado (53-59% ee) similar al obtenido con el ligando L9 (Tabla 
3.2, entradas 2 y 4). Mientras que cuando se utilizó el ligando L11, el producto de alquinilación 3aa se 
obtuvo con una enantioselectividad elevada (93% ee) y un buen rendimiento de 90%. Sin embargo, la 
reacción con el ligando L11 condujo también al producto de alquilación 16, producto de reacción entre 
el Me2Zn y la imina (se pudo observar un 5% de alquilación por 1H RMN) (Tabla 3.2, entrada 3). Aunque 
la cantidad de producto de alquilación no era significativa, decidimos evaluar diferentes disolventes 
con el objetivo de evitar la adición de Me2Zn a la benzoxatiazina 1a.  
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El uso de disolventes clorados, como diclorometano o dicloroetano (Tabla 3.2, entradas 5 y 6) 
dio como resultado una disminución de la cantidad del producto de alquilación 16 pero también a una 
disminución de la enantioselectividad. Por su parte, el uso de disolventes tipo éter como Et2O o MTBE 
(Tabla 3.2, entradas 7 y 8) proporcionó el producto del alquinilación 3aa con una enantioselectividad 
más elevada, pero con un efecto negativo sobre el rendimiento y no evitó la formación del producto 
de alquilación. Por tanto decidimos seguir utilizando el tolueno como disolvente.   
El uso de Et2Zn como reactivo de dialquilzinc (Tabla 3.2, entrada 9) dio como resultado en un 
aumento considerable del producto no deseado de alquilación (1:0.3), debido a la adición directa de 
Et2Zn a la imina 1a. 
Para evitar formación del producto de alquilación 16, decidimos generar el complejo de zinc 
quiral a una temperatura más elevada, obteniendo el producto 3aa con enantioselectividad y 
rendimiento más elevados (Tabla 3.2, entrada 10), pero todavía se pudo observar el producto de 
alquilación no deseado 16 (1:0.02). Al disminuir la temperatura a 0 °C, después de formar el complejo 
de zinc a 70 °C y antes de añadir la imina dio como resultado un incremento de la enantioselectividad 
hasta 96% ee (Tabla 3.2, entrada 11). Cuando la formación del complejo de zinc se realizó calentando 
a 70 °C durante 1 hora y la reacción se llevó a cabo a 0 °C el producto de alquinilación se obtuvo con 
una enantioselectividad elevada (97% ee) y sin disminución de rendimiento (Tabla 3.2, entrada 12). La 
formación del producto de alquilación 16 fue insignificante (menos de 5%).  
Finalmente, la disminución de la cantidad de Me2Zn (Tabla 3.2, entrada 13) o de la cantidad 
de ligando hasta 10 mol % (Tabla 3.2, entrada 14) produjo un descenso en la enantioselectividad de la 
reacción. Por tanto consideramos como óptimas las condiciones mostradas en la entrada 12 de la 
tabla 3.2 en la que el producto 3aa se obtuvo con un rendimiento de 96% y una enantioselectividad 
de 97% ee. 
3.3.3. Alcance y limitaciones de la reacción 
Una vez optimizadas las condiciones de reacción, se procedió a evaluar el alcance y 
limitaciones de la misma.  
3.3.3.1. Evaluación de distintas 2,2-dióxido benzoxatiazinas 
En primer lugar se evaluó la reacción entre fenilacetileno (2a) y varias 2,2-dióxido 
benzoxatiazinas con diferentes sustituyentes (Esquema 3.10). Se puede observar que la reacción 
tolera bien tanto grupos electrón-donantes (3ba-3da) como electrón-aceptores (3ea) en la posición 6 
del anillo aromático obteniéndose los productos correspondientes con rendimientos altos (87-96%) y 
enantioselectividades elevadas (80-96% ee). Un sustituyente electrón-donante (Me) en la posición 8 
del anillo dio un resultado en el producto 3fa con un rendimiento de 85% y una enantioselectividad 
de 94% ee. Sin embargo, la imina cíclica con un grupo metoxi en la posición 5 dio como resultado el 
producto 3ha con rendimiento y enantioseletividad inferiores (76%, 70% ee), seguramente debido a 
un aumento en el impedimiento estérico en la proximidad del átomo de carbono electrofílico. 
Notablemente, la presencia de dos grupos voluminosos (tBu) en posiciones 6 y 8 del anillo aromático, 
dio lugar al producto de adición 3ia con una enantioselectividad excelente del 97% ee. Las condiciones 
de la reacción permitían también el uso de una imina incorporada a un grupo naftilo conduciendo al 




Esquema 3.10. Adición enantioselectiva de fenilacetileno (2a) a 2,2-dióxido benzoxatiazinas con L11/Me2Zn: 1 
(0,100 mmol), 2a (0,700 mmol), 1,2 M Me2Zn en tolueno (0,400 mmol) y L11 (0,020 mmol) en tolueno a 0 °C. 
Rendimiento tras la cromatografía de columna. Exceso enantiomérico determinado mediante HPLC usando fases 
estacionarias quirales. 
Con objeto de ampliar el alcance de la reacción decidimos evaluar diferentes tipos de 
cetiminas cíclicas (Esquema 3.11), para obtener sulfamidatos quirales con un centro estereogénico 
tetrasustituido. Con el sustrato 9 (R = H), una cetimina sustituida con un grupo metilo, no tuvo lugar 
la reacción bajo las condiciones optimizadas. Después se evaluaron dos cetiminas activadas con un 
grupo éster etílico y con un grupo trifluorometilo. La reacción con la cetimina activada con un éster 
(12, R = H), dio lugar al producto resultante 17 (R = H) (después de una posterior N-metilación 
necesaria para llevar a cabo la separación por HPLC) con un rendimiento de 60% y un exceso 
enantiomérico de 22%. La reacción con el sustrato activado por el grupo trifluorometilo (15, R = H), 
condujo al producto 18 (R = H) con un rendimiento de 44% y prácticamente racémico. En este caso 
también fue necesario llevar a cabo la N-metilación del producto, dado que la amina libre no permite 




Esquema 3.11. Adición de fenilacetileno (2a) a cetiminas cíclicas 9, 12, y 15: cetimina (0,100 mmol), 2a (0,700 
mmol), 1,2 M Me2Zn en tolueno (0,400 mmol) y L11 (0,020 mmol) en tolueno a 0 °C. Rendimiento tras la 
cromatografía de columna. Exceso enantiomérico determinado mediante HPLC usando fases estacionarias 
quirales. 
3.3.3.2. Evaluación de distintos alquinos terminales  
Una vez evaluadas diferentes 2,2-dióxido benzoxatiazinas en la reacción de adición del 
fenilacetileno, decidimos estudiar la influencia del alquino terminal en esta reacción. De esta manera 
evaluamos la reacción entre diferentes alquinos terminales 2 con diferente demanda electrónica y 
estérica y la 2,2-dióxido benzoxatiazina 1a (Esquema 3.12). Se puede observar que las características 
electrónicas del anillo aromático del alquino terminal afecta ligeramente la enantioselectividad de la 
reacción. La presencia de un grupo electrón-donante en la posición para del anillo aromático dio lugar 
a la formación del producto 3ab con rendimiento y enantioselectividad excelentes (96% y 97% ee 
respectivamente), de la misma manera que el producto 3ac, formado a partir del alquino 2c sustituido 
con un grupo metoxi en la posición orto del anillo  aromático, que también se obtuvo con una 
enantioselectividad excelente (95% ee). La presencia de un grupo electrón-aceptor (Cl) en la posición 
para, dio lugar al producto 3ae con un exceso enantiomérico un poco inferior (90% ee) pero con 
excelente rendimiento (97%). Un alquino con un átomo de flúor en meta dio como resultado el 
producto 3af con buen rendimiento y un exceso enantiomérico del 91%. También se pudo demostrar 
que alquinos heteroaromáticos dan buenos resultados en esta reacción. Por ejemplo, los productos 
resultantes de la reacción con los alquinos 2g y 2h, alquinos con un grupo tiofeno, se obtuvieron con 
enantioselectividades elevadas de 92-94% ee. Una vez estudiados los efectos de los sustituyentes de 
diferentes alquinos terminales aromáticos decidimos estudiar el comportamiento de los alquinos 
alifáticos (2i-2m). Con los alquinos alifáticos se llevaron a cabo la reacciones a temperatura ambiente 
permitiendo así una mayor conversión. Cuando se utilizaron los alquinos 2i y 2j se obtuvieron los 
correspondientes sulfamidatos propargílicos 3ai y 3aj con excesos enantioméricos inferiores  (80%), 
mientras que la reacción con un alquino con un grupo terc-butilo dio lugar al producto de alquinilación 
3ak con mejor enantioselectividad (88% ee). Se utilizaron también alquinos terminales unidos a un 
sistema cíclico los quales dieron lugar a los correspondientes sulfamidatos quirales 3al y 3am con 
elevados rendimientos y excesos enantioméricos (91% ee). Finalmente, se ensayó un alquino terminal 
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sustituido con un grupo triisopropilsililo (TIPS) 3n, pero no se consiguió un buen resultado; tanto el 
rendimiento (33%) como la enantioselectividad (44% ee) fueron bajos. 
 
Esquema 3.12. Adición enantioselectiva de diferentes alquinos terminales 2 a la 2,2-dióxido benzoxatiazina (1a): 
1a (0,100 mmol), 2 (0,700 mmol), 1,2 M Me2Zn en tolueno (0,400 mmol) y L11 (0,020 mmol) en tolueno a 0 °C. 
Rendimiento tras la cromatografía de columna. Exceso enantiomérico determinado mediante HPLC usando fases 
estacionarias quirales. a 1:0.01 ratio de productos de alquinilación:metilación. b 1:0.03 ratio de productos de 
alquinilación:metilación. c 1:0.04 ratio de productos de alquinilación:metilación. d Reacción a temperatura 
ambiente.e 
3.3.4. Determinación de la configuración absoluta 
La configuración absoluta fue determinada por comparación con compuestos descritos en el 
capítulo anterior. Concretamente, se comparó el signo de la rotación óptica resultando que la 
configuración absoluta del centro estereogénico formado en la reacción es (R). La configuración de los 




3.3.5. Propuesta mecanística para la alquinilación de 2,2-dióxido 
benzoxatiazinas con complejos de (S)-diarilprolinol-Zn 
El esquema 3.13 muestra un posible mecanismo para la reqcción de alquinilación de 2,2-
dióxido benzoxatiazinas con el complejo preparado a partir de Me2Zn y un ligando de tipo 
diarilprolinol. Como se ha estudiado ya en alquilación con Et2Zn y Me2Zn catalizadas por ligandos de 
tipo amino alcohol, se forma en primer lugar un complejo A entre Me2Zn y el ligando L11.7 Este 
complejo de tipo alcóxido de zinc está en equilibrio con el complejo B, un dímero del complejo A. El 
complejo B es más estable, pero no puede participar en la reacción de alquinilación, debido que su 
tamaño impide la coordinación del alquino y el sustrato. El complejo A esta también en equilibrio con 
el complejo C, donde se ha incorporado el zincato-mixto (metilalquinilzinc), formado previamente en 
la reacción de desprotonación del alquino por parte del Me2Zn. Este metilalquiniluro de zinc se 
coordina con el oxígeno del diarilprolinol del complejo A. La siguiente etapa es la incorporación del 
sustrato 1, la 2,2-dióxido benzoxatiazina, al complejo C, mediante la coordinación del átomo de 
nitrógeno de la imina a un átomo de zinc del complejo. La coordinación se produce con el átomo de 
zinc quelado al amino alcohol. La coordinación a este átomo de Zn se debe a su mayor acidez de Lewis, 
precisamente por su quelación con el amino alcohol. La coordinación da lugar a la formación del 
complejo D. En acetiluros de alquilzinc, el grupo alquinil es más reactivo que el grupo alquil. Por este 
motivo tiene lugar una transferencia del acetiluro a la cara Re de la imina cíclica, generando el 
sulfamidato propargílico de zinc E. Después de la disociación del sulfamidato, se obtiene el producto 
final 3 y una nueva molécula del complejo A, que incorpora el metilalquinilzinc generando de nuevo 
el complejo C, completando el ciclo catalítico.     
 
Esquema 3.13. Propuesta mecanística para la alquinilación de 2,2-dióxido benzoxatiazinas con un complejo de 





1. Se ha diseñado un método enantioselectivo de adición de alquinos terminales a aldiminas 
cíclicas de tipo 2,2-dióxido benzoxatiazina catalizada por un sistema formado por un ligando 
del tipo diaril (S)-prolinol y Me2Zn en tolueno a 0 °C.  
2. Se ha estudiado la reacción con diferentes ligandos de tipo diarilprolinol, obteniéndose los 
productos de alquinilación con enantioselectividades moderadas. La reacción con (S)-bis(3,5-
bis(trifluorometil)fenil)(pirrolidin-2-il)metanol (L11) condujo a un exceso enantiomérico 
excelente. 
3. Los sustituyentes sobre el anillo aromático de la aldimina cíclica afectan en cierta manera a la 
enantioselectividad y al rendimiento de la reacción de adición enantioselectiva de 
fenilacetileno. Un sustituyente en la posición 5 conduce a una enantioselectividad moderada, 
mientras que sustituyentes en posiciones 6 y 8 conducen a enantioselectividades elevadas.  
4. Se han ensayado seis alquinos aromáticos con grupos electrón-donantes y electrón-aceptores 
en la reacción con diferentes 2,2-dióxido benzoxatiazina  con rendimientos y 
enantioselectividades elevadas. La reacción con alquinos heteroaromáticos y alifáticos  
también condujo a los productos de alquinilación con enantioselectividades elevadas. 
5. Se ha propuesto un posible mecanismo para la alquinilación de 2,2-dióxido benzoxatiazinas 




3.5. EXPERIMENTAL SECTION 
3.5.1. General experimental methods 
Reactions were carried out under nitrogen in test tubes or round bottom flasks oven-dried 
overnight at 120 °C. Dicloromethane, 1,2-dichloroethane and toluene were distilled from CaH2. THF 
was distilled from sodium benzophenone ketyl. Reactions were monitored by TLC analysis using Merck 
Silica Gel 60 F-254 thin layer plates. Flash column chromatography was performed on Merck silica gel 
60, 0.040-0.063 mm. Melting points were determined in capillary tubes. NMR spectra were run at 300 
MHz for 1H and at 75 MHz for 13C NMR using residual non-deuterated solvent  as internal standard 
(CHCl3: δ  7.26 and 77.0 ppm). Chemical shifts are given in ppm. The carbon type was determined by 
DEPT experiments. High resolution mass spectra (ESI) were recorded on a AB SCIEX Triple TOFTM 
spectrometer equipped with an electrospray source with a capillary voltage of 4.5 kV(ESI). Optical 
rotations were measured using sodium light (D line 589 nm). Chiral HPLC analyses were performed in 
a chromatograph equipped with a UV diode-array detector using chiral stationary columns from 
Daicel. Commercially available alkynes were used as received. 
3.5.2. General synthetic procedure and characterization data for compounds 1 
  Formic acid (20 mmol) was carefully added (dropwise) to chlorosulfonylisocyanate (20 mmol) 
at 0 °C. The mixture was stirred for 2 hours at room temperature to form 5. After 2 hours, the reaction 
was placed at 0 °C and diluted with DMA (15 mL). This solution was then added dropwise to a solution 
of salicylaldehyde 4 (10 mmol) in DMA (15 mL) at 0 °C. After addition, the reaction was placed at room 
temperature and stirred for 18 h. After, the reaction was quenched with 100 mL ice cold water. The 
solution was then extracted with 3 x 50 mL dichloromethane, washed with 3 x 50 mL water and brine 
(50 mL). The organic layer was dried with MgSO4 and concentrated in vacuo. The residue was then 
purified by flash chromatography obtaining product 1. The products previously described in literature, 
are only characterized with 1H and 13C NMR.  
 6-Methoxybenzo[e][1,2,3]oxathiazine 2,2-dioxide (1d)8 
White solid; 111-113 °C; 1H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 7.36-7.26 (m, 2H), 7.14 (d, 
J = 2.8 Hz, 1H), 3.93 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 167.5 (CH), 157.1 (C), 148.1 (C), 
124.4 (CH), 119.8 (CH), 115.7 (C), 113.0 (CH), 56.1 (CH3) ppm.  
 
5-Methoxybenzo[e][1,2,3]oxathiazine 2,2-dioxide (1h)  
White solid; 102-104 °C; 1H NMR (300 MHz, CDCl3) δ 9.01 (d, J = 0.4 Hz, 1H), 7.64 (t, J = 
8.5 Hz, 1H), 6.83 – 6.79 (m, 2H), 3.99 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 164.0 (CH), 
159.7 (C), 155.2 (C), 138.9 (CH), 110.1 (CH), 107.6 (CH), 106.2 (C), 56.6 (CH3) ppm. HRMS 
(ESI) m/z: 214.0173 [M + H]+, C8H8NO4S requires 214.0169. 
6,8-Di-tert-butylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (1i)9 
White solid; 93-96 °C; 1H NMR (300 MHz, CDCl3) δ 8.63 (s, 1H), 7.76 (d, J = 2.4 Hz, 1H), 
7.46 (d, J = 2.4 Hz, 1H), 1.47 (s, 9H), 1.36 (s, 9H) ppm. 13C NMR (75 MHz, CDCl3) δ 168.9 
(CH), 151.1 (C), 148.9 (C), 139.9 (C), 132.7 (CH), 125.43 (CH), 115.8 (C), 35.1 (C), 34.9 (C), 
31.2 (CH3), 29.7 (CH3) ppm. 
70 
 
Naphtho[1,2-e][1,2,3]oxathiazine 3,3-dioxide (1j)10 
White solid; 187-189 °C; 1H NMR (300 MHz, CDCl3) δ 9.43 (s, 1H), 8.30 (d, J = 8.1 Hz, 1H), 
8.23 (d, J = 9.0 Hz, 1H), 8.01 – 7.94 (m, 1H), 7.82 (ddd, J = 8.5, 7.0, 1.4 Hz, 1H), 7.67 (ddd, J = 
8.1, 7.0, 1.1 Hz, 1H), 7.38 (d, J = 9.0 Hz, 1H) ppm. 13C NMR (75 MHz, CDCl3) δ 164.5 (C), 155.7 
(C), 139.6 (CH), 130.7 (CH), 130.6 (C), 129.7 (CH), 127.3 (CH), 120.6 (CH), 117.2 (CH), 109.7 
(C) ppm.  
3.5.3. General synthetic procedure and characterization data for compound 9 
Formic acid (20 mmol) was carefully added (dropwise) to chlorosulfonylisocyanate (20 mmol) 
at 0 °C. The mixture was stirred for 2 hours at room temperature to form 5. After 2 hours, the reaction 
was placed at 0 °C and diluted with DMA (15 mL). This solution was then added dropwise to a solution 
of 2-hydroxyacetophenone 8 (R = H) (10 mmol) in DMA (15 mL) at 0 °C. After addition, the reaction 
was placed at room temperature and in the next hour, NaH (60% in oil, 24 mmol) is added in portions. 
Afterwards, the reaction was stirred for 18 h. Afterwards, the reaction was quenched with 100 mL ice 
cold water. The solution was then extracted with 3 x 50 mL dichloromethane, washed with 3 x 50 mL 
water and brine (50 mL). The organic layer was dried with MgSO4 and concentrated in vacuo. The 
residue was then purified by flash chromatography obtaining product 9 (R = H).  
4-Methylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (9a)11  
White solid; mp 114-116 °C; 1H NMR (300 MHz, CDCl3) δ 7.80 (dd, J = 7.9, 1.4 Hz, 1H), 7.72 
(ddd, J = 8.3, 7.5, 1.6 Hz, 1H), 7.43 – 7.35 (m, 1H), 7.32 – 7.28 (m, 1H), 2.73 (s, 3H) ppm. 
13C NMR (75 MHz, CDCl3) δ 177.2 (C), 137.1 (CH), 128.4 (CH), 125.8 (CH), 119.1 (CH), 116.4 
(C), 23.7 (CH3) ppm. 
3.5.4. Synthetic procedures and characterization data for compound 12 
To a solution of phenol (10, R = H) (10 mmol) in dichloromethane (12 mL) at -5 °C, TiCl4 (11 
mmol) was added. After 5 minutes, ethyl chlorooxoacetate (11 mmol) was added dropwise over 2 
minutes. Th reaction was stirred at -5 °C overnight. After completion, the resulting mixture was diluted 
with dichloromethane (10 mL) and was poured into a previously cooled 1M HCl (50 mL) solution. The 
mixture was further acidified with concentrated HCl (1 mL) and extracted with dichloromethane (3x50 
mL). The organic layer was dried with MgSO4 and concentrated in vacuo. The residue was purified by 
flash chromatography obtaining product 11 (R = H). 
Formic acid (20 mmol) was carefully added (dropwise) to chlorosulfonylisocyanate (20 mmol) 
at 0 °C. The mixture was stirred for 2 hours at room temperature to form 5. After 2 hours, the reaction 
was placed at 0 °C and diluted with DMA (15 mL). This solution was then added dropwise to a solution 
of product 11 (R = H) (10 mmol) in DMA (15 mL) at 0 °C. After the addition, the reaction was placed at 
room temperature and stirred for 18 h. After, the reaction was quenched with 100 mL ice cold water. 
The solution was then extracted with 3 x 50 mL dichloromethane, washed with 3 x 50 mL water and 
brine (50 mL). The organic layer was dried with MgSO4 and concentrated in vacuo. The residue purified 
by flash chromatography obtaining product 12 (R = H).  
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Ethyl benzo[e][1,2,3]oxathiazine-4-carboxylate 2,2-dioxide (12)12  
Oil; 1H NMR (300 MHz, CDCl3) δ 8.00 (dd, J = 8.0, 1.6 Hz, 1H), 7.79 (ddd, J = 8.4, 7.5, 
1.6 Hz, 1H), 7.46 – 7.40 (m, 1H), 7.35 (dd, J = 8.4, 1.1 Hz, 1H), 4.53 (q, J = 7.1 Hz, 2H), 
1.46 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.1 (C), 160.8 (C), 154.8 (C), 138.1 
(CH), 130.2 (CH), 126.3 (CH), 119.2 (CH), 113.6 (C), 64.0 (CH2), 14.0 (CH3). 
3.5.5. Synthetic Procedures and characterization data for compound 15 
To a solution of NaH (60% in oil, 30 mmol) in THF (10 mL) at 0 °C, 2-bromophenol (10, R = 2-
Br) (20 mmol) dissolved in THF (20 mL) was added.13 The reaction was stired at 0 °C for 1 hour. MOMCl 
was added after 1 hour at 0 °C. The reaction was then stirred overnight at room temperature. The 
reaction was quenched with saturated NH4Cl, extracted with Et2O (3x30 mL) and the organic phase 
was dried over Na2SO4. To the crude product 13 (20 mmol), dissolved in THF (50 mL) at -78 °C, nBuLi 
(24 mmol) was added dropwise. After 1 hour CF3COOEt was added at -78 °C. After 1.5 hours, the 
reaction was quenched with saturated NH4Cl, extracted with Et2O (3x50 mL), washed with brine and 
the organic phase was dried with Na2SO4. The crude product was then dissolved in 50 mL CH2Cl2 and 
TFA (100 mmol) was added. This solution was stirred for 18 hours. Afterwards, the reaction was 
washed with 3x30 mL 1M KH2PO4/NaOH pH7 buffer and brine (50 mL). The organic phase was then 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography, obtaining product 14. 
Formic acid (20 mmol) was carefully added (dropwise) to chlorosulfonylisocyanate (20 mmol) 
at 0 °C. The mixture was stirred for 2 hours at room temperature to form 5. After, the reaction was 
placed at 0 °C and diluted with DMA (15 mL). This solution was then added dropwise to a solution of 
product 14 (10 mmol) in DMA (15 mL) at 0 °C. After addition, the reaction was placed at room 
temperature and stirred for 18 h. After, the reaction was quenched with 100 mL ice cold water. The 
solution was then extracted with 3 x 50 mL dichloromethane, washed with 3 x 50 mL water and brine 
(50 mL). The organic layer was dried with MgSO4 and concentrated in vacuo. The residue was purified 
by flash chromatography obtaining product 15.  
4-(Trifluoromethyl)benzo[e][1,2,3]oxathiazine 2,2-dioxide (15)13  
Oil; 1H NMR (300 MHz, CDCl3) δ 7.95 (dp, J = 8.1, 1.8 Hz, 1H), 7.86 (ddd, J = 8.3, 7.4, 1.5 
Hz, 1H), 7.51 (ddd, J = 8.0, 7.6, 1.1 Hz, 1H), 7.43 (dd, J = 8.4, 1.1 Hz, 1H) ppm. 13C NMR 
(75 MHz, CDCl3) δ 162.1 (q, JC-F = 37.6 Hz, C), 155.1 (C), 138.8 (CH), 128.5 (q, JC-F = 3.2 Hz, 
CH), 126.7 (CH), 119.6 (CH), 118.3 (q, JC-F = 281.4 Hz, C), 111.7 (C). 
3.5.6. General synthetic procedures and characterization data for compounds 3, 
17 and 18 
General procedure for the enantioselective alkynylation reaction: A 1.2 M Me2Zn solution in 
toluene (0.400 mmol) was added dropwise to a solution of L11 (0.020 mmol) and alkyne 2 (0.700 
mmol) in toluene (0.3 mL) and was heated to 70 °C under nitrogen atmosphere. After stirring for 1 
hour, the reaction mixture was cooled to 0 °C and a solution of benzoxathiazine 2,2-dioxide 1 (0.100 
mmol) in toluene (1.0 mL) was added via syringe at 0 °C. The reaction was stirred at this temperature 
until TLC analysis indicated full conversion of the starting material. The reaction was quenched with 
NH4Cl (10 mL), extracted with dichloromethane (3x15 mL), washed with brine (10 mL) and dried over 
MgSO4. After the solvent was removed under reduced pressure, purification by flash chromatography 
on silica gel affording compound 3. 
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General procedure for the non-enantioselective alkynylation reaction: A 1.2 M Me2Zn 
solution in toluene (0.300 mmol) was added dropwise to a solution of racemic BINOL (0.020 mmol) 
and alkyne 2 (0.700 mmol) in toluene (0.4 mL) at room temperature under nitrogen atmosphere. After 
stirring for 1 hour, a solution of benzoxathiazine 2,2-dioxide 1 (0.100 mmol) in toluene (1.0 mL) was 
added via syringe. The reaction was stirred until TLC analysis indicated full conversion of the starting 
material. The reaction was quenched with NH4Cl (10 mL), extracted with dichloromethane (3x15 mL), 
washed with brine (10 mL) and dried over MgSO4. The solvent was removed under reduced pressure. 
Purification by flash chromatography on silica gel affording racemic compound 3. 
The products described in the previous chapter are not fully characterized again. 
 (R)-4-(Phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3aa) 
The enantiomeric excess (97%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 22.57 min, minor 
enantiomer tr = 14.77 min. Oil; []D
20 = +46.1 (c 1.0, CHCl3, 97% ee). 
 
(R)-6-Methyl-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ba) 
The enantiomeric excess (80%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 27.09 min, minor 
enantiomer tr = 17.62 min. Oil; []D
20 = +76.6 (c 1.0, CHCl3, 80% ee). 
 
(R)-6-(tert-Butyl)-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ca) 
The enantiomeric excess (96%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 17.73 min, minor 
enantiomer tr = 12.60 min. Oil; []D
20 = +112.9 (c 1.0, CHCl3, 96% ee).  
 
(R)-6-Methoxy-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3da) 
The enantiomeric excess (96%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 32.60 min, minor 
enantiomer tr = 21.05 min. 
Oil; []D
20 = +125.5 (c 1.0, CHCl3, 96% ee); 1H NMR (300 MHz, CDCl3) δ 7.52 – 7.46 
(m, 2H), 7.42 – 7.32 (m, 3H), 7.09 (dd, J = 2.9, 0.9 Hz, 1H), 6.98 (d, J = 9.0 Hz, 1H), 
6.90 (ddd, J = 9.0, 2.9, 0.7 Hz, 1H), 5.89 (s, 1H), 4.90 (s, 1H), 3.82 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) 
δ 156.9 (C), 144.3 (C), 132.0 (2 x CH), 129.5 (CH), 128.5 (2 x CH), 121.0 (C), 120.4 (C), 119.6 (CH), 115.8 
(CH), 112.2 (CH), 87.7 (C), 82.3 (C), 55.8 (CH3), 50.3 (CH) ppm. HRMS (ESI) m/z: 316.0651 [M + H]+, 




(R)-6-Bromo-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ea) 
The enantiomeric excess (84%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 13.45 min, minor 
enantiomer tr = 11.57 min. Oil; []D
20 = +119.4 (c 1.0, CHCl3, 84% ee). 
 
 (R)-8-Methyl-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3fa) 
The enantiomeric excess (94%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 22.05 min, minor 
enantiomer tr = 13.09 min. Oil; []D
20 = +6.5 (c 1.0, CHCl3, 94% ee).  
 
(R)-5-Methoxy-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ha) 
The enantiomeric excess (70%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 32.77 min, minor 
enantiomer tr = 18.69 min.  
Oil; []D
20 = +94.0 (c 1.0, CHCl3, 70% ee); 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.38 
(m, 2H), 7.36 – 7.27 (m, 4H), 6.78 (dd, J = 8.4, 0.9 Hz, 1H), 6.69 (dd, J = 8.4, 1.0 Hz, 1H), 5.78 (s, 1H), 
4.99 (s, 1H), 3.93 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 157.1 (C), 151.0 (C), 131.8 (2 x CH), 130.3 
(CH), 128.8 (CH), 128.3 (2 x CH), 122.0 (C), 111.2 (CH), 108.8 (C), 107.9 (CH), 84.9 (C), 83.9 (C), 56.2 
(CH3), 47.1 (CH) ppm. HRMS (ESI) m/z: 316.0649 [M + H]+, C16H14NO4S requires 316.0638. 
(R)-6,8-Di-tert-butyl-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ia) 
The enantiomeric excess (97%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 16.61 min, minor 
enantiomer tr = 9.01 min. 
Oil; []D
20 = +61.0 (c 1.0, CHCl3, 97% ee); 1H NMR (300 MHz, CDCl3) δ 7.56 – 
7.47 (m, 3H), 7.43 – 7.33 (m, 4H), 5.89 (d, J = 10.1 Hz, 1H), 4.84 (d, J = 10.1 Hz, 
1H), 1.44 (s, 9H), 1.34 (s, 9H) ppm. 13C NMR (75 MHz, CDCl3) δ 147.8 (C), 147.6 (C), 139.2 (C), 131.9 (2 
x CH), 129.4 (CH), 128.5 (2 x CH), 125.0 (CH), 122.1 (CH), 121.3 (C), 120.3 (C), 87.7 (C), 82.9 (C), 50.4 
(CH), 35.2 (C), 34.8 (C), 31.3 (3 x CH3), 30.1 (3 x CH3) ppm. HRMS (ESI) m/z: 398.1800 [M + H]+, 
C23H28NO3S requires 398.1784. 
(R)-1-(Phenylethynyl)-1,2-dihydronaphtho[1,2-e][1,2,3]oxathiazine 3,3-dioxide (3ja) 
The enantiomeric excess (86%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 32.14 min, minor 
enantiomer tr = 18.95 min. 
Oil; []D
20 = +191.8 (c 1.0, CHCl3, 86% ee); 1H NMR (300 MHz, CDCl3) δ 8.27 – 8.20 
(m, 1H), 7.89 (d, J = 9.1 Hz, 2H), 7.64 (ddd, J = 8.5, 6.8, 1.5 Hz, 1H), 7.55 (ddd, J = 
8.1, 6.9, 1.2 Hz, 1H), 7.41 – 7.34 (m, 2H), 7.33 – 7.23 (m, 3H), 7.18 (d, J = 9.1 Hz, 1H), 6.23 (s, 1H), 5.30 
(s, 1H) ppm. 13C NMR (75 MHz, CDCl3) δ 148.4 (C), 131.8 (2 x CH), 131.5 (CH), 131.4 (C), 129.8 (CH), 
129.2 (CH), 129.0 (CH), 128.3 (2 x CH), 127.7 (CH), 126.0 (CH), 123.5 (CH), 121.4 (C), 118.6 (CH), 112.6 




(R)-4-((4-Methoxyphenyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ab) 
The enantiomeric excess (97%) was determined by chiral HPLC (Chiralpak 
IC), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 35.21 min, minor 
enantiomer tr = 26.54 min. Oil; []D
20 = +28.0 (c 1.0, CHCl3, 97% ee).  
 
(R)-4-((4-Chloroyphenyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ae) 
The enantiomeric excess (90%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 19.61 min, minor 
enantiomer tr = 13.48 min. Mp 93 °C; []D
20 = +29.0 (c 1.0, CHCl3, 90% ee). 
 
(R)-4-((4-Fluorophenyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3af) 
The enantiomeric excess (91%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 19.62 min, minor 
enantiomer tr = 12.44 min. 
Oil; []D
20 = +41.6 (c 1.0, CHCl3, 91% ee); 1H NMR (300 MHz, CDCl3) δ 7.60 – 7.55 
(m, 1H), 7.40 (dddd, J = 8.2, 7.4, 1.7, 0.8 Hz, 1H), 7.36 – 7.24 (m, 3H), 7.22 – 7.16 (m, 1H), 7.15 – 7.07 
(m, 1H), 7.06 (dd, J = 8.2, 1.2 Hz, 1H), 5.94 (d, J = 9.3 Hz, 1H), 4.94 (d, J = 9.3 Hz, 1H) ppm. 13C NMR (75 
MHz, CDCl3) δ 162.3 (d, J = 247.5 Hz, C), 150.6 (C), 130.5 (CH), 130.2 (d, J = 8.6 Hz, CH), 127.9 (d, J = 3.2 
Hz, CH), 127.5 (CH), 125.7 (CH), 122.8 (d, J = 9.5 Hz, C), 119.3 (C), 118.8 (CH, d, J = 23.2 Hz), 118.8 (CH), 
117.0 (CH, d, J = 21.1 Hz), 86.4 (d, J = 3.5 Hz, C), 83.3 (C), 50.1 (CH) ppm. HRMS (ESI) m/z: 304.3010 [M 
+ H]+, C15H11FNO3S requires 304.0438.  
(R)-4-((2-Methoxyphenyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ac) 
The enantiomeric excess (95%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 34.63 min, minor 
enantiomer tr = 22.80 min. mp 103-105 °C; []D
20 = +31.2 (c 1.0, CHCl3, 95% ee). 
 
(R)-4-(Thiophen-2-ylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ag) 
The enantiomeric excess (94%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 23.13 min, minor 
enantiomer tr = 16.82 min. Oil; []D
20 = +43.6 (c 1.0, CHCl3, 94% ee).  
 
(R)-4-(Thiophen-3-ylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ah) 
The enantiomeric excess (92%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 24.90 min, minor 
enantiomer tr = 17.25 min. 
Oil; []D
20 = +46.1 (c 1.0, CHCl3, 92% ee); 1H NMR (300 MHz, CDCl3) δ 7.62 – 7.55 
(m, 2H), 7.39 (dddd, J = 8.2, 7.4, 1.7, 0.8 Hz, 1H), 7.32 (dd, J = 5.0, 3.0 Hz, 1H), 7.26 (td, J = 7.6, 1.2 Hz, 
1H), 7.16 (dd, J = 5.0, 1.2 Hz, 1H), 7.04 (dd, J = 8.2, 1.2 Hz, 1H), 5.92 (d, J = 7.9 Hz, 1H), 4.94 (d, J = 8.0 
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Hz, 1H) ppm. 13C NMR (75 MHz, CDCl3) δ 150.5 (C), 130.7 (CH), 130.4 (CH), 129.8 (CH), 127.6 (CH), 
125.9 (CH), 125.6 (CH), 120.1 (C), 119.5 (C), 118.7 (CH), 83.0 (C), 82.1 (C), 50.3 (CH) ppm. HRMS (ESI) 
m/z: 292.0107 [M + H]+, C13H10NO3S2 requires 292.0097.  
(R)-4-(4-Phenylbut-1-yn-1-yl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ai) 
The enantiomeric excess (78%) was determined by chiral HPLC (Chiralpak 
ADH), hexane-iPrOH 95:05, 1 mL/min, major enantiomer tr = 24.64 min, 
minor enantiomer tr = 26.71 min. Oil; []D
20 = +31.0 (c 1.0, CHCl3, 78% ee). 
 
(R)-4-(Hex-1-yn-1-yl)-4H-benzo[e][1,2,3]oxathiazin-3-ide 2,2-dioxide (3aj) 
The enantiomeric excess (80%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 95:05, 1 mL/min, major enantiomer tr = 20.09 min, minor 
enantiomer tr = 17.12 min. 
Oil; []D
20 = +58.2 (c 1.0, CHCl3, 80% ee); 1H NMR (300 MHz, CDCl3) δ 7.53 – 7.49 
(m, 1H), 7.36 (dddd, J = 8.2, 7.4, 1.7, 0.8 Hz, 1H), 7.27 – 7.19 (m, 1H), 7.01 (dd, J = 8.2, 1.2 Hz, 1H), 5.73 
– 5.64 (m, 1H), 4.71 (d, J = 10.0 Hz, 1H), 2.30 (td, J = 7.0, 2.3 Hz, 2H), 1.61 – 1.49 (m, 3H), 1.48 – 1.35 
(m, 2H), 0.93 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 150.5 (C), 130.1 (CH), 127.6 (CH), 125.4 
(CH), 120.2 (C), 118.5 (CH), 89.1 (C), 73.9 (C), 50.00 (CH), 30.3 (CH2), 21.9 (CH2), 18.3 (CH2), 13.5 (CH3) 
ppm. HRMS (ESI) m/z: 266.0848 [M + H]+, C13H16NO3S requires 266.0845.  
(R)-4-(3,3-Dimethylbut-1-yn-1-yl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ak) 
The enantiomeric excess (88%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 4.90 min, minor enantiomer 
tr = 5.37 min. Oil; []D
20 = +71.9 (c 1.0, CHCl3, 88% ee). 
 
(R)-4-(Cyclopropylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3al) 
The enantiomeric excess (91%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 9.77 min, minor enantiomer 
tr = 11.17 min. mp 84-86 °C; []D
20 = +55.7 (c 1.0, CHCl3, 91% ee). 
 
(R)-4-(Cyclopentylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3am) 
The enantiomeric excess (91%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 95:05, 1 mL/min, major enantiomer tr = 21.96 min, minor 
enantiomer tr = 17.32 min. 
Oil; []D
20 = +62.0 (c 1.0, CHCl3, 91% ee); 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.40 
(m, 1H), 7.28 (dddd, J = 8.2, 7.4, 1.7, 0.8 Hz, 1H), 7.20 – 7.12 (m, 1H), 6.93 (dd, J = 8.2, 1.2 Hz, 1H), 5.65 
– 5.55 (m, 1H), 4.65 (d, J = 10.0 Hz, 1H), 2.70 – 2.58 (m, 1H), 1.97 – 1.81 (m, 2H), 1.70 – 1.48 (m, 6H) 
ppm. 13C NMR (75 MHz, CDCl3) δ 150.5 (C), 130.1 (CH), 127.6 (CH), 125.4 (CH), 120.3 (C), 118.5 (CH), 
93.4 (C), 73.3 (C), 50.0 (CH), 33.6 (CH2), 33.5 (CH2), 29.9 (CH), 25.0 (CH2) ppm. HRMS (ESI) m/z: 
276.0705 [M - H]-, C14H14NO3S requires  276.0700.  
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(R)-4-((Triisopropylsilyl)ethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3an) 
The enantiomeric excess (44%) was determined by chiral HPLC (Chiralpak ASH), 
hexane-iPrOH 99:01, 1 mL/min, major enantiomer tr = 16.97 min, minor 
enantiomer tr = 11.94 min. 
Oil; []D
20 = +25.1 (c 1.0, CHCl3, 44% ee); 1H NMR (300 MHz, CDCl3) δ 7.59 - 7.51 
(m, 1H), 7.37 (dddd, J = 8.2, 7.4, 7.1, 1.8 Hz, 1H), 7.25 (td, J = 7.6, 1.2 Hz, 1H), 7.03 (dd, J = 8.2, 1.2 Hz, 
1H), 5.76 (d, J = 10.2 Hz, 1H), 4.73 (d, J = 10.0 Hz, 1H), 1.10 – 1.09 (21H) ppm. 13C NMR (75 MHz, CDCl3) 
δ 150.6 (C), 130.3 (CH), 127.5 (CH), 125.5 (CH), 119.5 (C), 118.6 (CH), 99.9 (C), 90.5 (C), 50.33 (CH), 18.5 
(CH3), 11.0 (CH) ppm. HRMS (ESI) m/z: 366.1557 [M + H]+, C18 h28NO3Si requires 366,1553.  
Ethyl 3-methyl-4-(phenylethynyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine-4-carboxylate 2,2-dioxide 
(17) 
Enantioselective alkynylation of product 12 was achieved following the general 
procedure for the enantioselective alkynylation reaction of products 1. 
Methylation of the product was performed after purification of the reaction 
mixture. The purified product was dissolved in MeCN (1 mL), K2CO3 (5 equiv) and 
MeI (5 equiv) were added the reaction was stirred for 1 h. Afterwards, the 
reaction was filtered and the final product 17 was obtained in quantitative yield.   
The enantiomeric excess (22%) was determined by chiral HPLC (Phenomenex Lux® 5µm Amylose-1), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 8.71 min, minor enantiomer tr = 9.24 min. 
Orange oil; []D20 = -3.4 (c 1.0, CHCl3, 22% ee); 1H NMR (300 MHz, CDCl3) δ 7.78 (dd, J = 7.9, 1.7 Hz, 
1H), 7.52 – 7.47 (m, 2H), 7.46 – 7.28 (m, 5H), 7.06 (dd, J = 8.2, 1.3 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 3.25 
(s, 3H), 1.33 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 166.8 (C), 149.2 (C), 132.0 (CH), 131.7 (CH), 
130.8 (CH), 129.8 (CH), 128.5 (CH), 125.4 (CH), 120.7 (C), 118.4 (C), 118.3 (CH), 90.0 (C), 82.2 (C), 69.0 
(C), 63.7 (CH2), 35.4 (CH3), 13.8 (CH3) ppm; HRMS (ESI) m/z: 372.3889 [M + H]+, C19H17NO5S requires 
372.3900. 
 4-(Phenylethynyl)-4-(trifluoromethyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (18) 
Enantioselective alkynylation of product 14 was achieved following the general 
procedure for the enantioselective alkynylation reaction of products 1. 
Methylation of the product was performed after purification of the reaction 
mixture. The purified product was dissolved in MeCN (1 mL), K2CO3 (5 equiv) and 
MeI (5 equiv) were added the reaction was stirred for 1 h. Afterwards, the 
reaction was filtered and the final product 18 was obtained in quantitative yield.   
The enantiomeric excess (2%) was determined by chiral HPLC (Chiralpak ADH), hexane-iPrOH 95:05, 1 
mL/min, major enantiomer tr = 6.46 min, minor enantiomer tr = 6.01 min. 
Orange oil; 1H NMR (300 MHz, CDCl3) δ 7.85 (dp, J = 8.0, 1.3 Hz, 1H), 7.59 – 7.50 (m, 3H), 7.49 – 7.35 
(m, 4H), 7.22 (dd, J = 8.2, 1.2 Hz, 1H), 3.38 (d, J = 0.7 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 149.2 
(C), 132.2 (CH), 132.1 (CH), 130.5 (q, Jc-f = 1.3 Hz, CH), 130.2 (CH), 128.6 (CH), 126.7 (CH), 123.3 (q, Jc-f 
= 288 Hz, C), 120.0 (C), 119.6 (C), 119.4 (CH), 91.7 (C), 78.1 (C), 67.5 (q, Jc-f = 32.5, C), 33.6 (q, Jc-f = 2.2 
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 Additions of organometallic reagents to imines and imine derived compounds such as 
hydrazones and oximes, is an old an well-known reaction.1 However, there are two important 
problems in the addition reactions to imines: the poor electrophilicity of the azomethine carbon and 
the tendency of the imines to undergo deprotonation rather than addition. As already discussed in 
the previous chapter, a method to increase the reactivity of the double C=N bond, is the introduction 
of electron-withdrawing groups on the nitrogen of the imine, which can be made by N-alkylation, N-
oxidation, N-acylation or N-sulfonylation among others. On the other hand, in order to avoid 
deprotonation, less strong basic reagents are used to obtain the alkyl addition products to the 
azomethine carbon. Examples of these reagents are allylboranes, allylboronates, alkylcoppers, alkyl 
cuprates and alkylzincs.  
 So, the catalytic asymmetric addition of organometallic reagents to C=N double bonds of 
imines is an excellent route to obtain optically active amines bearing a stereogenic center at the α-
position (the importance of the synthesis of optically active compounds has already been discussed).2 
The optically active α-branched amines are important building blocks and this type of structure can 
be found in numerous biologically and pharmacologically active compounds, such as 
Methoxyphenamine (a β2-adrenergic antagonist for treatment of asthma) (Figure 4.1, A),3 
Rivastigmine (an acetylcholine esterase inhibitor for treatment of Alzheimer’s disease) (Figure 4.1, B)4 
and Tamsulosin (a selective α1- adrenergic antagonist in the treatment of prostatic hyperplasia) (Figure 
4.1, C).5  
 
Figure 4.1. (A) Methoxyphenamine (B) Rivastigmine (C) Tamsulosin. 
As mentioned before, a possible way to prepare chiral amines is the addition of dialkylzinc 
reagents to imines. However, dialkylzinc reagents are nucleophilic organometallic compounds with 
low reactivity and generally react slowly or not react at all with imines due to the rather nonpolar 
character of the C-Zn bond. There are a few methods to overcome this problem. One method is based 
in the use of transition metal salts inducing transmetalation or complexation, forming functionalized 
dialkylzinc reagents, improving the reactivity of the dialkylzinc towards the imine. Examples of 
transition metals that are often used are copper,2, 6-8 rhodium,9 zirconium10-12 and titanium.13 Another 
method of activation of dialkylzinc reagents is the use of Lewis basic ligands, making the Zn more Lewis 
acidic. This methodology is highly desirable in order to avoid the use of other transition metal salts. 
Next, the most important examples of alkylation of imines with dialkylzinc reagents in the absence of 
other transition metals is described. 
4.1.1. Catalytic enantioselective alkylation of imines with dialkylzinc reagents 
 A striking observation in the catalytic enantioselective alkylation of imines using a dialkylzinc 
reagents is that most of the examples described in absence of other transition metals are performed 
with N-diphenylphosphinoylimines, which can be explained by the stronger electrophilicity of the 
carbon atom of the imine group and the easy removing of the phosphinoyl group to give free amines. 
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In this part, we will limit our discussion to those examples that use substoichiometric amounts of 
ligand. Methods using stoichiometric amounts of ligand are very abundant in the literature.14-17 
4.1.1.1. Catalytic enantioselective alkylation of N-diphenylphosphinoylimines with 
dialkylzinc reagents 
 The first example of a highly enantioselective addition of dialkylzinc reagents to the C=N 
double bonds of imines (N-diphenylphosphinoylimines) using from stoichiometric to catalytic amounts 
of ligand was described by Soai in 1992.18 This group used 0.5-1 equivalents of a chiral β-amino alcohol 
I (Scheme 4.1) to obtain various ethylated, methylated and n- butylated aromatic phosphinoylamines 
in good yields and good to excellent enantioselectivities. The enantioselectivities varied from 84-91% 
ee when a stoichiometric amount of ligand is used to 85-87% ee when 0.5 equivalents of ligand were 
used. Even when the authors used 0.1 equivalents of ligand, the enantioselectivity was still high (75% 
ee), but the yield decreased to only 12%. This article was also the first one that described an alkylation 
reaction of a carbon-nitrogen double bond with an enantiomeric excess higher than 90%. 
   
Scheme 4.1. Catalytic enantioselective alkylation of N-diphenylphosphinoylimines promoted by (1S,2R)-2-
(Dibutylamino)-1-phenylpropan-1-ol. 
 In 2002, the same group described an addition of dialkylzinc reagents to N-
diphenylphosphinoylimines using catalytic amounts of chiral carbosilane dendritic ligands bearing 
aminol alcohol moeities.19 Although these ligands have a flexible backbone and are known to be 
difficult to coordinate with organometallic reagents, this research group achieved interesting results. 
When ligand I (4 chiral sites, 0.25 equivalents) and ligand II (12 chiral sites, 0.083-0.13 equivalents) 
(Figure 4.2) were used in the Et2Zn and iPr2Zn addition reaction  to various aromatic N-
diphenylphosphinoylimines, the corresponding products were obtained in good yields (70-79 %) and 
good to excellent enantiomeric excesses (82-92% ee). Ligand III was also used in the same reaction, 
though the reaction needed 0.5 equivalents of the ligand to obtain good results (71-81%, 86-94% ee).   
 
Figure 4.2. Chiral carbosilane dendritic ligands bearing aminol alcohol moieties. 
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 In 2007, Yus group described the addition of dialkylzinc reagents to N-
diphenylphosphinoylimines catalyzed by β-amino alcohols derived from L-prolinol.20, 21 The 
commercially available N-benzyl-L-prolinol IV (0.5 equivalents) (Figure 4.3) was tested in the Et2Zn 
addition reaction with various substituted imines obtaining the corresponding chiral 
diphenylphosphinoylamines in moderate to good yields (36-86%) and moderate to excellent 
enantiomeric excesses (58-92% ee). The reaction, under the same reaction conditions, was also 
performed with Me2Zn (51%, 90% ee), iPr2Zn (80%, 90% ee) and nBu2Zn (64%, 90% ee). In the same 
article, the authors performed a further screening of ligands of various β-amino alcohols derived from 
L-prolinol, in which ligand V led to a good yield (80%) and an excellent enantioselectivity (94% ee) for 
the reaction between Et2Zn and N-(diphenylphosphinoyl)benzaldimine. 
 
Figure 4.3. β-Aminoalcohols derived from L-prolinol. 
 Recently, in 2015, Uang and collaborators published their efforts on the enantioselective 
addition of dialkylzinc to aromatic aldimines mediated by β-amino alcohols derived from camphor 
(Figure 4.4).22 The reaction conditions (0.6 equivalents of ligand VI, 3 equivalents of Et2Zn at 28 °C in 
toluene/hexane) were used with various aromatic N-diphenylphosphinoylimines, obtaining excellent 
results both in yield (85-97%) as in enantioselectivity (85-98% ee). For the reaction with Me2Zn, 1 
equivalent of ligand was needed to obtain excellent yields (85-86%) and enantioselectivities (97-98% 
ee). The researchers also used different N-monosubstituted amino alcohols VII (0.6 equivalents) and 
all of them gave excellent results (91-99% yield, 91-95% ee). To decrease the number of equivalents 
of chiral ligand in the reaction, they tested various additives in the Et2Zn addition to N-
(diphenylphosphinoyl)benzaldimine. The use of MeOH (1.8 equivalents) and only 0.1 equivalents of 
ligand lead to the reaction product with similar results than when used 0.6 equivalents of ligand. Again, 
they applied the optimized reaction conditions to various imines, using 0.1 equivalents of the phenyl 
substituted ligand VII, for the addition of Et2Zn leading to good results (52-92% yield, 79-92% ee). The 
addition of Me2Zn could also be made with 0.1 equivalents of ligand VII, obtaining the resulting 
product in a yield of 78% and an enantiomeric excess of 93% ee.   
 
Figure 4.4. β-Amino alcohols derived from camphor. 
4.1.1.2. Catalytic enantioselective alkylation of cyclic imines 
 There are only few reports of catalytic enantioselective alkylation of cyclic imines in the 
literature. In 2001, Chrzanowska described an enantioselective addition of organolithium reagents to 
3,4-dihydroisoquinoline.23 On the other hand, Alexakis described the enantioselective addition of  
organolithium reagents to isoquinoline24 in 2002 and to quinoline in 200425 and 2005.26 However, all 
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of the authors use stoichiometric amounts of chiral ligands (Scheme 4.2). However, the catalytic 
enantioselective alkylation of cyclic imines with dialkylzinc reagents is, to the best of our knowledge, 
not described in the literature. 
 
Scheme 4.2. Enantioselective alkylation of cyclic imines. 
4.1.2. Catalytic enantioselective reactions of dibenzo[b,f][1,4]oxazepines  
As we have mentioned, the enantioselective addition of dialkylzinc reagents to cyclic imines 
has not been described in the literature except in the case of quinoline and isoquinoline. 
Consequently, we thought in the use of seven membered cyclic imines (dibenzo[b,f][1,4]oxazepines) 
as electrophiles.  
The dibenzo[b,f][1,4]oxazepine structure A (Figure 4.5) is a privileged scaffold in medicinal 
chemistry. This motif is present in many physiologically and biologically active compounds (Figure 4.5) 
such as non-nucleoside HIV-1 reverse transcriptase inhibitors B,27 histamine H4 receptor agonist C28 
and  PGE2 antagonist D.29-31 Furthermore the compound A is commonly known as CR gas  and is used 
as an incapacitating agent and a lachrymatory agent (it is 6 to 10 times more powerful than CS gas, 2-
chlorobenzalmalononitrile, the active compound of tear gas) as it works as an extremely potent 
activator of the human transient receptor potential Ankyrin 1 (TRPA1) channel.32 
 
Figure 4.5. (A) Structure of dibenzo[b,f][1,4]oxazepane (B) HIV-1 reverse transcriptase inhibitor (C) Histamine 
H4 receptor agonist (D) PGE2 antagonist. 
 Despite that the cyclic seven membered dibenzoxazepines are very interesting scaffolds, very 
few examples of catalytic enantioselective reactions with this kind of imines have been described in 





4.1.2.1. Catalytic enantioselective hydrogenations of dibenzo[b,f][1,4]oxazepines 
 
Scheme 4.3. Hydrogenation of dibenzoxazepines. 
 In 2011, the first catalytic enantioselective hydrogenation (Scheme 4.3) of benzoxazepines 
was described by Zhang and collaborators.33 The hydrogenation was performed with an 
[Ir(COD)Cl]2/(S)-Xyl-C3*-TunePhos (VIII) complex (Figure 4.6), which was chosen after an intensive 
optimization of the reaction conditions. The reaction conditions include the presence of 20 mol % of 
an additive (morpholine-HCl, Brønsted acid), while only a 2.2 mol % of ligand is needed. Various 
differently substituted alkyl and aryl ketimines were hydrogenated under the reaction conditions, 
obtaining the corresponding chiral amines in poor to good yields (12-98%) and moderate to excellent 
enantioselectivities (52-94% ee). The worst results were obtained in the case of aryl ketimines. 
 
Figure 4.6. (S)-Xyl-C3*-TunePhos ligand. 
 Vidal-Ferran and collaborators described in 2015, the asymmetric hydrogenation of seven 
membered imines using also a chiral iridium complex.34 In this report, the authors not only describe 
the hydrogenation of dibenzoxazepines, but they also apply the same reaction conditions to the 
sulphur, carbon, nitrogen and sulphur dioxide analogues. Optimized conditions for the hydrogenation 
reactions were: in situ prepared [{Ir(µ-Cl)(COD)}2]/phosphine-phosphite complex (0.5 mol % metal, 1.1 
mol % ligand IX) (Figure 4.7) and MeTHF as solvent in the presence of HCl (10 mol %). In general, good 
results were obtained, both in yields (24-99%) as in enantioselectivities (9-97% ee). However, some 
remarks have to be made. In first place, aryl ketimines were less reactive than the alkyl ketimines, 
leading to the final products with low yields and enantioselectivities. Another remark is the low 
enantioselectivity of the reaction with the carbon-analogue, which is lower when compared with the 
other analogues. 
 
Figure 4.7. Phosphine-phosphite ligand. 
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4.1.2.2. Catalytic enantioselective Mannich reactions of dibenzo[b,f][1,4]oxazepines  
 The first catalytic enantioselective direct Mannich reaction using benzoxazepines as 
electrophiles was published in 2014 (Scheme 4.4).35 Wang and collaborators described the Mannich 
reaction between dibenzo[b,f][1,4]oxazepines and acetophenone under the following optimized 
conditions: 30 mol % of (S)-azetidine-2-carboxylic acid, which functions as a organocatalyst, in DMSO 
at room temperature. The corresponding Mannich product was obtained in good yield (94%) and 
excellent enantiomeric excess (93% ee). Various substituted acetophenones were tested under the 
reaction conditions, obtaining in general similar yields and enantioselectivities. However, a methoxy 
group in ortho position of the aromatic ring did not allow the reaction to take place, which can be 
explained by steric effects. The scope of the reaction was extended by using various substituted 
dibenzoxazepines, leading to similar yields (89-99%) and enantioselectivities (89-95% ee). No 
enantioselectivity was obtained when an α-substituted acetophenone was used (64% yield, 0% ee) 
 
Scheme 4.4. Mannich reaction between dibenzo[b,f][1,4]oxazepines and acetophenone. 
 More recently, the same group described the enantioselective Mannich reaction using 
acetone as nucleophile (Scheme 4.5).36 Interestingly, in the reaction with acetone, compared with the 
reaction with acetophenone, the best organocatalyst was (S)-proline (30 mol %). The presence of 3Å 
molecular sieves in the solution with DMF, increases the enantioselectivity. This beneficial effect of 
the molecular sieves can be attributed to the minimization of the moisture or to the reduction of the 
basicity of the nitrogen atom. These reaction conditions were applied to several differently substituted 
cyclic seven membered imines, obtaining good to excellent yields (60-90%) and high to excellent 
enantiomeric excess (91-98%). The reaction conditions could also be applied to the reaction of 2-
butanone with dibenzo[b,f][1,4]oxazepine, obtaining the resulting product in good yield (92%) and 
excellent enantiomeric excess (96%)     
 
Scheme 4.5. Mannich reaction between dibenzo[b,f][1,4]oxazepine and acetone. 
4.1.2.3. Catalytic enantioselective alkynylation of dibenzo[b,f][1,4]oxazepines  
 In 2014, Wang and collaborators described the first and only alkynylation reaction with 
dibenzoxazepines.37 This publication is also the first report of an catalytic enantioselective alkynylation 
of seven membered cyclic imines in general. The optimized conditions of the reaction consists in 
performing the alkynylation reaction at 15 °C in 1,4-dioxane, in the presence of an AgOAc/chiral 
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phosphoric acid complex (5 mol % AgOAc and 10 mol % chiral phosphoric acid) (Scheme 4.6). These 
conditions allowed the authors to test various terminal aromatic, heteroaromatic and alkyl alkynes as 
nucleophiles, which led to good results (38-92% yield, 78-95% ee). With the alkyne that gave the best 
result in the reaction with dibenzo[b,f][1,4]oxazepine (ethynylcyclohexane; 92% yield, 95% ee), the 
reaction was tested with different substituted dibenzo[b,f][1,4]oxazepines. Excellent results were 
obtained both in yield (78-96%) and enantioselectivity (86-99% ee). The reaction conditions were also 
used for the addition of a terminal 1,3-diyne, which resulted in slightly lower values for yield (53-90%) 
and enantioselectivity (63-96% ee). The authors also performed various transformations on the 
reaction product such as the reduction of the triple bond of the alkyne to the corresponding alkane 
and alkene, without any loss of enantiopurity.  
 
Scheme 4.6. Catalytic enantioselective alkynylation reaction of dibenzo[b,f][1,4]oxazepines. 
4.1.2.4. Catalytic enantioselective propargylation of dibenzo[b,f][1,4]oxazepines  
 Very recently, Fandrick and coworkers presented a copper-catalyzed asymmetric 
propargylation of cyclic aldimines in general.38 The authors performed the propargylation reaction for 
a series of cyclic imines, one of which was a dibenzo[b,f][1,4]oxazepine. The reaction conditions were 
optimized for the reaction between a propargyl borolane and a dihydroisoquinoline. The reaction 
gives the best results when performed in toluene at -15 °C in the presence of a 
Cu(isobutyrate)/MeOBIBOP complex. These conditions were also applied on the reaction with 
dibenzo[b,f][1,4]oxazepine, obtaining the chiral homopropargylic cyclic amine in good yield (86%) and 
good enantiomeric ratio (96:4) (Scheme 4.7). 
 






 El objetivo general de este capítulo es el desarrollo de un método catalítico y enantioselectivo 
de adición de reactivos de dialquilzinc a aldiminas cíclicas de tipo dibenzo[b,f][1,4]oxazepina que 
transcurra con buenos rendimientos y excesos enantioméricos.  
 
En el estudio de este proyecto se consideran los siguientes aspectos: 
1. Influencia de la estructura de diversos ligandos de tipo (R)-BINOL (L1-L6), (R)-VAPOL (L7), (R)-VANOL 
(L8), ligandos derivados de (S)-prolinol (L9-L12), quinina (L13), ligando de Trost (L14) y dos α-
hidroxiamidas (L15 y L16) sobre el rendimiento y la enantioselectividad de la reacción. 
 
2. La influencia de la naturaleza del reactivo de dialquilzinc utilizado (Me2Zn y Et2Zn) y disolvente de la 
reacción. 
3. Evaluación de diversas aldiminas cíclicas de tipo dibenzo[b,f][1,4]oxazepina con diferente 
naturaleza electrónica y estérica en la reacción con reactivos de dialquilzinc. 
 




4.3. RESULTADOS Y DISCUSIÓN 
4.3.1. Síntesis de dibenzo[b,f][1,4]oxazepinas 
4.3.1.1. Síntesis de dibenzo[b,f][1,4]oxazepinas sustituidas en posiciones 7 y 8 
Las dibenzo[b,f][1,4]oxazepinas sustituidas en posiciones 7 y 8 se han preparado a partir de 
varios 2-aminofenoles con diferentes sustituyentes 19 y 2-fluorobenzadehido 20 en un único paso, 
utilizando K2CO3 como base y PEG (polietilenoglicol) como disolvente (Esquema 4.8). Se trata de una 
reacción de condensación de la amina y el aldehído seguido por una sustitución nucleofílica aromática. 
La síntesis transcurre con rendimientos que van de moderados a excelentes. Los mejores rendimientos 
se obtuvieron con 2-aminofenoles con sustituyentes de tipo electrón-donante (21b, 21c y 21f). 
 
Esquema 4.8. Síntesis de dibenzo[b,f][1,4]oxazepinas sustituidos en posiciones 7 y 8. 19 (5,5 mmol), 20 (5,0 
mmol), K2CO3 (5,0 mmol).  Rendimiento después de purificación por cromatografía de columna. 
4.3.1.2. Dibenzo[b,f][1,4]oxazepinas sustituidas en posiciones 1-4 
 La síntesis de este tipo de dibenzo[b,f][1,4]oxazepinas también se puede llevar a cabo por el 
método anterior, a partir de 2-fluorobenzaldehidos convenientemente sustituidos. Pero estos son 
caros y por este motivo se ha optado por una síntesis que, aunque más larga, resulta más asequible y 




Esquema 4.9. Síntesis de dibenzo[b,f][1,4]oxazepinas sustituidas en posiciones 1-4. 
La primera etapa de la secuencia sintética consiste en la reacción entre derivados de fenol 
(10) y derivados de 1-fluoro-2-nitrobenceno (22). En primer lugar se desprotona el fenol con NaH y el 
fenóxido resultante actúa como nucleófilo en la sustitución nucleofílica aromática con el 1-fluoro-2-
nitrobenceno 22. Las reacciones muestran una alta conversión y selectividad siendo los rendimientos 
obtenidos elevados (89-99%) (Esquema 4.10). 
 
Esquema 4.10. Primera etapa de la síntesis de dibenzo[b,f][1,4]oxazepinas en posiciones 1-4. 10 (15 mmol), 22 
(10 mmol), NaH (16 mmol).  Rendimiento después de purificación por cromatografía de columna. 
La segunda etapa consiste en la reducción del grupo nitro con Zn metálico en una disolución 
ácida para la obtención de las aminas 24. La reacción funciona muy bien y los rendimientos son 
practicamente cuantitativos (Esquema 4.11). Los productos se obtienen suficientemente puros 




Esquema 4.11. Segunda etapa de la síntesis de dibenzo[b,f][1,4]oxazepinas en posiciones 1-4. 23 (8 mmol), Zn 
(240 mmol).  Rendimiento después de purificación por cromatografía de columna. 
 La amina formada en la etapa anterior se disuelve en ácido fórmico y se calienta hasta 100 °C 
durante 12 horas, lo cual da lugar a la formación de la amida 25. Estas amidas no requieren purificación 
y se utilizaron directamente en la siguiente etapa de la síntesis (Esquema 4.12). 
 
Esquema 4.12. Tercera etapa de la síntesis de dibenzo[b,f][1,4]oxazepinas en posiciones 1-4. 24 (7,5 mmol), 
HCOOH (5 mL).   
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 La última etapa es la ciclación del producto 25 mediante la reacción de Bischler-Napieralski 
(Esquema 4.13). El tricloruro de fosforilo se coordina al oxígeno de la amida, aumentando la electrofilia 
del átomo de carbono del grupo carbonilo, facilitando la reacción de Friedel-Crafts. Tras la eliminación 
del grupo fosforilo se obtiene la imina 21. Los rendimientos obtenidos son muy variable, desde bajos 
(23%) a excelentes (94%), dependiendo de los sustituyentes del anillo aromático.  
 
Esquema 4.13. Última etapa de la síntesis de dibenzo[b,f][1,4]oxazepinas en posiciones 1-4. 25 (4 mmol), POCl3 
(20 mmol).  Rendimiento después de purificación por cromatografía de columna. 
4.3.1.3. Síntesis de dibenzo[b,f][1,4]tiazepina  
La dibenzo[b,f][1,4]tiazepina 27 se preparó mediante la reacción entre 2-aminotiofenol 26 y 
el 2-fluorobenzadehido 20 en una única etapa, utilizando K2CO3 como base en PEG (polietilenoglicol) 
(Esquema 4.14). Esta reacción es del mismo tipo que la utilizada anteriormente para la síntesis de las 
dibenzoxazepinas (21a-21f). El rendimiento de la reación de formación de la dibenzotiazepina 27 es 
moderado (56%). 
 
Esquema 4.14. Síntesis de dibenzo[b,f][1,4]tiazepina. 
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4.3.2. Optimización de las condiciones de la reacción  
 El proceso de optimización de las condiciones de la reacción se inició estudiando la reacción 
entre Et2Zn y la dibenzo[b,f][1,4]oxazepina (21a), en presencia de un ligando quiral utilizando 
diclorometano como disolvente. Se han ensayado varios tipos de ligandos [de tipo (R)-BINOL (L1-L6), 
(R)-VAPOL (L7), (R)-VANOL (L8), ligandos  derivados de (S)-prolinol (L9-L12), quinina (L13), el ligando 
de Trost (L14) y dos α-hidroxiamidas (L15 y L16)] (Tabla 4.1).  
En la evaluación de los ligandos se ensayaron, en primer lugar, varios derivados de tipo (R)-
BINOL. Se puede observar que en general, los rendimientos (16-36%) y las enantioselectividades (8-
50% ee) son bajos (Tabla 4.1, Entradas 1-6), aunque la presencia de un átomo de bromo en las 
posiciones 6 y 6’ (Tabla 4.1, entrada 2) da lugar al producto correspondiente 28a con una 
enantioselectividad moderada (50% ee), pero con un rendimiento bajo (34%).   
 Cuando se utilizó (R)-VAPOL (L7) como ligando, se observó un aumento en la 
enantioselectividad de la reacción hasta un 61% ee, sin embargo, el rendimiento obtenido resultó bajo 
(36%) (Tabla 4.1, entrada 7). (R)-VANOL (L8), un ligando menos voluminoso comparado con (R)-VAPOL 
(L7), condujo al producto 28a en forma  prácticamente racémica (5% ee) (Tabla 4.1, entrada 8). 
 Aunque el resultado con (R)-VAPOL (L7) era prometedor, decidimos evaluar otros ligandos 
quirales. En primer lugar se ensayaron ligandos derivados de (S)-prolinol (L9-L12) (Tabla 4.1, entradas 
9-12). Los rendimientos obtenidos con estos ligandos fueron más elevados (40-53%). Sin embargo, la 
enantioselectividad de la reacción fue prácticamente nula (0-5%). El uso de quinina (L13) tampoco dio 
lugar a mejores resultados (30% rendimiento, 5% ee) (Tabla 4.1, entrada 13). El ligando de Trost (L14), 
un ligando descrito anteriormente en reacciones de alquilación,39 dio como resultado un rendimiento 
de 48%, pero un exceso enantiomérico de 20%, lo cual no mejora el resultado obtenido con L7 (Tabla 
4.1, entrada 14).  
 Por último, también se utilizaron como ligandos la bis-α-hidroxiamida L15 y la α-hidroxiamida 
L16, obteniéndose resultados decepcionantes (Tabla 4.1, entradas 15 y 16). 
Una vez identificado el ligando L7 como el que proporcionaba los mejores resultados entre los 
ligandos examinados, continuamos el proceso de optimización ensayando la reacción con diferentes 





Tabla 4.1. Adición enantioselectiva de Et2Zn a dibenzo[b,f][1,4]oxazepina 21a. Screening de ligandos.a 
 
 
Entrada Ligando t (h) R (%)b ee (%)c 
1 L1 22 36 37 
2 L2 22 34 50 
3 L3 23 20 14 
4 L4 21 16 8 
5 L5 21 22 18 
6 L6 22 18 19 
7 L7 22 36 61 
8 L8 24 40 5 
9 L9 22 47 0 
10 L10 22 53 0 
11 L11 22 48 1 
12 L12 22 55 5 
13 L13 22 30 5 
14 L14 22 48 20 
15 L15 22 19 -11 
16 L16 22 33 8 
a 21a (0,100 mmol), Ligando L (0,020 mmol) y 1M Et2Zn en hexanos (0,500 mmol). b Rendimiento después de 





Tabla 4.2. Reacción de adición enantioselectiva de Et2Zn a dibenzo[b,f][1,4]oxazepina 21a. Screening de 
reactivos de dialquilzinc y disolvente.a 
 
Entrada Disolvente R2Zn (R) t (h) R (%)b ee (%)c 
1 DCM Et 22 53 61 
2 DCM Me 96 / / 
3 DCE Et 22 68 38 
4 Tolueno Et 22 49 45 
5 AcOEt Et 22 58 44 
6 THF Et 22 70 27 
7 Et2O Et 22 53 69 
8 IPr2O Et 22 49 42 
9 MTBE Et 22 52 54 
a 21a (0,100 mmol), Ligando L7 (0,020 mmol) y 1M Et2Zn en hexanos (0,500 mmol). b Rendimiento después de 
purificación por cromatografía de columna. c Exceso enantiomérico determinado mediante HPLC usando fases 
estacionarias quirales. 
 En primer lugar se ensayó la adición de Me2Zn a la dibenzo[b,f][1,4]oxazepina 21a, sin 
embargo no se observó la formación del producto de adición de Me2Zn a la imina (Tabla 4.2, Entrada 
2)  
Como se puede observar en la tabla 4.2, el uso de dicloroetano (entrada 3) aumenta el 
rendimiento de la reacción con Et2Zn (68%), pero la enantioselectividad disminuye hasta un 38% ee. 
Cuando se utiliza tolueno como disolvente (Tabla 4.2, Entrada 4), se observa una disminución de la 
enantioselectividad, aunque el rendimiento se mantiene. Cuando se utiliza acetato de etilo (Tabla 4.2, 
entrada 5) como disolvente el producto de adición se obtuvo con un rendimiento de 58% y una 
enantioselectividad de 44% ee.  
 Se ensayaron también diferentes disolventes de tipo éter. El mejor rendimiento (70%) de la 
reacción se observa cuando se utilizó THF (Tabla 4.2, Entrada 5) como disolvente, pero la 
enantioselectividad disminuyó hasta un 27% ee. El éter etílico resultó ser el mejor disolvente para la 
reacción de adición de Et2Zn a la dibenzo[b,f][1,4]oxazepina (Tabla 4.2, entrada 7). El uso de éter 
isopropílico o metil terc-butil éter no condujo a ninguna mejora en el rendimiento y tampoco en la 
enantioselectividad de la reacción (Tabla 4.2, entradas 8 y 9).  
 En resumen, se obtuvieron los mejores resultados cuando la reacción entre la 





4.3.3. Alcance y limitaciones de la reacción 
4.3.3.1. Reacción entre dietilzinc y diferentes dibenzo[b,f][1,4]oxazepinas 
 Para estudiar el alcance y las limitaciones de la reacción, se decidió ensayar las condiciones de 
reacción optimizadas con varias iminas de tipo dibenzo[b,f][1,4]oxazepina con diferentes 
sustituyentes en ambos anillos aromáticos (21) (Esquema 4.15).  
 
Esquema 4.15. Reacción de adición enantioselectiva de Et2Zn a dibenzo[b,f][1,4]oxazepinas 21. 21 (0,100 mmol), 
Ligando L7 (0,020 mmol) y 1M Et2Zn en hexanos (0,500 mmol). Rendimiento después de purificación por 
cromatografía de columna. Exceso enantiomérico determinado mediante HPLC usando fases estacionarias 
quirales. 
 Primero se estudió la reacción con las iminas sustituidas en posiciones 7 y 8. La presencia de 
un grupo electrón-donante (metilo) en la posición 7 conduce al producto de reacción 28b con una 
enantioselectividad (49% ee) inferior a la obtenida para el compuesto que lleva el mismo grupo en la 
posición 8 (28c, 65% ee). El mismo efecto se puede observar si el sustituyente es un grupo electrón-
atrayente (28d, 54% ee y 28e, 60% ee). Los rendimientos de las reacciones con iminas cíclicas 
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sustituidas en posiciones 7 y 8 son generalmente bajos (35-48%). Sin embargo, la presencia de grupo 
metoxi en la posición 8 (28f) conduce a un rendimiento mucho mayor de 71% con una 
enantioselectividad de un 62% ee, la cual es parecida a la enantioselectividad observado en la 
formación del compuesto 28c (con un grupo metilo en posición 8). Se puede concluir que la presencia 
de un sustituyente (electrón-donante o electrón-atrayente) en posición 8 da lugar a mejores 
resultados que la presencia de un sustituyente en la posición 7.  
 A continuación, se ensayaron iminas cíclicas con diferentes sustituyentes en las posiciones 1-
4. La reacción de adición de Et2Zn a dibenzo[b,f][1,4]oxazepina 21g (con un grupo metilo en la posición 
4) dio lugar al producto 28g con un buen rendimiento de 76% y una enantioselectividad de 60% ee. La 
presencia del mismo grupo, pero en posición 2 condujo al producto 28h con una enantioselectividad 
parecida (62% ee) pero con un rendimiento inferior (42%). Un grupo electrón-atrayente (cloro) en la 
posición 2 conduce al producto de reacción (28i) con una enantioselectividad baja de 34% ee y con un 
rendimiento de 49%. Sin embargo la presencia de un grupo metoxi en la posición 2 conduce a los 
mejores resultados, con un rendimiento de 61% y una enantioselectividad de 70% ee (28j). Como se 
puede observar, la presencia de un grupo electrón-donante en la posición 4 aumenta el rendimiento 
de la reacción, mientras la presencia de un grupo electrón-atrayente en la posición 2 disminuye la 
enantioselectividad de la reacción.  
 También se aplicaron las condiciones optimizadas en la reacción con iminas cíclicas di- y tri-
sustituidas en las posiciones 1-4. El sustrato 21k (1,3-dimetoxi) experimentó la reacción de adición 
enantioselectiva de Et2Zn dando lugar al compuesto 28k con un rendimiento de 40% y una 
enantioselectividad de 56% ee. En la reacción con el sustrato 21l (8-fluoro-2,4-
dimetildibenzo[b,f][1,4]oxazepina) se pudo observar un rendimiento algo inferior (31%), aunque la 
enantioselectividad observada fue ligeramente superior (59% ee). Así pues, la reacción con las iminas 
di- y trisustituidas condujo a los productos resultantes con rendimientos y enantioselectividades 
ligeramente inferiores a los obtenidos en las reacciones con las iminas monosustituidas.  
 Finalmente, se llevaron a cabo las reacciones de adición enantioselectiva de Et2Zn a las iminas 
derivadas de 1- y 2-naftol. La reacción con la imina derivada del 1-naftol 21m conduce al producto de 
reacción con un rendimiento de 53% y una enantioselectividad de 59% ee, mientras que la reacción 
con la imina derivada del 2-naftol da lugar al producto 28n con un rendimiento muy inferior (25%), 
pero una enantioselectividad de 57% ee. Curiosamente, la presencia de un grupo bromo en la posición 
3 del sustrato 21o, derivado del 2-naftol, conduce a un aumento en el rendimiento (45%) y la 
enantioselectividad (67% ee). Así pues, la reacción con la imina derivada del 1-naftol da mejores 
resultados que con la imina derivada de 2-naftol, aunque la presencia de un grupo bromo en la 
posición 3 del 2-naftol mejora el rendimiento y la enantioselectividad. También se evaluó la reacción 
con la dibenzotiazepina 27, pero desafortunadamente la reacción no tuvo lugar.   
4.3.4. Determinación de la configuración absoluta 
 La configuración absoluta fue determinada por comparación con compuestos descritos 
anteriormente en la literatura. Concretamente, se comparó el signo de la rotación especifica del 
compuesto 28a con la del mismo compuesto descrito por Zhou, resultando que la configuración 
absoluta del centro estereogénico formado en la reacción es (S).33 La configuración de los productos 




4.3.5. Propuesta mecanística para la alquilación de benzoxazepinas catalizada 
por complejos de (R)-VAPOL-Zn 
El esquema 4.16 muestra un posible mecanismo para la reacción de alquilación de 
benzoxazepinas catalizada por complejos de (R)-VAPOL-Zn, el cual está basado en el mecanismo de la 
alquinilación de 2,2-dioxido benzoxatiazinas catalizada por complejos de (R)-VAPOL-Zn que hemos 
propuesto en el capítulo 2. En primer lugar se produce la desprotonación del ligando VAPOL por parte 
del dietilzinc, lo cual da lugar al complejo A (VAPOL zincato-dietilzinc). Este complejo A se coordina 
con la imina cíclica (benzoxazepina) formando el complejo B. En este complejo se produce la 
transferencia del grupo etilo desde el etilzinc al carbono azometínico de la imina, lo cual libera el 
producto de reacción y el VAPOL-zincato C. Se completa el ciclo catalítico tras la coordinación de una 
nueva molecula de dietilzinc al complejo C, generando de nuevo el complejo A. 
 





1. Se ha diseñado un método enantioselectivo de adición de Et2Zn a aldiminas cíclicas de tipo 
dibenzo[b,f][1,4]oxazepina catalizada por un complejo (R)-VAPOL-Zn(II) a temperatura 
ambiente y utilizando éter etílico como disolvente.  
2. La reacción con iminas con un sustituyente (electrón-donante o atrayente) en posición 8 dio 
lugar a mejores resultados que la reacción con iminas con un  sustituyente en la posición 7. 
3. La presencia de un grupo electrón-donante en la posición 4 aumenta el rendimiento de la 
reacción, mientras la presencia de un grupo electrón-atrayente en la posición 2 disminuye la 
enantioselectividad de la reacción. 
4. La reacción con iminas di- y trisustituidas conduce a los productos resultantes con 
rendimientos y enantioselectividades ligeramente inferiores a los obtenidos en las reacciones 
con iminas monosustituidas. 
5. La reacción con la imina derivada del 1-naftol da mejores resultados que con la imina derivada 
de 2-naftol, aunque la presencia de un grupo bromo en la posición 3 del 2-naftol mejora el 
rendimiento y la enantioselectividad. 
6. La configuración absoluta fue determinada por comparación de los datos del compuesto 28a 
con los descritos en la bibliografía para este mismo compuesto, resultando ser (S). Al resto de 
productos se les asignó la misma configuración absoluta asumiendo que la reacción sigue el 
mismo curso estereoquímico. 
7. Se ha propuesto un posible mecanismo para la alquilación de dibenzoxazepinas con un 










4.5. EXPERIMENTAL SECTION 
4.5.1. General experimental methods 
Reactions were carried out under nitrogen in test tubes or round bottom flasks oven-dried 
overnight at 120 °C. Dicloromethane, 1,2-dichloroethane and toluene were distilled from CaH2. THF 
was distilled from sodium benzophenone ketyl. Reactions were monitored by TLC analysis using Merck 
Silica Gel 60 F-254 thin layer plates. Flash column chromatography was performed on Merck silica gel 
60, 0.040-0.063 mm. Melting points were determined in capillary tubes. NMR spectra were run at 300 
MHz for 1H and at 75 MHz for 13C NMR using residual non-deuterated solvent  as internal standard 
(CHCl3: δ  7.26 and 77.0 ppm). Chemical shifts are given in ppm. The carbon type was determined by 
DEPT experiments. High resolution mass spectra (ESI) were recorded on a AB SCIEX Triple TOFTM 
spectrometer equipped with an electrospray source with a capillary voltage of 4.5 kV(ESI). Optical 
rotations were measured using sodium light (D line 589 nm). Chiral HPLC analyses were performed in 
a chromatograph equipped with a UV diode-array detector using chiral stationary columns from 
Daicel. 
4.5.2. General synthetic procedure and characterization data for compounds 21 
substituted in positions 7 and 8  
2-Aminophenol 19 (5.5 mmol, 1.1 eq.) was dissolved in 10 mL PEG. 2-Fluorobenzaldehyde 20 
(5.0 mmol, 1 eq) and K2CO3 (5.0 mmol, 1 eq.) were added. The reaction mixture was heated to 100 °C 
for 2 h. The reaction process was followed by TLC. Once the reaction was finished, the reaction mixture 
was cooled to rt and 20 mL water was added to quench the reaction. The reaction mixture was 
extracted with EtOAc (3x20 mL), washed with brine (20 mL) and dried over MgSO4. The solvent was 
removed by evaporation and the crude product was purified by flash chromatography, obtaining 
product 21.35  
Dibenzo[b,f][1,4]oxazepine (21a)35   
Orange solid; mp 69-71 °C; 1H NMR (300 MHz, CDCl3) δ 8.63 (s, 1H), 7.56 (ddd, J = 8.1, 7.4, 
1.8 Hz, 1H), 7.50 – 7.42 (m, 2H), 7.37 – 7.33 (m, 1H), 7.32 – 7.28 (m, 2H), 7.27 – 7.21 (m, 
2H). 13C NMR (75 MHz, CDCl3) δ 160.6 (CH), 160.4 (C), 152.7 (C), 140.5 (C), 133.3 (CH), 130.1 
(CH), 129.2 (CH), 128.8 (CH), 127.3 (C), 125.7 (CH), 125.1 (CH), 121.4 (CH), 120.7 (CH).  
8-Methyldibenzo[b,f][1,4]oxazepine (21b)35 
Brown solid; mp 46-47 °C; 1H NMR (300 MHz, CDCl3) δ 8.49 (s, 1H), 7.42 (ddd, J = 8.1, 7.4, 
1.8 Hz, 1H), 7.32 (dd, J = 7.6, 1.7 Hz, 1H), 7.19 (dd, J = 7.5, 1.1 Hz, 1H), 7.15 (dt, J = 2.5, 1.0 
Hz, 1H), 7.11 (dt, J = 8.1, 0.7 Hz, 1H), 7.01 – 6.98 (m, 2H), 2.30 (d, J = 0.6 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 160.6 (CH), 150.5 (C), 140.0 (C), 135.4 (C), 133.2 (CH), 130.1 (CH), 129.5 
(CH), 129.3 (CH), 127.4 (C), 124.9 (CH), 120.9 (CH), 120.6 (CH), 20.6 (CH3).  
7-Methyldibenzo[b,f][1,4]oxazepine (21c)35 
Brown oil; 1H NMR (300 MHz, CDCl3) δ 8.45 (s, 1H), 7.42 (ddd, J = 8.1, 7.3, 1.8 Hz, 1H), 7.31 
(dd, J = 7.6, 1.7 Hz, 1H), 7.22 – 7.19 (m, 1H), 7.16 (dd, J = 7.5, 1.1 Hz, 1H), 7.11 (ddd, J = 
8.1, 1.0, 0.5 Hz, 1H), 7.00 – 6.90 (m, 2H), 2.31 (d, J = 0.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 160.3 (C), 159.8 (CH), 152.3 (C), 139.4 (C), 138.0 (C), 133.2 (CH), 130.1 (CH), 129.0 (CH), 




Brown solid; mp 93-94 °C; 1H NMR (300 MHz, CDCl3) δ 8.50 (s, 1H), 7.45 (ddd, J = 8.1, 7.3, 
1.7 Hz, 1H), 7.37 – 7.31 (m, 2H), 7.25 – 7.18 (m, 1H), 7.16 (dd, J = 8.6, 2.6 Hz, 1H), 7.13 – 
7.08 (m, 1H), 7.03 (d, J = 8.5 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 161.7 (CH), 160.3 (C), 151.3 
(C), 141.4 (C), 133.6 (CH), 130.6 (C), 130.3 (CH), 128.9 (CH), 128.4 (CH), 127.1 (C), 125.3 (CH), 
122.4 (CH), 120.7 (CH). 
7-Chlorodibenzo[b,f][1,4]oxazepine (21e)35 
Brown solid; mp 76-77 °C; 1H NMR (300 MHz, CDCl3) δ 8.47 (s, 1H), 7.45 (ddd, J = 8.1, 7.3, 
1.8 Hz, 1H), 7.32 (d, J = 1.8 Hz, 1H), 7.30 – 7.25 (m, 1H), 7.25 – 7.17 (m, 1H), 7.17 – 7.09 (m, 
3H). 13C NMR (75 MHz, CDCl3) δ 160.8 (CH), 159.9 (C), 152.8 (C), 139.2 (C), 133.9 (C), 133.6 
(CH), 130.2 (CH), 130.0 (CH), 127.2 (C), 125.9 (CH), 125.4 (CH), 121.8 (CH), 120.7 (CH).  
 
8-Methoxydibenzo[b,f][1,4]oxazepine (21f)  
Orange oil; 1H NMR (300 MHz, CDCl3) δ 8.51 (s, 1H), 7.43 (ddd, J = 8.1, 7.4, 1.7 Hz, 1H), 
7.32 (dd, J = 7.6, 1.7 Hz, 1H), 7.18 (td, J = 7.5, 1.1 Hz, 1H), 7.13 – 7.09 (m, 1H), 7.02 (d, J 
= 8.8 Hz, 1H), 6.87 (d, J = 3.1 Hz, 1H), 6.75 (dd, J = 8.8, 3.1 Hz, 1H), 3.76 (s, 3Ht), 13C NMR 
(75 MHz, CDCl3) δ 161.1 (CH), 160.7 (C), 157.1 (C), 146.5 (C), 141.0 (C), 133.4 (CH), 130.1 
(CH), 127.3 (C), 124.9 (CH), 121.7 (CH), 120.5 (CH), 114.6 (CH), 113.0 (CH), 55.7 (CH3). 
HRMS (ESI) m/z: 226.0859 [M + H]+, C14H12NO2 requires 226.0863. 
4.5.3. General synthetic procedures and characterization data for compounds 21 
substituted in positions 1-4 
Synthetic procedure and characterization data for compounds 23  
NaH (16 mmol, 1.6 eq.) was added to 10 mL of DMF. Next, a solution of phenol (10) (15 mmol, 
1.5 eq.) in DMF (10 mL) was added dropwise to the reaction mixture. The mixture was stirred for 30 
minutes, and a solution of 1-fluoro-2-nitrobenzene (22) (10 mmol, 1 eq.) in 4 mL DMF was added 
dropwise. After stirring for 12 h at 50 °C, the mixture was cooled to room temperature and 25mL of 
saturated aqueous NH4Cl solution was added, the mixture was extracted with 50 mL EtOAc, washed 
with H2O (4x 20 mL) and dried over MgSO4. The solvent was removed and the crude product was 
purified by flash chromatography, obtaining product 23. 
1-Methyl-2-(2-nitrophenoxy)benzene (23g)40  
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 8.2, 1.7 Hz, 1H), 7.42 (ddd, J = 8.3, 
7.4, 1.7 Hz, 1H), 7.30 – 7.24 (m, 1H), 7.23 – 7.16 (m, 1H), 7.16 – 7.08 (m, 2H), 6.92 (dd, 
J = 7.8, 1.5 Hz, 1H), 6.79 (dd, J = 8.4, 1.2 Hz, 1H), 2.22 (s, 3H). 13C NMR (75 MHz, CDCl3) 
δ 153.0 (C), 151.2 (C), 140.4 (C), 134.0 (CH), 131.8 (CH), 130.1 (C), 127.4 (CH), 125.8 







1-Nitro-2-(p-tolyloxy)benzene (23h)41  
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 8.2, 1.7 Hz, 1H), 7.44 (ddd, J = 8.5, 7.4, 
1.7 Hz, 1H), 7.20 – 7.09 (m, 3H), 6.99 – 6.89 (m, 3H), 2.33 (s, 3H). 13C NMR (75 MHz, CDCl3) 
δ 153.3 (C), 151.3 (C), 141.1 (C), 134.4 (C), 134.0 (CH), 130.5 (CH), 125.6 (CH), 122.6 (CH), 
119.8 (CH), 119.4 (CH), 20.7 (CH3).  
 
1-(4-Chlorophenoxy)-2-nitrobenzene (23i)42  
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.94 (dd, J = 8.1, 1.7 Hz, 1H), 7.51 (ddd, J = 8.3, 7.4, 
1.7 Hz, 1H), 7.33 (d, J = 2.3 Hz, 1H), 7.30 (d, J = 2.3 Hz, 1H), 7.25 – 7.18 (m, 1H), 7.01 (dd, J 
= 8.3, 1.3 Hz, 1H), 6.97 (d, J = 2.3 Hz, 1H), 6.95 (d, J = 2.2 Hz, 1H). 13C NMR (75 MHz, CDCl3) 
δ 154.6 (C), 150.1 (C), 142.7 (C), 134.2 (CH), 130.1 (CH), 129.7 (C), 125.8 (CH), 123.7 (CH), 
120.8 (CH), 120.2 (CH).  
1-(4-Methoxyphenoxy)-2-nitrobenzene (23j)41  
 Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.90 (dd, J = 8.1, 1.7 Hz, 1H), 7.42 (ddd, J = 8.4, 7.4, 
1.7 Hz, 1H), 7.10 (ddd, J = 8.1, 7.4, 1.2 Hz, 1H), 7.02 – 6.96 (m, 2H), 6.94 – 6.86 (m, 3H), 
3.79 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 156.8 (C), 151.9 (C), 148.6 (C), 140.7 (C), 134.0 
(CH), 125.6 (CH), 122.2 (CH), 121.1 (CH), 118.9 (CH), 115.1 (CH), 55.7 (CH3).  
 
1,3-Dimethoxy-5-(2-nitrophenoxy)benzene (23k)43  
 Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.92 (dd, J = 8.1, 1.7 Hz, 1H), 7.49 (ddd, J = 
8.3, 7.4, 1.7 Hz, 1H), 7.18 (ddd, J = 8.3, 7.4, 1.3 Hz, 1H), 7.07 (dd, J = 8.3, 1.3 Hz, 1H), 
6.26 (t, J = 2.2 Hz, 1H), 6.17 (d, J = 2.2 Hz, 2H), 3.74 (s, 6H). 13C NMR (75 MHz, CDCl3) 
δ 161.7 (C), 157.6 (C), 150.2 (C), 141.3 (C), 134.1 (CH), 125.7 (CH), 123.4 (CH), 120.9 
(CH), 97.6 (CH), 96.6 (CH), 55.5 (CH3).  
1-(2,4-Dimethylphenoxy)-4-fluoro-2-nitrobenzene (23l)  
 Orange oil; 1H NMR (300 MHz, CDCl3) δ 7.66 (dd, J = 7.7, 3.1 Hz, 1H), 7.15 (ddd, J = 
9.2, 7.2, 3.1 Hz, 1H), 7.06 (s, 1H), 6.98 (ddt, J = 8.0, 2.4, 0.7 Hz, 1H), 6.82 – 6.76 (m, 
2H), 2.30 (s, 3H), 2.17 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 156.2 (d, Jc-f = 245.8 Hz, 
CF), 150.9 (C), 147.9 (d, Jc-f = 3.0 Hz, C), 139.9 (d, Jc-f = 7.6 Hz, C), 135.0 (C), 132.5 
(CH), 129.5 (C), 128.0 (CH), 121.2 (d, Jc-f = 23.0 Hz, CH), 119.6 (d, Jc-f = 7.7 Hz, CH), 
119.4 (CH), 112.8 (d, Jc-f = 27.8 Hz, CH), 20.7 (CH3), 15.9 (CH3). 19F NMR (282 MHz, 
CDCl3) δ -119.1. HRMS (ESI) m/z: 262.0873 [M + H]+, C14H13FNO3 requires 262.0874. 
1-(2-Nitrophenoxy)naphthalene (23m)44  
 Orange oil; 1H NMR (300 MHz, CDCl3) δ 8.14 – 8.10 (m, 1H), 7.99 (dd, J = 8.1, 1.7 Hz, 
1H), 7.88 (dd, J = 7.0, 2.4 Hz, 1H), 7.70 (d, J = 8.3 Hz, 1H), 7.57 – 7.47 (m, 2H), 7.45 – 
7.37 (m, 2H), 7.20 – 7.13 (m, 1H), 7.03 (dd, J = 7.6, 1.0 Hz, 1H), 6.88 (dd, J = 8.4, 1.3 
Hz, 1H). 13C NMR (75 MHz, CDCl3 δ 151.3 (C), 151. (C), 140.9 (C), 135.0 (C), 134.2 (CH), 
127.9 (CH), 126.9 (CH), 126.6 (CH), 126.5 (C), 125.8 (CH), 125.6 (CH), 124.9 (CH), 122.9 
(CH), 121.8 (CH), 119.6 (CH), 114.5 (CH).  
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2-(2-Nitrophenoxy)naphthalene (23n)45  
Orange oil; 1H NMR (300 MHz, CDCl3) δ 7.98 (dd, J = 8.2, 1.7 Hz, 1H), 7.89 – 7.81 (m, 2H), 
7.74 – 7.69 (m, 1H), 7.53 – 7.48 (m, 1H), 7.48 – 7.43 (m, 2H), 7.42 – 7.34 (m, 1H), 7.29 – 
7.18 (m, 2H), 7.05 (dd, J = 8.3, 1.3 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 153.5 (C), 150.7 (C), 
141.4 (C), 134.2 (CH), 134.1 (C), 130.7 (C), 130.3 (CH), 127.8 (CH), 127.3 (CH), 126.8 (CH), 
125.8 (CH), 125.4 (CH), 123.3 (CH), 120.8 (CH), 119.6 (CH), 115.0 (CH).  
2-Bromo-6-(2-nitrophenoxy)naphthalene (23o)  
 Orange solid; mp 97-100 °C; 1H NMR (300 MHz, CDCl3) δ 8.03 – 7.93 (m, 2H), 7.76 (ddd, J 
= 8.2, 1.7, 0.6 Hz, 1H), 7.60 – 7.50 (m, 3H), 7.34 – 7.20 (m, 3H), 7.07 (dd, J = 8.4, 1.2 Hz, 
1H). 13C NMR (75 MHz, CDCl3) δ 154.1 (C), 150.1 (C), 147.3 (C), 134.3 (CH), 132.6 (C), 131.6 
(CH), 130.2 (C), 129.9 (CH), 129.4 (CH), 128.9 (CH), 125.9 (CH), 123.8 (CH), 121.2 (CH), 
120.5 (CH), 119.1 (C), 114.5 (CH).  HRMS (ESI) m/z: 343.9918 [M + H]+, C16H11BrNO3 
requires 343.9917. 
Synthetic procedure and characterization data for compounds 24  
Compound 23 (8 mmol, 1 eq.) was dissolved in 50 mL of EtOAc and 62.5 mL of AcOH was 
added dropwise. The mixture was cooled to 0 °C and 62.5 mL of concentrated HCl was added dropwise. 
Afterwards, zinc powder (240 mmol, 30 eq.) was added in portions. The mixture was warmed to room 
temperature and stirred for 16 h. The mixture was cooled to 0 °C and 150 mL of 33% NH3 in water 
solution was added dropwise. The crude mixture was extracted DCM (4x100 mL), dried over MgSO4 
and the solvent was removed by evaporation, obtaining the crude amine 24.40 
2-(o-Tolyloxy)aniline (24g)40   
 Brown oil; 1H NMR (300 MHz, CDCl3) δ 7.25 – 7.20 (m, 1H), 7.15 – 7.08 (m, 1H), 7.00 
(td, J = 7.4, 1.3 Hz, 1H), 6.92 (ddd, J = 7.9, 5.3, 3.5 Hz, 1H), 6.83 – 6.76 (m, 2H), 6.70 – 
6.62 (m, 2H), 3.80 (s, 2H), 2.29 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 154.9 (C), 144.1 (C), 
137.8 (C), 131.3 (CH), 128.7 (C), 127.1 (CH), 123.9 (CH), 123.2 (CH), 118.7 (CH), 118.2 
(CH), 117.5 (CH), 116.2 (CH), 16.1 (CH3).   
2-(p-Tolyloxy)aniline (24h) 40  
 Brown oil; 1H NMR (300 MHz, CDCl3) δ 7.12 – 7.06 (m, 2H), 6.99 – 6.91 (m, 1H), 6.89 – 6.84 
(m, 2H), 6.81 (td, J = 7.8, 1.5 Hz, 2H), 6.68 (ddd, J = 8.0, 7.2, 1.6 Hz, 1H), 3.75 (s, 2H), 2.30 
(s, 3H). 13C NMR (75 MHz, CDCl3) δ 155.1 (C), 143.7 (C), 138.5 (C), 132.2 (C), 130.1 (CH), 
124.5 (CH), 119.7 (CH), 118.7 (CH), 117.3 (CH), 116.3 (CH), 20.6 (CH3).  
  
2-(4-Chlorophenoxy)aniline (24i)42   
 Brown oil; 1H NMR (300 MHz, CDCl3) δ 7.26 – 7.22 (m, 1H), 7.21 (d, J = 2.3 Hz, 1H), 6.97 
(ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 6.87 – 6.77 (m, 3H), 6.69 (ddd, J = 8.1, 
7.3, 1.7 Hz, 1H), 3.74 (s, 2H). 13C NMR (75 MHz, CDCl3) δ 156.2 (C), 142.7 (C), 138.7 (C), 





2-(4-Methoxyphenoxy)aniline (24j)46  
 Brown oil; 1H NMR (300 MHz, CDCl3) δ 6.95 – 6.88 (m, 3H), 6.87 – 6.82 (m, 2H), 6.81 – 6.73 
(m, 2H), 6.66 (ddd, J = 8.1, 7.2, 1.6 Hz, 1H), 3.77 (s, 5H). 13C NMR (75 MHz, CDCl3) δ 155.4 
(C), 150.7 (C), 144.6 (C), 138.1 (C), 124.0 (CH), 119.0 (CH), 118.6 (CH), 118.6 (CH), 116.2 
(CH), 114.8 (CH), 55.7 (CH3).  
 
2-(3,5-Dimethoxyphenoxy)aniline (24k)  
 Brown oil; 1H NMR (300 MHz, CDCl3) δ 6.97 (ddd, J = 7.9, 7.2, 1.5 Hz, 1H), 6.90 (dd, 
J = 8.0, 1.5 Hz, 1H), 6.79 (dd, J = 7.9, 1.6 Hz, 1H), 6.70 (ddd, J = 8.0, 7.3, 1.6 Hz, 1H), 
6.23 – 6.14 (m, 1H), 6.13 (d, J = 2.2 Hz, 2H), 3.74 (s, 2H), 3.77 (s, 6H). 13C NMR (75 
MHz, CDCl3) δ 161.6 (C), 159.5 (C), 142.5 (C), 138.8 (C), 125.1 (CH), 120.7 (CH), 118.8 
(CH), 116.5 (CH), 95.6 (CH), 94.8 (CH), 55.4 (CH3). HRMS (ESI) m/z: 246,1125 [M + 
H]+, C14H16NO3 requires 246,1125. 
2-(2,4-Dimethylphenoxy)-5-fluoroaniline (24l)  
 Brown oil; 1H NMR (300 MHz, CDCl3) δ 7.03 (d, J = 1.9 Hz, 1H), 6.91 (ddt, J = 8.2, 2.3, 
0.7 Hz, 1H), 6.65 (d, J = 8.2 Hz, 1H), 6.58 (dd, J = 8.8, 5.3 Hz, 1H), 6.50 (dd, J = 9.9, 
2.9 Hz, 1H), 6.32 (ddd, J = 8.8, 8.2, 3.0 Hz, 1H), 3.91 (s, 2H), 2.28 (s, 3H), 2.24 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 159.3 (d, Jc-f = 239.2 Hz, CF), 152.8 (C), 140.2 (d, Jc-f = 2.4 
Hz, C), 139.0 (d, Jc-f = 11.5 Hz, C), 132.7 (C), 132.0 (CH), 128.2 (C), 127.5 (CH), 118.7 
(d, Jc-f = 10.1 Hz, CH), 117.0 (CH), 104.2 (d, Jc-f = 23.4 Hz, CH), 102.7 (d, Jc-f = 26.8 Hz, 
CH), 20.6 (CH3), 16.0 (CH3). 19F NMR (282 MHz, CDCl3) δ -120.02. HRMS (ESI) m/z: 232.1130 [M + H]+, 
C14H15FNO requires 232.1132. 
2-(Naphthalen-1-yloxy)aniline (24m)44   
 Brown oil; 1H NMR (300 MHz, CDCl3) δ 8.37 – 8.29 (m, 1H), 7.91 – 7.81 (m, 1H), 7.58 
– 7.47 (m, 3H), 7.32 (dd, J = 8.2, 7.6 Hz, 1H), 7.01 (ddd, J = 8.0, 7.3, 1.5 Hz, 1H), 6.87 
(ddd, J = 7.9, 4.5, 1.5 Hz, 2H), 6.80 (dd, J = 7.6, 1.0 Hz, 1H), 6.72 (ddd, J = 7.9, 7.2, 1.5 
Hz, 1H), 3.84 (s, 2H). 13C NMR (75 MHz, CDCl3) δ 153.1 (C), 143.4 (C), 138.5 (C), 134.9 
(C), 127.7 (CH), 126.6 (CH), 126.0 (C), 125.8 (CH), 124.9 (CH), 122.5 (CH), 121.9 (CH), 
120.2 (CH), 118.9 (CH), 116.5 (CH), 110.3 (CH).  
2-(Naphthalen-2-yloxy)aniline (24n)45  
 Orange solid; mp 75-80 °C; 1H NMR (300 MHz, CDCl3) δ 7.84 – 7.75 (m, 2H), 7.65 (d, J = 
8.1 Hz, 1H), 7.46 – 7.32 (m, 2H), 7.27 (dd, J = 8.9, 2.5 Hz, 1H), 7.20 (d, J = 2.4 Hz, 1H), 7.02 
(ddd, J = 7.9, 7.3, 1.4 Hz, 1H), 6.93 (dd, J = 8.0, 1.5 Hz, 1H), 6.85 (dd, J = 7.9, 1.6 Hz, 1H), 
6.74 (ddd, J = 7.9, 7.2, 1.6 Hz, 1H), 3.77 (s, 2H). 13C NMR (75 MHz, CDCl3) δ 155.3 (C), 143.0 
(C), 138.8 (C), 134.3 (C), 129.9 (C), 129.9 (CH), 127.7 (CH), 127.0 (CH), 126.5 (CH), 125.1 







2-((6-Bromonaphthalen-2-yl)oxy)aniline (24o)  
 White solid; mp 92-94 °C; 1H NMR (300 MHz, CDCl3) 7.94 (d, J = 1.7 Hz, 1H), 7.70 (d, J = 
9.0 Hz, 1H), 7.52 (d, J = 8.7 Hz, 1H), 7.47 (dd, J = 8.8, 1.8 Hz, 1H), 7.28 (dd, J = 8.9, 2.5 Hz, 
1H), 7.13 (d, J = 2.5 Hz, 1H), 7.07 – 6.99 (m, 1H), 6.93 (dd, J = 8.1, 1.5 Hz, 1H), 6.86 (dd, J = 
7.9, 1.6 Hz, 1H), 6.75 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 3.79 (s, 2H).13C NMR (75 MHz, CDCl3) δ 
156.1 (C), 142.9 (C), 139.3 (C), 133.2 (C), 131.3 (C), 130.3 (CH), 130.1 (CH), 129.4 (CH), 
129.1 (CH), 125.9 (CH), 121.2 (CH), 120.2 (CH), 119.3 (CH), 118.4 (C), 117.1 (CH), 111.7 
(CH). HRMS (ESI) m/z: 314.0184 [M + H]+, C16H13BrNO requires 314.0175. 
Synthetic procedure for compound 25 
The amine 24 (7.5 mmol, 1 eq.) was dissolved in 5 mL of formic acid. The mixture was heated 
under reflux (100 °C) for 12 h. Afterwards, the reaction mixture was cooled to room temperature and 
quenched with 20  mL of NaHCO3 (sat.) solution. Followed by an extraction with dichloromethane 
(3x20 mL), washed with  brine (20mL) and dried over MgSO4. The solvent was removed and the crude 
product 25 was used for the next step without purification.35 
Synthetic procedure and characterization data for compounds 21 substituted in positions 1-4 
Compound 25 (4.0 mmol, 1 eq.), polyphosphoric acid (PPA) (106 mmol, 10.4 g) and phosphoryl 
chloride (POCl3)(20 mmol, 5 eq.) were mixed. The reaction mixture was stirred 3 h at 120 °C. 
Afterwards the mixture was cooled to room temperature, it was poured on 200 mL iced water and 
treated with 33% NH3 in water solution. The mixture was extracted with 3x100 mL of DCM, washed 
with 100 mL of brine and dried over MgSO4. The solvent was removed by evaporation and the crude 
product was purified by flash chromatography, obtaining product 21.33 
4-Methyldibenzo[b,f][1,4]oxazepine (21g)35  
 Orange oil; 1H NMR (300 MHz, CDCl3) δ 8.51 (s, 1H), 7.38 – 7.34 (m, 1H), 7.31 (ddd, J = 
7.4, 1.8, 0.8 Hz, 1H), 7.24 – 7.18 (m, 1H), 7.18 – 7.13 (m, 3H), 7.07 (t, J = 7.5 Hz, 1H), 
2.45 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 161.0 (CH), 158.3 (C), 152.6 (C), 140.8 (C), 134.6 
(CH), 130.2 (C), 129.1 (CH), 128.5 (CH), 127.7 (CH), 127.3 (C), 125.6 (CH), 124.6 (CH), 
121.6 (CH), 16.1 (CH3).  
2-Methyldibenzo[b,f][1,4]oxazepine (21h)35  
 Orange solid; mp 59-60 °C; 1H NMR (300 MHz, CDCl3) δ 8.46 (s, 1H), 7.36 – 7.31 (m, 1H), 
7.24 – 7.17 (m, 2H), 7.17 – 7.12 (m, 1H), 7.12 – 7.07 (m, 2H), 7.01 (d, J = 8.3 Hz, 1H), 2.30 
(d, J = 0.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 160.7 (CH), 158.3 (C), 152.8 (C), 140.5 (C), 
134.7 (C), 133.9 (CH), 130.3 (CH), 129.2 (CH), 128.7 (CH), 127.0 (C), 125.5 (CH), 121.3 (CH), 
120.4 (CH), 20.5 (CH3).  
2-Chlorodibenzo[b,f][1,4]oxazepine (21i)  
 Yellow solid; mp 98-100 °C; 1H NMR (300 MHz, CDCl3) δ 8.42 (s, 1H), 7.43 – 7.30 (m, 2H), 
7.29 (d, J = 2.6 Hz, 1H), 7.26 – 7.15 (m, 2H), 7.11 – 7.05 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 
158.9 (CH), 154.4 (C), 152.4 (C), 140.2 (C), 133.0 (CH), 130.5 (C), 129.6 (CH), 129.4 (CH), 
129.1 (CH), 128.4 (C), 126.0 (CH), 122.2 (CH), 121.3 (CH). HRMS (ESI) m/z: 230.0365 [M + 
H]+, C13H9ClNO requires 230.0367. 
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2-Methoxydibenzo[b,f][1,4]oxazepine (21j)35  
 Orange solid; mp 75-76 °C; 1H NMR (300 MHz, CDCl3) δ 8.47 (s, 1H), 7.34 (dd, J = 7.2, 2.3 
Hz, 1H), 7.24 – 7.12 (m, 2H), 7.11 – 7.08 (m, 1H), 7.06 (d, J = 8.9 Hz, 1H), 6.95 (dd, J = 8.8, 
3.0 Hz, 1H), 6.80 (d, J = 3.0 Hz, 1H), 3.77 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 160.2 (CH), 
156.7 (C), 154.1 (C), 152.9 (C), 140.4 (C), 129.1 (CH), 128.8 (CH), 127.7 (C), 125.6 (CH), 121.5 
(CH), 121.2 (CH), 118.9 (CH), 113.9 (CH), 55.8 (CH3).  
1,3-Dimethoxydibenzo[b,f][1,4]oxazepine (21k)  
 Yellow solid; mp 102-105 °C; 1H NMR (300 MHz, CDCl3) δ 8.63 (s, 1H), 7.31 – 7.26 
(m, 1H), 7.18 – 7.11 (m, 2H), 7.08 – 7.01 (m, 1H), 6.27 (dd, J = 2.3, 0.6 Hz, 1H), 6.21 
(d, J = 2.3 Hz, 1H), 3.81 (s, 3H), 3.80 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 164.8 (C), 
164.0 (C), 160.2 (C), 157.2 (CH), 152.6 (C), 141.6 (C), 128.5 (CH), 127.8 (CH), 125.7 
(CH), 121.2 (CH), 109.8 (C), 97.3 (CH), 95.1 (CH), 55.9 (CH3), 55.7 (CH3). HRMS (ESI) 
m/z: 256.0972 [M + H]+, C15H14NO3 requires 256.0968. 
8-Fluoro-2,4-dimethyldibenzo[b,f][1,4]oxazepine (21l)  
 Yellow solid; mp 73-76 °C; yellow solid; 1H NMR (300 MHz, CDCl3) δ 8.48 (s, 1H), 7.13 
(dt, J = 2.3, 0.7 Hz, 1H), 7.10 – 7.01 (m, 2H), 6.96 (d, J = 2.1 Hz, 1H), 6.88 (ddd, J = 8.9, 
7.6, 3.1 Hz, 1H), 2.39 (s, 3H), 2.27 (s, 3H).13C NMR (75 MHz, CDCl3) δ 162.2 (C), 159.7 
(d, Jc-f = 243.2 Hz, CF), 156.2 (C), 148.9 (d, Jc-f = 2.7 Hz, C), 141.8 (d, Jc-f = 10.8 Hz, C), 
135.6 (CH), 134.4 (C), 129.6 (C), 128.0 (CH), 126.8 (C), 122.0 (d, Jc-f = 9.4 Hz, CH), 115.2 
(d, Jc-f = 24.1 Hz, CH), 114.6 (d, Jc-f = 23.3 Hz, CH) 20.5 (CH3), 16.0 (CH3). 19F NMR(282 
MHz, CDCl3) δ -118.31. HRMS (ESI) m/z: 242.0971 [M + H]+, C15H13FNO requires 
242.0976. 
Benzo[b]naphtho[2,1-f][1,4]oxazepine (21m)  
 Yellow solid; mp 90-92 °C; 1H NMR (300 MHz, CDCl3) δ 8.70 (s, 1H), 8.59 – 8.54 (m, 1H), 
7.85 (dd, J = 7.1, 2.4 Hz, 1H), 7.70 – 7.57 (m, 3H), 7.46 – 7.37 (m, 2H), 7.33 – 7.27 (m, 
2H), 7.27 – 7.18 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 161.3 (CH), 156.5 (C), 152.7 (C), 
141.1 (C), 136.2 (C), 129.1 (CH), 129.0 (CH), 128.3 (CH), 127.8 (CH), 127.1 (CH), 126.5 
(C), 125.8 (CH), 125.1 (CH), 124.8 (CH), 123.1 (CH), 122.0 (C), 121.4 (CH). HRMS (ESI) 
m/z: 246.0921 [M + H]+, C17H12NO requires 246.0913. 
Benzo[b]naphtho[1,2-f][1,4]oxazepine (21n)  
 Orange solid; mp 124-127 °C; 1H NMR (300 MHz, CDCl3) δ 9.28 (s, 1H), 8.10 (dd, J = 8.5, 0.9 
Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.85 – 7.79 (m, 1H), 7.58 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H), 7.47 
(ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.41 – 7.34 (m, 1H), 7.30 (d, J = 8.9 Hz, 1H), 7.24 – 7.17 (m, 
2H), 7.17 – 7.13 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 161.0 (C), 159.1 (CH), 153.2 (C), 141.5 
(C), 134.2 (CH), 131.6 (C), 131.0 (C), 128.7 (CH), 128.4 (CH), 128.1 (CH), 125.8 (CH), 125.7 
(CH), 122.7 (CH), 121.1 (CH), 120.3 (CH), 120.0 (C). HRMS (ESI) m/z: 246.0912 [M + H]+, 
C17H12NO requires 246.0913. 
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3-Bromobenzo[b]naphtho[1,2-f][1,4]oxazepine (21o)  
 Yellow solid; mp 170-173 °C; 1H NMR (300 MHz, CDCl3) δ 9.21 (s, 1H), 8.01 – 7.93 (m, 2H), 
7.83 (d, J = 8.8 Hz, 1H), 7.65 (dd, J = 8.9, 2.1 Hz, 1H), 7.41 – 7.35 (m, 1H), 7.32 (d, J = 8.8 Hz, 
1H), 7.23 – 7.10 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 161.1 (C), 158.3 (CH), 153.0 (C), 141.3 
(C), 133.1 (CH), 132.1 (C), 131.3 (CH), 130.6 (CH), 130.1 (C), 128.6 (CH), 128.2 (CH), 126.0 
(CH), 124.4 (CH), 121.6 (CH), 121.1 (CH), 120.2 (C), 119.7 (C). HRMS (ESI) m/z: 324.0023 [M 
+ H]+, C17H11BrNO requires 324.0019. 
4.5.4. Synthetic procedure and characterization data for compound 27  
2-Aminobenzenethiol 26 (1.1 mmol, 1.1 eq.) was dissolved in 10 mL of PEG. 2-
Fluorobenzaldehyde 20 (1 mmol, 1 eq.) and K2CO3 (1 mmol, 1 eq.) were added. The reaction mixture 
was heated to 100 °C for 3 h. The mixture was cooled to room temperature and 20 mL of water was 
added to quench the reaction. The mixture was extracted with EtOAc (3x20 mL), washed with brine 
(20 mL) and dried over MgSO4. The solvent was removed by evaporation and the crude product was 
purified by flash chromatography, obtaining product 27.33 
Dibenzo[b,f][1,4]thiazepine (27)47  
 Yellow solid; mp 123-125 °C; 1H NMR (300 MHz, CDCl3) δ 8.88 (s, 1H), 7.44 – 7.26 (m, 7H), 
7.15 (ddd, J = 7.7, 5.6, 3.3 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 162.2 (CH), 148.5 (C), 139.4 
(C), 137.2 (C), 132.7 (CH), 131.6 (CH), 131.4 (CH), 129.4 (CH), 129.2 (CH), 128.8 (C), 128.2 
(CH), 127.2 (CH), 126.9 (CH). 
4.5.5. General synthetic procedures and characterization data for compounds 28  
General procedure for the enantioselective alkylation reaction: A 1M Et2Zn solution in 
hexanes (0.50 mmol) was added dropwise on a solution of L7 (0.020 mmol) in diethyl ether (0.3 mL) 
at room temperature under nitrogen atmosphere. After stirring 30 min., a solution of 
dibenzo[b,f][1,4]oxazepine 21 (0.10 mmol) in diethyl ether (1.0 mL) was added via syringe. The 
reaction was stirred until the reaction was complete (TLC). The reaction mixture was quenched with 
NH4Cl (10 mL), extracted with dichloromethane (3x15 mL), washed with brine (10 mL), dried over 
MgSO4 and dried under reduced pressure. Purification by flash chromatography on silica gel afforded 
compound 28. 
General procedure for the non-enantioselective alkylation reaction: A 1M Et2Zn solution in 
hexanes (0.50 mmol) was added dropwise in diethyl ether (0.3 mL) at room temperature under 
nitrogen atmosphere. After stirring 30 minutes, a solution of dibenzo[b,f][1,4]oxazepine 21 (0.10 
mmol) in diethyl ether (1.0 mL) was added via syringe. The reaction was stirred until the reaction was 
complete (TLC). The reaction mixture was quenched with NH4Cl (10 mL), extracted with 
dichloromethane (3x15 mL), washed with brine (10 mL), dried over MgSO4 and dried under reduced 
pressure. Purification by flash chromatography on silica gel afforded compound 28. 
(S)-11-Ethyl-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28a)33 
The enantiomeric excess (69%) was determined by chiral HPLC (Chiralpak IC), hexane-





20 = +13.8 (c 1.0, CHCl3, 69% ee); 1H NMR (300 MHz, CDCl3) δ 7.24 (ddd, J = 8.0, 7.0, 1.9 Hz, 1H), 
7.18-7.13 (m, 2H), 7.11 – 7.02 (m, 2H), 6.85 (ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.66 (ddd, J = 7.9, 7.3, 1.6 
Hz, 1H), 6.57 (dd, J = 7.9, 1.6 Hz, 1H), 4.33 (dd, J = 8.0, 6.9 Hz, 1H), 3.96 (s, 1H), 2.21 – 1.95 (m, 2H), 
1.02 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 157.2 (C), 144.0 (C), 137.6 (C), 134.0 (C), 128.7 (C), 
127.1 (C), 124.4 (C), 124.1 (C), 121.7 (C), 121.0 (C), 118.8 (C), 118.5 (C), 58.8 (CH), 27.8 (CH2), 11.4 
(CH3). 
(S)-11-Ethyl-7-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28b) 
The enantiomeric excess (49%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 9.34 min, minor 
enantiomer tr = 10.19 min. 
Oil; []D
20 = +2.7 (c 1.0, CHCl3, 49% ee); 1H NMR (300 MHz, CDCl3) δ 7.27 – 7.19 (m, 1H), 
7.14 (ddd, J = 7.5, 3.4, 1.6 Hz, 2H), 7.09 – 7.03 (m, 1H), 6.93 – 6.90 (m, 1H), 6.70 – 6.65 
(m, 1H), 6.50 (d, J = 8.0 Hz, 1H), 4.29 (dd, J = 7.9, 6.8 Hz, 1H), 3.87 (s, 1H), 2.23 (s, 3H), 2.17 – 1.79 (m, 
2H), 1.02 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 157.0 (C), 144.0 (C), 134.8 (C), 134.0 (C), 128.8 
(C), 128.6 (CH), 127.2 (CH), 124.8 (CH), 123.9 (CH), 122.0 (CH), 121.0 (CH), 118.8 (CH), 59.0 (CH), 27.7 
(CH2), 20.2 (CH3), 11.4 (CH3). HRMS (ESI) m/z: 240.1383 [M + H]+, C16H18NO requires 240.1383. 
(S)-11-Ethyl-8-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28c) 
The enantiomeric excess (65%) was determined by chiral HPLC (Chiralpak IC) hexane-
iPrOH 95:05, 1 mL/min, major enantiomer tr = 7.26 min, minor enantiomer tr = 6.63 min. 
Oil; []D
20 = +13.6 (c 1.0, CHCl3, 65% ee); 1H NMR (300 MHz, CDCl3) δ 7.28 – 7.19 (m, 1H), 
7.14 (ddd, J = 7.5, 3.3, 1.6 Hz, 2H), 7.09 – 7.03 (m, 1H), 6.97 (d, J = 8.1 Hz, 1H), 6.50 – 
6.43 (m, 1H), 6.38 (dd, J = 1.9, 0.5 Hz, 1H), 4.32 (dd, J = 7.9, 6.9 Hz, 1H), 3.93 (s, 1H), 2.18 
(s, 3H), 2.16 – 1.98 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H).13C NMR (75 MHz, CDCl3) δ 157.3 (C), 142.0 (C), 
137.2 (C), 134.0 (C), 133.9 (C), 128.7 (CH), 127.1 (CH), 124.0 (CH), 121.4 (CH), 120.9 (CH), 119.4 (CH), 
118.9 (CH), 58.7 (CH), 27.8 (CH2), 20.6 (CH3), 11.4 (CH3). HRMS (ESI) m/z: 240.1383 [M + H]+, C16H18NO 
requires 240.1383. 
(S)-7-Chloro-11-ethyl-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28d) 
The enantiomeric excess (54%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 9.51 min, minor 
enantiomer tr = 7.78 min. 
Oil; []D
20 = +2.2 (c 1.0, CHCl3, 54% ee); 1H NMR (300 MHz, CDCl3) δ 7.30 – 7.21 (m, 1H), 
7.17 – 7.12 (m, 2H), 7.12 – 7.05 (m, 2H), 6.81 (dd, J = 8.5, 2.4 Hz, 1H), 6.48 (d, J = 8.5 Hz, 
1H), 4.30 (dd, J = 8.0, 6.9 Hz, 1H), 3.95 (s, 1H), 2.19 – 1.97 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 156.7 (C), 144.0 (C), 136.4 (C), 133.8 (C), 128.9 (CH), 127.2 (CH), 124.5 (CH), 124.2 (CH), 
122.5 (C), 121.8 (CH), 121.0 (CH), 119.1 (CH), 58.7 (CH), 27.7 (CH2), 11.4 (CH3). HRMS (ESI) m/z: 








The enantiomeric excess (60%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 11.19 min, minor 
enantiomer tr = 8.89 min. 
Oil; []D
20 = +14.3 (c 1.0, CHCl3, 60% ee); 1H NMR (300 MHz, CDCl3) δ 7.30 – 7.21 (m, 1H), 
7.18 – 7.05 (m, 3H), 6.98 (d, J = 8.5 Hz, 1H), 6.58 (dd, J = 8.5, 2.5 Hz, 1H), 6.53 (d, J = 2.2 
Hz, 1H), 4.30 (t, J = 7.4 Hz, 1H), 4.06 (s, 1H), 2.20 – 1.97 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 157.0 (C), 142.4 (C), 138.8 (C), 133.8 (C), 129.2 (C), 129.0 (CH), 127.2 (CH), 124.4 (CH), 
122.8 (CH), 120.9 (CH), 118.1 (CH), 117.5 (CH), 58.6 (CH), 27.8 (CH2), 11.4 (CH3). HRMS (ESI) m/z: 
260.0835 [M + H]+, C15H15ClNO requires 260.0837. 
(S)-11-Ethyl-8-methoxy-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28f) 
The enantiomeric excess (62%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 16.89 min, minor 
enantiomer tr = 15.65 min. 
Oil; []D
20 = +19.5 (c 1.0, CHCl3, 62% ee); 1H NMR (300 MHz, CDCl3) δ 7.29 – 7.20 (m, 1H), 
7.17 – 7.11 (m, 2H), 7.10 – 7.04 (m, 1H), 7.00 (d, J = 8.7 Hz, 1H), 6.21 (dd, J = 8.7, 2.9 Hz, 
1H), 6.10 (d, J = 2.9 Hz, 1H), 4.41 – 4.28 (m, 1H), 4.00 (s, 1H), 3.70 (s, 3H), 2.15 – 1.98 (m, 2H), 1.02 (t, 
J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 161.1 (C), 157.6 (C), 156.5 (C), 138.4 (C), 134.0 (C), 128.8 
(CH), 127.0 (CH), 124.1 (CH), 122.2 (CH), 120.8 (CH), 103.6 (CH), 103.3 (CH), 58.4 (CH), 55.4 (CH3), 27.8 
(CH3), 11.4 (CH3). HRMS (ESI) m/z: 256.1328 [M + H]+, C16H18NO2 requires 256.1332. 
(S)-11-Ethyl-4-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28g) 
The enantiomeric excess (60%) was determined by chiral HPLC (Phenomenex Lux® 
5µm Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 6.55 min, 
minor enantiomer tr = 5.71 min. 
Oil; []D
20 = +26 (c 1.0, CHCl3, 60% ee); 1H NMR (300 MHz, CDCl3) δ 7.15 – 7.08 (m, 
2H), 7.01 – 6.96 (m, 2H), 6.85 (ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.64 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 6.55 
(dd, J = 7.9, 1.6 Hz, 1H), 4.37 (dd, J = 8.0, 6.9 Hz, 1H), 3.97 (s, 1H), 2.42 (s, 3H), 2.25 – 1.93 (m, 2H), 1.03 
(t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 155.4 (C), 143.2 (C), 138.2 (C), 134.2 (C), 130.3 (C), 130.2 
(CH), 124.4 (CH), 123.9 (CH), 122.0 (CH), 118.3 (CH), 118.2 (CH), 58.2 (CH), 27.5 (CH2), 16.3 (CH3), 11.5 
(CH3). HRMS (ESI) m/z: 240.1381 [M + H]+, C16H18NO requires 240.1383. 
(S)-11-Ethyl-2-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28h) 
The enantiomeric excess (62%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 8.69 min, minor 
enantiomer tr = 7.96 min. 
Oil; []D
20 = +17.5 (c 1.0, CHCl3, 62% ee); 1H NMR (300 MHz, CDCl3) δ 7.10 – 7.02 (m, 3H), 
6.94 (d, J = 1.2 Hz, 1H), 6.84 (ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.65 (ddd, J = 7.9, 7.3, 1.6 Hz, 
1H), 6.56 (dd, J = 7.9, 1.6 Hz, 1H), 4.28 (dd, J = 8.0, 6.8 Hz, 1H), 2.31 (s, 3H), 2.23 – 1.71 (m, 2H), 1.02 
(t, J = 7.4 Hz, 3H).   13C NMR (75 MHz, CDCl3) δ 155.0 (C), 144.1 (C), 137.7 (C), 133.6 (C), 129.0 (CH), 
127.6 (CH), 124.3 (C), 124.2 (CH), 121.6 (CH), 120.7 (CH), 118.7 (CH), 118.5 (CH), 58.8 (CH), 27.8 (CH2), 





The enantiomeric excess (34%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose 1), hexane-iPrOH 95:05, 1 mL/min, major enantiomer tr = 11.79 min, minor 
enantiomer tr = 12.69 min. 
Oil; []D
20 = +11.2 (c 1.0, CHCl3, 34% ee); 1H NMR (300 MHz, CDCl3) δ 1H NMR (300 MHz, 
CDCl3) δ 7.19 (dd, J = 8.5, 2.6 Hz, 1H), 7.13-7.07 (m, 2H), 7.06 (dd, J = 8.0, 1.5 Hz, 1H), 
6.87 (ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.68 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 6.57 (dd, J = 7.9, 1.6 Hz, 1H), 4.30 
(t, J = 7.4 Hz, 1H), 3.96 (s, 1H), 2.28 – 1.79 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
155.6 (C), 143.7 (C), 137.3 (C), 135.7 (C), 129.0 (CH), 128.5 (CH), 127.0 (CH), 124.6 (CH), 122.5 (CH), 
121.6 (CH), 119.1 (CH), 118.6 (CH), 58.3 (CH), 27.5 (CH2), 11.3 (CH3). HRMS (ESI) m/z: 260.0837 [M + 
H]+, C15H15ClNO requires 260.0837. 
(S)-11-Ethyl-2-methoxy-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28j) 
The enantiomeric excess (70%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 15.15 min, minor 
enantiomer tr = 12.7 min. 
Oil; []D
20 = +14.2 (c 1.0, CHCl3, 70% ee); 1H NMR (300 MHz, CDCl3) δ  7.09 (d, J = 8.6 Hz, 
1H), 7.06 (dd, J = 8.0, 1.5 Hz, 1H), 6.84 (ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.74 (dd, J = 8.7, 3.1 
Hz, 1H), 6.69 (d, J = 3.1 Hz, 1H), 6.65 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 6.55 (dd, J = 7.9, 1.6 
Hz, 1H), 4.31 (dd, J = 8.0, 6.8 Hz, 1H), 3.78 (s, 3H), 2.21 – 1.94 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 155.9 (C), 151.1 (C), 144.2 (C), 137.7 (C), 135.0 (C) 124.3 (CH), 121.6 (CH), 121.6 (CH), 
118.6 (CH), 118.4 (CH), 112.8 (CH), 112.7 (CH), 58.5 (CH), 55.6 (CH3), 27.5 (CH2), 11.4 (CH3). HRMS (ESI) 
m/z: 256.1341 [M + H]+, C16H18NO2 requires 256.1332. 
(S)-11-Ethyl-1,3-dimethoxy-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28k) 
The enantiomeric excess (56%) was determined by chiral HPLC (Phenomenex Lux® 
5µm Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 30.15 min, 
minor enantiomer tr = 39.63 min. 
Oil; []D
20 = -6.8 (c 1.0, CHCl3, 56% ee); 1H NMR (300 MHz, CDCl3) δ 7.04 (dd, J = 7.9, 
1.5 Hz, 1H), 6.85 (ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.64 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 
6.56 (dd, J = 7.9, 1.6 Hz, 1H), 6.35 (d, J = 2.4 Hz, 1H), 6.23 (d, J = 2.4 Hz, 1H), 4.51 (dd, J = 8.4, 6.9 Hz, 
1H), 4.14 (s, 1H), 2.16 – 1.87 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H).  13C NMR (75 MHz, CDCl3) δ 159.9 (C), 
158.2 (C), 157.0 (C), 143.4 (C), 137.7 (C), 124.4 (CH), 121.6 (CH), 118.5 (CH), 118.3 (CH), 115.3 (C), 98.0 
(CH), 94.7 (CH), 55.8 (CH3), 55.4 (CH3), 51.5 (CH), 29.0 (CH2), 11.3 (CH3). HRMS (ESI) m/z: 286.1435 [M 
+ H]+, C17H20NO3 requires 286.1438. 
(S)-11-Ethyl-8-fluoro-2,4-dimethyl-10,11-dihydrodibenzo[b,f][1,4]oxazepine (28l) 
The enantiomeric excess (59%) was determined by chiral HPLC (Phenomenex Lux® 
5µm Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 7.31 min, 
minor enantiomer tr = 4.83 min. 
Oil; []D
20 = +23.6 (c 1.0, CHCl3, 59% ee); 1H NMR (300 MHz, CDCl3) δ 7.01 (dd, J = 
8.7, 5.7 Hz, 1H), 6.92 (dd, J = 1.4, 0.7 Hz, 1H), 6.77 (d, J = 1.7 Hz, 1H), 6.27 (ddd, J = 
8.7, 7.8, 3.0 Hz, 1H), 6.21 (dd, J = 10.3, 2.9 Hz, 1H), 4.30 (t, J = 7.4 Hz, 1H), 4.03 (s, 
1H), 2.35 (s, 3H), 2.26 (s, 3H), 2.18 – 1.97 (m, 3H), 1.02 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
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159.6 (d, J = 239.3 Hz, C), 153.3 (C), 139.5 (d, J = 11.1 Hz, C), 133.6 (C), 130.9 (CH), 129.9 (C), 125.0 
(CH), 122.68 (d, J = 10.2 Hz, CH), 112.1 (C), 104.1 (d, J = 1.4 Hz, CH), 103.8 (d, J = 4.8 Hz, CH), 58.0 (CH), 
27.6 (CH2), 20.8 (CH3), 16.1 (CH3), 11.5 (CH3). HRMS (ESI) m/z: 272.1444 [M + H]+, C17H19FNO requires 
272.1445. 
(S)-7-Ethyl-7,8-dihydrobenzo[b]naphtho[2,1-f][1,4]oxazepine (28m) 
The enantiomeric excess (59%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 95:05, 0.5 mL/min, major enantiomer tr = 15.43 min, minor 
enantiomer tr = 14.21 min. 
Oil; []D
20 = +6.6 (c 1.0, CHCl3, 59% ee); 1H NMR (300 MHz, CDCl3) δ 8.47 (ddd, J = 
3.0, 1.3, 0.8 Hz, 1H), 7.82-7.79 (m, 1H), 7.60 – 7.51 (m, 2H), 7.48 (ddd, J = 8.1, 6.8, 1.4 Hz, 1H), 7.32 
(dd, J = 7.9, 1.5 Hz, 1H), 7.27 (d, J = 7.9 Hz, 1H), 6.87 (ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.71 (ddd, J = 7.9, 
7.3, 1.6 Hz, 1H), 6.61 (dd, J = 7.9, 1.6 Hz, 1H), 4.49 (dd, J = 8.0, 6.8 Hz, 1H), 2.39 – 2.02 (m, 2H), 1.06 (t, 
J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 152.1 (C), 144.0 (C), 138.1 (C), 134.1 (C), 129.0 (C), 127.6 
(CH), 127.5 (C), 126.2 (CH), 126.1 (CH), 125.2 (CH), 124.5 (CH), 123.6 (CH), 122.0 (CH), 121.8 (CH), 118.8 
(CH), 118.8 (CH), 59.1 (CH), 28.2 (CH2), 11.5 (CH3). HRMS (ESI) m/z: 276.1378 [M + H]+, C19H18NO 
requires 276.1383. 
(S)-13-Ethyl-12,13-dihydrobenzo[b]naphtho[1,2-f][1,4]oxazepine (28n) 
The enantiomeric excess (57%) was determined by chiral HPLC (Chiralpak IC), hexane-
iPrOH 95:05, 0.5 mL/min, major enantiomer tr = 59.66 min, minor enantiomer tr = 29.82 
min. 
Oil; []D
20 = -126.7 (c 1.0, CHCl3, 57% ee); 1H NMR (300 MHz, CDCl3) δ 7.98 (d, J = 8.5 Hz, 
1H), 7.82 (dd, J = 8.1, 1.4 Hz, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.53 (ddd, J = 8.5, 6.8, 1.5 Hz, 
1H), 7.41 (ddd, J = 8.0, 6.8, 1.1 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.14 (dd, J = 7.9, 1.5 Hz, 
1H), 6.88 (ddd, J = 7.8, 7.3, 1.5 Hz, 1H), 6.71 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 6.63 (dd, J = 7.9, 1.6 Hz, 1H), 
4.88 (dd, J = 8.6, 6.4 Hz, 1H), 2.40 – 2.09 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H).  13C NMR (75 MHz, CDCl3) δ 
154.3 (C), 143.9 (C), 137.4 (C), 131.2 (C), 130.8 (C), 129.1 (CH), 128.8 (CH), 127.0 (CH), 126.6 (C), 124.4 
(CH), 124.3 (CH), 122.2 (CH), 121.9 (CH), 121.4 (CH), 119.0 (CH), 118.6 (CH), 54.7 (CH), 29.0 (CH2), 11.6 
(CH3). HRMS (ESI) m/z: 276.1382 [M + H]+, C19H18NO requires 276.1383. 
(S)-3-Bromo-13-ethyl-12,13-dihydrobenzo[b]naphtho[1,2-f][1,4]oxazepine (28o) 
The enantiomeric excess (67%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose 1), hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 37.28 min, minor 
enantiomer tr = 16.95 min. 
Oil; []D
20 = -80.2 (c 1.0, CHCl3, 67% ee); 1H NMR (300 MHz, CDCl3) δ 7.97 (d, J = 2.1 Hz, 
1H), 7.83 (d, J = 9.2 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.57 (dd, J = 9.1, 2.1 Hz, 1H), 7.37 (d, 
J = 8.8 Hz, 1H), 7.12 (dd, J = 7.9, 1.5 Hz, 1H), 6.89 (ddd, J = 7.8, 7.3, 1.5 Hz, 1H), 6.72 (ddd, 
J = 7.9, 7.4, 1.6 Hz, 1H), 6.64 (dd, J = 7.8, 1.5 Hz, 1H), 4.80 (dd, J = 8.5, 6.4 Hz, 1H), 2.33 – 2.09 (m, 2H), 
0.99 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 154.4 (C), 143.8 (C), 137.1 (C), 132.0 (C), 130.7 (CH), 
129.9 (CH), 128.2 (CH), 127.2 (C), 124.4 (CH), 124.1 (CH), 123.7 (CH), 123.2 (C), 121.3 (CH), 119.3 (CH), 
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The classical Reformatsky reaction, discovered in 1887,1 provides a convenient synthesis of β-
hydroxy esters through a zinc mediated reaction between α-haloesters and aldehydes or ketones 
(Scheme 5.1).2-4 Nowadays the Reformatsky reaction includes all those reactions resulting from the 
metal insertion into the carbon-halogen bond activated by carbonyl or carbonyl related groups in 
vicinal or vinylogous positions, with a variety of different electrophiles. There are many examples with 
different metals such as samarium, tin, cobalt and indium (all metals that are used in low oxidation 
state). The reaction is a powerful methodology for C-C bond formation and an important alternative 
for the base induced aldol reaction, with a wide application in organic synthesis, due to the remarkable 
functional group tolerance and mild reaction conditions.  
 
Scheme 5.1. Classical Reformatsky reaction 
 The classical problem of the Reformatsky reaction due to the difference in  the activation 
degree of different zinc sources could be tackled with the introduction of special forms of activated 
zinc. This fact made that more efficient and mild conditions could be used and opened the possibility 
for the development of stereoselective variants of the Reformatsky reaction.5 However, although 
these methodologies had various limitations due to its intrinsic heterogeneous character, of which the 
most important are low yields and stereoselectivities, with narrow substrate scope compared with the 
classical aldol reaction. 
 These limitations were a major drawback until 2000, when Honda introduced the 
homogeneous Reformatsky reaction based on the use of Me2Zn or Et2Zn as a zinc source.6, 7 Although 
the introduction of the homogeneous Reformatsky reaction opened doors for the development of 
catalytic enantioselective methodologies, until today, its applications are rather scarce.  
5.1.1. Catalytic enantioselective Reformatsky reactions of aldehydes 
 The first catalytic enantioselective Reformatsky reaction with aldehydes was described in 
2008 by Feringa and coworkers (Scheme 5.2).8 A possible explanation for the late appearance of this 
first example, is the high reactivity of aldehydes and therefore the low control of the 
enantioselectivity. The procedure described by Feringa consists in the slow addition (10 minutes) of 
the aldehyde to the reaction mixture using 20 mol % of ligand, ethyl iodoacetate and Me2Zn in Et2O 
under air atmosphere. The chiral ligand used was a readily available BINOL type ligand. The slow 
addition was required to avoid the non catalyzed reaction (background reaction). Several aromatic, 
heteroaromatic and aliphatic aldehydes were applied in the reaction, leading to the corresponding 




Scheme 5.2. First catalytic enantioselective Reformatsky reaction with aldehydes. 
 In the same year, Cozzi described a dimethylzinc mediated, oxidatively promoted Reformatsky 
reaction of  ethyl iodoacetate using aldehydes and ketones as electrophiles.9 This group describes two 
protocols for the non-enantioselective Reformatsky reaction of aldehydes and ketones. Method A is 
more suited for non enolizable aldehydes and consists in the addition of the latter to a solution of 
Me2Zn and ethyl iodoacetate in Et2O, connecting the reaction flask to air. Method B, on the other 
hand, consists in the addition of all the reagents consecutively in the reaction flask. This method was 
more appropriate for aliphatic enolizable ketones and aldehydes. Triphenylphosphine oxide was 
added to the reaction as an additive to speed up the reaction allowing also the reaction with rather 
unreactive and challenging ketones. In the same work, they evaluated also an enantioselective version 
of the reaction, with the addition of a chiral aminoalcohol ligand [(1R, 2S)-N-pyrrolidinylephedrine] 
(Scheme 5.3). The products were obtained in good yields and enantioselectivities.  
 
Scheme 5.3. Catalytic enantioselective Reformatsky reaction with ketones and aldehydes. 
 Few months later, the same research group described a Me2Zn mediated, tert-
butylhydroperoxide promoted, catalytic enantioselective Reformatsky reaction with aldehydes 
(Scheme 5.4).10 In this report, the authors tried to decrease the big amounts of Me2Zn used in the 
previous report described by Feringa.8 They observed that in the reaction between benzaldehyde and 
ethyl iodoacetate promoted by Me2Zn and a norephedrine derived chiral ligand [(1R, 2S)-N-
pyrrolidinylephedrine] under air atmosphere and at low temperature there were problems in the 
initiation step of the radical cycle with oxygen. They reasoned that the addition of tBuOOH as 
promotor could favor the establishment of a radical cycle at low temperature, while Ph3P=O functions 
as a reaction accelerator. They were able to decrease the number of equivalents needed of Me2Zn to 





Scheme 5.4. Catalytic enantioselective Reformatsky reaction with aldehydes in the presence of tBuOOH. 
 In 2011, Wolf described a bisoxazolidine catalyzed enantioselective Reformatsky reaction with 
aldehydes (Scheme 5.5).11 They used 4-bromobenzaldehyde, which is significantly less prone to 
descomposition than benzaldehyde, for optimization of the reaction conditions. They noticed that the 
Reformatsky reaction is sensitive to various, unusual, parameters such as flask size, the timing of the 
exposure to air and the addition sequence of the Me2Zn. After optimization, various aldehydes were 
tested, with slow addition, in the reaction with ethyl iodoacetate, in the presence of Me2Zn and a 
chiral bisoxazolidine ligand. The corresponding products were obtained in good yields and moderate 
to good enantioselectivities (26-80% ee). Noteworthy is the use of stoichiometric amounts of 
trimethoxyborane, which induces transmetalation and so facilitates the catalyst turnover.  
 
Scheme 5.5. Bisoxazolidine catalyzed enantioselective Reformatsky reaction with aldehydes. 
 In 2014, Li and He described an asymmetric Reformatsky reaction of aldehydes catalyzed by 
novel β-amino alcohols and zinc complexes (Scheme 5.6).12 The researchers performed the addition 
of ethyl iodoacetate to various aldehydes under air conditions in the presence of 2.25 equivalents of 
Me2Zn and 20 mol % of 2,4-di-tert-butyl-6-(((2-hydroxy-1,2-diphenylethyl)amino)methyl)phenol as a 
ligand. The corresponding products were obtained in moderate yields and moderate to good 






Scheme 5.6. Asymmetric Reformatsky reaction with aldehydes catalyzed by novel β-amino alcohols and zinc 
complexes. 
5.1.2. Catalytic enantioselective Reformatsky reactions of ketones 
 In 2006, Cozzi described the first catalytic enantioselective Reformatsky reaction with ketones 
(Scheme 5.7).13 The researcher tested various esters in the reaction with acetophenone in the 
presence of Me2Zn and a manganese salen complex, noticing that an increase in the steric hindrance 
led to a decrease in the enantioselectivity of the reaction, giving the best enantioselectivity when ethyl 
iodoacetate was used (63% ee). The reaction was performed in MTBE at reflux temperature in the 
presence of 4-phenylpyridine N-oxide. Other ketones were also tested, but although the conversions 
were good, the enantioselectivities were low. Lowering the temperature brought better results; at 
room temperature, the use of various ketones led to the corresponding products in good yields (30-
90%) and moderate enantioselectivities (21-86% ee). 
 
Scheme 5.7. The first catalytic enantioselective Reformatsky reaction with ketones. 
 Two years later, in 2008, Feringa and coworkers reported a catalytic enantioselective 
Reformatsky reaction with ketones using chiral BINOL type ligands (Scheme 5.8).14 With the optimized 
conditions in hand, consisting in the slow addition (30 minutes) of the ketone to a solution of Me2Zn, 
ethyl iodoacetate and a BINOL type ligand in diethyl ether in the presence of air, they were able to 
obtain the β-hydroxyesters from aromatic, heteroaromatic and aliphatic ketones in good yields (53-
85%) and moderate to good enantioselectivities (28-90% ee). In the same report, the researchers also 
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mention the enantioselective Reformatsky reaction of phenyl(o-tolyl)-methanone, resulting in 
moderate yield (40%), but good enantioselectivity (82% ee).  
 
Scheme 5.8. Catalytic enantioselective Reformatsky reaction with ketones using (S)-3,3'-bis(trimethylsilyl)-
[1,1'-binaphthalene]-2,2'-diol. 
 The same researchers reported in the same year a catalytic enantioselective Reformatsky 
reaction with ortho-substituted diarylketones, which they already introduced earlier (Scheme 5.9).14, 
15 In the optimization of the reaction conditions it became clear that only ortho substituted 
diaryketones are suitable substrates; meta and para substituted substrates resulted in racemic 
carbinols. The reaction conditions include the presence of triphenylphosphine oxide, which enhances 
the yield of the reaction, but especially the enantioselectivity. The reaction is performed in the 
presence of 12 equivalents of  Me2Zn and 6 equivalents of ethyl iodoacetate and 30 mol % of a readily 
available BINOL type ligand. The corresponding β-hydroxyesters were obtained in low to good yields 
(33-84%) and moderate to good enantioselectivities (30-91% ee). 
 
Scheme 5.9. Catalytic enantioselective Reformatsky reaction with ortho-substituted diarylketones. 
In 2010, Cozzi and Benfatti described a copper promoted enantioselective Reformatsky type 
reaction with ketones (Scheme 5.10).16 Cozzi and collaborators observed in previous works that the 
reproducibility of the Reformatsky reactions may present some problems and they suggest that such 
problems must lie in the formation of radicals. Therefore they investigated new methods of generating 
radicals in an easier and controlled way. For this purpose, they used copper(I) or copper(II) salts. The 
reaction took place at lower temperature (-25 °C), using a catalytic amount of N-pyrrolidinyl 
norephedrine (25 mol %), CuCN (15 mol %), a phosphine additive [1,3-
bis(diphenylphosphanyl)propane, dppp] (15 mol %), Me2Zn and ethyl iodoacetate. The reactions, with 
rather long reaction times (14-48 h) led to moderate to high yields (50-90%), but low to moderate 
enantioselectivities (50-72% ee), with aromatic and aliphatic ketones. Altough the objective was to 
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improve the previously described results, Cozzi´s reaction conditions did not improve the  results 
described in the literature. 
 
Scheme 5.10. Copper promoted enantioselective Reformatsky reaction of ketones. 
5.1.3. Catalytic enantioselective Reformatsky reactions of imines 
Imines can be used as electrophiles in Reformatsky reactions, instead of the typical aldehydes 
and ketones. However, due to the low reactivity of imines, the catalytic enantioselective aza-
Reformatsky reaction is scarcely explored, despite the possibility of easy synthesis of chiral β-amino 
acids, an important building block in synthetic organic chemistry.17, 18 On the other hand, this 
transformation can be problematic, since it can lead to an undesired mixture of β-amino esters and β-
lactams. These problems can be avoided by the use of chelating imines derived from 2-
methoxyaniline, as described by Snapper and collaborators in a non-enantioselective nickel catalyzed 
aza-Reformatsky reaction.19 Hoveyda and collaborators described in the same year, the three-
component enantioselective synthesis of propargylamines catalyzed by Zr, using imines derived from 
the more bulky o-phenoxyaniline instead of 2-methoxyaniline, getting an improvement in the 
enantioselectivity of the reaction.20 This is exactly what Cozzi and coworker did when they described 
the first enantioselective aza-Reformatsky reaction in 2005, using 1.6 equivalents of ligand (N-
methylephedrine).21 One year later, Cozzi described the catalytic version of this reaction, using 20-30 
mol % of the same ligand (Scheme 5.11).22 In the catalytic version of the reaction, 1 equivalent of 
differently substituted benzaldehydes and o-phenoxyaniline are mixed with 4 equivalents of Me2Zn to 
form the imine under nitrogen atmosphere. After more than 3 hours, the nitrogen atmosphere was 
carefully changed to an air atmosphere, followed by an addition of solvent and N-methylephedrine. 
After placing the reaction at 0 °C, ethyl iodoacetate was added to give the formation of the β-amino 
esters in high yields (67-90%)  and enantioselectivities (80-95% ee). A drawback of the reaction is the 
necessity of a bulky directing group in ortho position of the aromatic ring. 
 
Scheme 5.11. Catalytic enantioselective one-pot three-component aza-Reformatsky reaction. 
 An important discovery made by Cozzi was the necessity for air in the reaction, what led him 
thinking in a radical mechanism with Me2Zn. Another aspect he reasoned is that the reaction is 
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dependent on several, uncommon, parameters such as the size of the flask, the surface area and the 
quantity of the solvent. In the same article he proposed a possible mechanism (Scheme 5.12), 
suggesting a radical mechanism. 
 






El objetivo general de este capítulo es el desarrollo de un método catalítico y enantioselectivo 
que permita llevar a cabo la reacción de aza-Reformatsky de iminas cíclicas de tipo 2,2-dióxido 
benzoxatiazina (1) con iodoacetato de etilo (29) que transcurra con buenos rendimientos y excesos 
enantioméricos.  
 
 En el estudio de este proyecto se considerarán los siguientes aspectos: 
1. La influencia de diferentes ligandos de tipo BINOL (L1-L6), (R)-VAPOL (L7), (R)-VANOL (L8), derivados 
de (S)-prolinol (L9-L12), quinina (L13) y N-metilefedrina (L17) sobre el rendimiento y la 
enantioselectividad de la reacción.  
 
2. La influencia de la naturaleza del reactivo de dialquilzinc utilizado (Me2Zn y Et2Zn), número de 
equivalentes de dialquilzinc, disolvente y temperatura de reacción. 
3. Evaluación de diversas aldiminas cíclicas de tipo 2,2-dióxido benzoxatiazina (1) con diferente 
naturaleza electrónica y estérica en la reacción con iodoacetato de etilo (45). 
 
4. Evaluación de diversas cetiminas cíclicas de tipo 2,2-dióxido benzoxatiazina (9) con diferente 




5. Evaluación de distintas transformaciones sintéticas de los productos obtenidos basadas en en la 
reactividad de los grupos éster y sulfamidato sin pérdida de pureza óptica.  




5.3. RESULTADOS Y DISCUSIÓN 
5.3.1. Síntesis de 2,2-dióxido benzoxatiazinas 
Con el objeto de llevar a cabo un estudio amplio del alcance y limitaciones de la reacción de 
aza-Reformatsky a aldiminas de tipo 2,2-dióxido benzoxatiazinas que incluyera iminas doblemente 
sustituidas se sintetizó la aldimina disustituida en las posiciones 6 y 8 del anillo aromático con átomos 
de cloro  (Esquema 5.13). Se siguió la misma metodología usada anteriormente, obteniendo la 
aldimina cíclica 1l con un rendimiento moderado (40%) 
 
Esquema 5.13. Síntesis de una aldimina de tipo 2,2-dióxido benzoxatiazina disustituida. 
Con el mismo propósito también se sintetizaron varias cetiminas de tipo 2,2-dióxido 
benzoxatiazinas (9). Estas iminas fueron sintetizadas a partir de diferentes 2-hidroxiacetofenonas 8  
en una reacción con clorosulfonilamina,  preparada in situ a partir de isocianato de clorosulfonilo, en 
DMA en presencia de hidruro sódico a 70 °C (Tabla 5.1). Los rendimientos de estas reacciones fueron 
más bajos que el de las reacciones llevadas a cabo con los correspondientes salicilaldehidos debido a 
la menor electrofilia del grupo carbonilo de las hidroxiacetofenonas.   
Tabla 5.1. Sintesis de cetiminas de tipo 2,2-dióxido benzoxatiazina. 
 
Entrada 8 R1 R2 t (h) 9 R (%)a 
1 8a H Me 18 9a 30 
2 8b 6-Me Me 18 9b 35 
3 8c 6-Cl Me 18 9c 32 
4 8d 7-Me Me 18 9d 40 
5 8e 7-OMe Me 18 9e 37 
6 8f 6-Cl, 7-Me Me 18 9f 29 
7b 8g H Me 18 9g 30 
8 8h H Et 18 9h 32 
9 8i H CH2CH2Ph 18 9i 28 
a Rendimiento después de purificación por cromatografía de columna. b La imina fue sintetizada a partir de 2-
acetil-1-naftol 
5.3.2. Síntesis de N-sulfonil cetiminas cíclicas de 5 miembros 
 También se sintetizaron dos  N-sulfonil cetiminas de cinco miembros (33) mediante la adición 
de reactivos de Grignard a sacarina (32) (Esquema 5.14).23 En la reacción de adición se genera el 
127 
 
correspondiente aminal el cual experimenta una deshidratación espontánea generando las N-sulfonil 
cetiminas 33. El rendimiento fue moderado (41%) para la reacción de la sacarina con MeMgBr, 
mientras que cuando se utilizó EtMgBr se obtuvo mejor rendimiento (71%)  
 
Esquema 5.14. Síntesis de N-sulfonil cetiminas cíclicas de 5 miembros. 
5.3.3. Optimización de las condiciones de reacción 
 Como se ha visto en los antecedentes bibliográficos solo hay descrito un ejemplo de una 
reacción catalítica enantioselectiva de tipo aza-Reformatsky descrito en la bibliografía. Por tanto 
decidimos estudiar este tipo de reacción utilizando iminas cíclicas, como son las benzoxatiazinas. El 
estudio de la reacción de aza-Reformatsky entre iodoacetato de etilo (45) y las iminas cíclicas de tipo 
2,2-dióxido benzoxatiazina se inició con la optimización de las condiciones de la reacción. El proceso 
de optimización se llevó a cabo ensayando un conjunto de ligandos en presencia de 7 equivalentes de 
Me2Zn (1,2 M en tolueno) empleando Et2O como disolvente a temperatura ambiente (Tabla 5.2). 
Como ligandos se utilizaron diferentes ligandos quirales de tipo BINOL (L1-L6), (R)-VAPOL (L7), (R)-
VANOL (L8), derivados de (S)-prolinol (L9-L12), quinina (L13) y N-metilefedrina (L17) (Tabla 5.2).  
 Como se puede observar en la tabla 5.2, la utilización de ligandos de tipo BINOL (L1-L6), 
conduce a los productos de adición con rendimientos altos entre 79 y 94%, aunque los excesos 
enantioméricos de los productos obtenidos fueron bajos (2-26% ee) (Tabla 5.2, entradas 1-6). El uso 
de (R)-VAPOL (L7) o de (R)-VANOL (L8), tampoco dio buenos resultados, obteniéndose rendimientos 
buenos, pero enantioselectividades bajas (16-20% ee) (Tabla 5.2, entradas 7 y 8). Con el objetivo de 
mejorar la enantioselectividad de la reacción, se ensayó un derivado del aminoácido (S)-prolina, un 
diarilprolinol (S)-difenil(pirrolidin-2-il)metanol] (L9). El uso de este ligando dio lugar a un resultado 
prometedor, obteniéndose el producto de adición con un rendimiento elevado (74%) y una 
enantioselectividad de 75% (Tabla 5.2, entrada 9). Para completar la evaluación de los ligandos de tipo 
aminoalcohol, también se ensayaron la quinina (L13) y la N-metilefedrina (L17), pero los excesos 
enantioméricos de los productos obtenidos fueron muy bajos (0-10% ee) (Tabla 5.2, entradas 10 y 11). 
Una vez identificado L7 como el mejor ligando para la reacción de aza-Reformatsky objeto del estudio, 
continuamos el proceso de optimización ensayando la reacción con diferentes reactivos de dialquilzinc 





Tabla 5.2. Reacción de aza-Reformatsky enantioselectiva de 2,2-dióxido benzoxatiazina (1a) con iodoacetato de 
etilo (29). Evaluación de ligandos.a 
 
 
Entrada Ligando t (h) R (%)b ee (%)c 
1 L1 1 86 15 
2 L2 1 81 26 
3 L3 1 87 2 
4 L4 1 94 15 
5 L5 1 79 5 
6 L6 1 92 -16 
7 L7 1 54 -20 
8 L8 1 78 4 
9 L9 1 74 75 
10 L13 1 84 0 
11 L17 1 79 -10 
a 1a (0,100 mmol), 29 (0,200 mmol), 1,2 M Me2Zn en tolueno (0,700 mmol), L (0,020 mmol). b Rendimiento 
después la purificación por cromatografía de columna. c Exceso enantiomérico determinado mediante HPLC 
usando fases estacionarias quirales. 
Como se puede observar en la tabla 5.3, una disminución en la cantidad de Me2Zn usado en 
la reacción, dio lugar a una disminución en el rendimiento y la enantioselectividad de la reacción (Tabla 
5.3, entrada 2). Cuando se ensayó la reacción en presencia de Et2Zn en lugar de Me2Zn dio lugar al β-
amino éster 30a con mayor rendimiento (88%), pero se observó también un descenso notable de la 
enantioselectividad hasta 60% ee (Tabla 5.3, entrada 3).  
 El uso de diferentes disolventes clorados y no clorados, como MTBE, iPr2O, THF, tolueno y 
CH2Cl2, no mejoró la enantioselectividad de la reacción (Tabla 5.3, entradas 4-8). No obstante se pudo 
observar un mejora en el rendimiento (hasta 91%) sin disminución de la enantioselectividad utilizando 
MTBE como disolvente (Tabla 5.3, entrada 4).  
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Tabla 5.3. Reacción de aza-Reformatsky enantioselectiva de 2,2-dióxido benzoxatiazina (1a) con iodoacetato de 
etilo (29). Evaluación de los reactivos de dialquilzinc, número de equivalentes de dialquilzinc, disolventes y 
temperatura de reacción.a 
 
Entrada Disolvente T ( °C) R (%)b ee (%)c 
1 Et2O ta 74 75 
2d Et2O ta 70 73 
3e Et2O ta 88 60 
4 MTBE ta 91 75 
5 iPr2O ta 87 69 
6 THF ta 42 28 
7 Tolueno ta 95 70 
8 CH2Cl2 ta 95 55 
9 MTBE 0 74 80 
10 MTBE -10 96 77 
a 1a (0,100 mmol), 29 (0,200 mmol), 1,2 M Me2Zn en tolueno (0,700 mmol), L9 (0,020 mmol). b Rendimiento 
después de purificación por cromatografía de columna. c Exceso enantiomérico determinado mediante HPLC 
usando fases estacionarias quirales. d Se usaron 3 equivalentes de Me2Zn (0,3 mmol) e Se usó 1M Et2Zn en 
hexanos (0,7 mmol). 
 Por último, se llevó a cabo la reacción a temperaturas más bajas (Tabla 5.3, entradas 9 y 10). 
Cuando la temperatura de la reacción fue 0 °C, el producto 30a se obtuvo con un 80% ee, aunque el 
rendimiento de la reacción fue menor (74%). Mientras que cuando se llevó  a cabo la reacción a -10 
°C, el β-amino éster 30a se obtuvo con mejor rendimiento pero con menor exceso enantiomérico. 
 No estando totalmente satisfechos con los resultados obtenidos, decidimos evaluar otros 
ligandos del tipo diarilprolinol en las condiciones optimizadas para L9 (Tabla 5.4).            
Tabla 5.4. Reacción de aza-Reformatsky enantioselectiva de 2,2-dióxido benzoxatiazina (1a) con iodoacetato de 
etilo (29) utilizando Me2Zn en MTBE a 0°C. Evaluación de ligandos de tipo diarilprolinol.a 
 
Entrada Ligando t (h) R (%)b ee (%)c 
1 L9 1 74 80 
2 L10 1 88 79 
3 L11 1 86 92 
4 L12 1 96 80 
5c L11 1 89 87 
a 1a (0,100 mmol), 29 (0,200 mmol), 1,2 M Me2Zn en tolueno (0,700 mmol), L9-L12 (0,020 mmol). b Rendimiento 
después de purificación por cromatografía de columna. c Exceso enantiomérico determinado mediante HPLC 
usando fases estacionarias quirales. c Se usó 10 mol % del ligando. 
130 
 
 El uso de los ligandos L10 y L12 dio resultados similares tanto de rendimiento como de 
enantioselectividad al obtenido con el ligando L9 (Tabla 5.4, entradas 2 y 4) . Sin embargo, el uso del 
ligando L11 [(S)-bis(3,5-bis(trifluorometil)fenil)(pirrolidin-2-il)metanol], dio lugar al producto final con 
un rendimiento elevado (86%) y un exceso enantiomérico excelente de 92% (Tabla 5.4, entrada 3). 
Finalmente, una disminución de la cantidad de ligando utilizando 10 mol % dio lugar a un descenso 
ligero en la enantioselectividad (87% ee) (Tabla 5.4, entrada 5). Por tanto, se consideran como 
condiciones óptimas las indicadas en la entrada 3 (Tabla 5.4).  
5.3.4. Alcance y limitaciones de la reacción 
En el estudio del alcance y limitaciones de la reacción, se utilizaron las condiciones 
optimizadas llevando a cabo la reacción de aza-Reformatsky de distintas aldiminas y cetiminas de tipo 
2,2-dióxido benzoxatiazina (1 y 9) con iodoacetato de etilo (29). 
5.3.4.1. Evaluación de distintas aldiminas de tipo 2,2-dióxido benzoxatiazina 
En primer lugar se evaluó la reacción de aza-Reformatsky enantioselectiva de varias aldiminas 
de tipo 2,2-dióxido benzoxatiazina (1) con iodoacetato de etilo (29). Los resultados se puede observar 
en el esquema 5.15.   
 
Esquema 5.15. Reacción de aza-Reformatsky enantioselectiva de varias aldiminas 1 con iodoacetato de etilo 
(29): 1 (0,10 mmol), 29 (0,200 mmol), 1,2 M Me2Zn en tolueno (0,700 mmol), L11 (0,020 mmol). Rendimiento 
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después de purificación por cromatografía de columna. Exceso enantiomérico determinado mediante HPLC 
usando fases estacionarias quirales. a Reacción a mayor escala (0,4 mmol). 
 Se ensayó la reacción bajo las condiciones optimizadas con varias aldiminas sustituidas en la 
posición 6. Se puede observar en el esquema 5.15 que la presencia de un grupo electrón-donante no 
influye en la enantioselectividad de la reacción de manera que aldiminas sustituidas con un grupo 
metilo (1b), terc-butil (1c) o metoxi (1d) proporcionan los correspondientes productos de adición con 
buenos rendimientos (70-95%) y excesos enatioméricos de 91-92%. La presencia de un grupo electrón-
atrayente (bromo) en la posición 6 da lugar al producto de la reacción de aza-Reformatsky 30e con 
buen rendimiento (74%) y una enantioselectividad un poco inferior (85% ee). La reacción incluso se 
pudo llevar a cabo con una aldimina sustituida en la posición 6 con un grupo nitro (1k) con buena 
enantioselectividad (85% ee) y con buen rendimiento (74%). También fueron evaluados aldiminas 
cíclicas sustituidas en las posiciones 8 y 5 con grupos electrón-donantes obteniéndose buenos 
resultados. Así la presencia de un grupo metilo en la posición 8 dio lugar al producto 30f con buen 
rendimiento (88%) y una enantioselectividad del 91% ee, mientras que la presencia de un grupo 
metoxi en la posición 5 condujo al producto 30h con buen rendimiento (70%) y una 
enantioselectividad elevada del 90% ee. La reacción con la imina 1j, una imina cíclica con un anillo de  
naftilo, dio lugar al producto correspondiente 30j con excelente rendimiento (98%) y un exceso 
enantiomérico elevado (93% ee). Por último, iminas cíclicas disustituidas en las posiciones 6 y 8 (1i y 
1l), con un impedimento estérico considerable, demostraron ser buenos sustratos para la reacción de 
aza-Reformatsky, dando lugar a los correspondientes productos de reacción con buenos rendimientos 
(73-97%) y enantioselectividades elevadas (79-88% ee). 
5.3.4.2. Evaluación de distintas cetiminas de tipo 2,2-dióxido benzoxatiazina 
También se evaluó la reacción de aza-Reformatsky de varias cetiminas de tipo 2,2-dióxido 
benzoxatiazina (9) con iodoacetato de etilo (29). Los resultados se pueden observar en el esquema 
5.16.  
Una importante observación que se deriva de los resultados recogidos en el esquema anterior, 
es que la utilización de cetiminas, generalmente menos reactivas que las aldiminas, conduce a los 
correspondientes productos de reacción con rendimientos y enantioselectividades excelentes y 
siempre superiores a las enantioselectividades de las correpondientes aldiminas. La reacción con la 
cetimina 9a conduce al β-amino éster 31a con un centro estereogénico cuaternario con un 
rendimiento del 93% y una enantioselectividad excelente del 99% ee. Incluso la utilización de un 10 
mol % de ligando permitió la obtención de 31a con un rendimiento similar y un ligero descenso del 
exceso enantiomérico (97%). La presencia de grupos electrón-donantes (9b) o electrón-atrayentes 
(9c) prácticamente no tiene ninguna influencia en los resultados obtenidos; se pudieron obtener los 
productos correspondientes con rendimientos altos (91-99%) y enantioselectividades excelentes (97-
99% ee). Cuando los grupos electrón-donantes están en la posición 7 (9d y 9e) también se obtienen 
rendimientos altos (91-94%) y enantioselectividades excelentes (98% ee). Las condiciones también 
permiten llevar a cabo la reacción con un sustrato disustituido (9f) obteniéndose el β-amino éster 31f 
con un rendimiento alto (87%) y una enantioselectividad excelente (96% ee). Un resultado similar se 
obtuvo en la reacción con el sustrato 9g, una cetimina con un grupo naftilo, dando lugar al producto 
31g con un exceso enantiomérico del 98%. También se utilizaron cetiminas con diferentes grupos 
alquilo en la posición 4. Cuando en esta posición hay un grupo etilo o un grupo 2-feniletilo, los 
productos resultantes (31h y 31i) se obtuvieron con rendimientos altos (92-98%) y 




Esquema 5.16. Reacción de aza-Reformatsky enantioselectiva de varias cetiminas con iodoacetato de etilo (29): 
9 (0,10 mmol), 29 (0,200 mmol), 1,2 M Me2Zn en tolueno (0,700 mmol), L11 (0,020 mmol). Rendimiento después 
de purificación por cromatografía de columna. Exceso enantiomérico determinado mediante HPLC usando fases 
estacionarias quirales. a Se usó 10 mol % L11 b Reacción a mayor escala (0,4 mmol). 
5.3.4.3. Evaluación de distintas N-sulfonil cetiminas cíclicas de 5 miembros 
 Una vez estudiado el comportamiento de diferentes cetiminas de 6 miembros decidimos 
ampliar el estudio del alcance y limitaciones de la reacción, ensayando la reacción con dos cetiminas 
cíclicas de 5 miembros de tipo N-sulfonil 33 bajo las condiciones optimizadas. Las benzosultamas 
resultantes 34a y 34b se obtuvieron con buenos rendimientos (79-86%) y enantioselectividades (70-
85% ee) (Esquema 5.17).    
 
Esquema 5.17. Reacción de aza-Reformatsky enantioselectiva de cetiminas cíclicas de 5 miembros con 
iodoacetato de etilo (29): 33 (0,100 mmol), 29 (0,200 mmol), 1,2 M Me2Zn en tolueno (0,700 mmol), L11 (0,020 
mmol). Rendimiento después de purificación por cromatografía de columna. Exceso enantiomérico determinado 
mediante HPLC usando fases estacionarias quirales. 
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5.3.5. Transformaciones sintéticas  
 Para demostrar la utilidad de los productos obtenidos, se realizaron varias transformaciones 
sintéticas con los β-amino esteres quirales (Esquema 5.18). La primera transformación que se realizó 
fue la reducción del éster 30a a alcohol primario con apertura del anillo del benzosulfamidato con 
LiAlH4 a 60 °C seguido por una protección de la amina resultante con carbonato di-terc-butilo (Boc2O). 
Se obtuvieron dos productos de reacción 35 y 36 con rendimientos bajos pero conservando la pureza 
óptica.   
 
Esquema 5.18. Transformaciones sintéticas 
Otra transformación que se llevó a cabo fue la reducción del éster 31a con hidruro de aluminio 
y litio a 0 °C, para evitar la apertura del anillo del benzosulfamidato, dando lugar al γ-amino alcohol 
37 con un rendimiento moderado, pero conservando el exceso enantiomérico. 
 Finalmente se abordó la saponificación del grupo éster, con la idea de obtener los 
correspondientes β-aminoácidos. Este tipo de compuestos son muy importantes en química orgánica 
y medicinal por ser precursores de péptidos y peptidomiméticos,24, 25 además de β-lactamas, que son 
uno de los antibióticos más importantes en química farmacéutica.26-28 La saponificación de 30a y 31a 
se llevó  a cabo con NaOH/EtOH obteniéndose los correspondientes β-aminoácidos 38 y 39 con buenos 
rendimientos y sin pérdida de pureza óptica. La β-lactama quiral 40, que contiene tres anillos 
fusionados y un estereocentro cuaternario, se preparó a partir del β-aminoácido 39 utilizando EDCI 
[1-etil-3-(3-dimetilaminopropil)carbodiimida] y N-metilmorfolina (NMM) como reactivos y se obtuvo 




5.3.6. Determinación de la configuración absoluta 
 La determinación de la estereoquímica para los compuestos 30 se hizo mediante correlación 
química del compuesto 35, el cual está descrito en la literatura,29 comparando el signo de la rotación 
especifica del compuesto. Así se pudo establecer que la configuración absoluta es (S). Por su parte la 
determinación de la configuración absoluta de los compuestos 31 se hizo mediante el estudio de 
difracción de Rayos X de monocristal del compuesto 31f. El carbono esterogénico también presenta 
la configuración (S) (parámetro de Flack: 0.01(2)) (Figura 5.1). La configuración de los productos 






Figura 5.1. Estructura del compuesto 31f determinada por Rayos X. 
5.3.7. Propuesta mecanística para la reacción de aza-Reformatsky de 2,2-dióxido 
benzoxatiazinas 
 El esquema 5.19 muestra un posible mecanismo para la reacción de aza-Reformatsky de 2,2-
dióxido benzoxatiazinas con un complejo formado a partir de Me2Zn y un ligando de tipo diarilprolinol 
(L11). Como ya se ha estudiado en las reacciones de alquilación con Et2Zn y Me2Zn catalizadas por 
ligandos de tipo amino alcohol, se forma en primer lugar un complejo A entre Me2Zn y el ligando L11. 
Este complejo de tipo alcóxido de zinc está en equilibrio con el complejo B, un dímero del complejo A 
formado por coordinación de átomos de oxígeno y de zinc.30 El complejo B es más estable, pero no 
puede participar en la reacción de Reformatsky, debido a que su tamaño impide la coordinación del 
reactivo y la imina. Al complejo A se adiciona el zincato-metilacetato de etilo formando el complejo C. 
Este zincato se forma a partir del iodoacetato de etilo y Me2Zn en presencia de oxígeno, mediante un 
ciclo donde el Me2Zn actúa como un precursor de radicales de metilo.31 La presencia de radicales se 
pudo demonstrar llevando a cabo la reacción en presencia de TEMPO en la que se obtuvo el producto 
27a con un rendimiento muy bajo (7%), lo cual se puede atribuir a la inhibición en la formación de 
radicales provocada por el TEMPO. Tras la coordinación de la imina 1/9 al complejo C, se obtiene el 
complejo D, sobre el cual tiene lugar la transferencia del nucleófilo a la cara Si de la imina cíclica 
generando el sulfamidato de zinc E. Después de la disociación del sulfamidato, se obtiene el β-amino 




Esquema 5.19. Propuesta mecanística para la reacción de aza-Reformatsky de 2,2-dióxido benzoxatiazinas con 
un complejo de Me2Zn-ligando de tipo diarilprolinol. 
Con objeto de obtener información sobre la estructura de la especie catalítica que participa en el ciclo 
catalítico propuesto, examinamos la posibilidad de efectos no lineales en la reacción de Reformatsky 
de la 2,2-dióxido benzoxazina 1a y el iodoacetato de etilo. Para ello se llevó a cabo la reacción, a partir 
de dimetilzinc y el diarilprolinol L11, con diferentes excesos enantioméricos. La gráfica (Figura 5.2) 
muestra una correlación no lineal positiva entre el ee del producto 30a y el exceso enantiomérico  del 
ligando L11. Este resultado sugiere que en disolución deben existir tres complejos dímeros: dos de 
ellos, homoquirales (S,S) y su enantiomero (R,R) formados mediante equilibrios de “auto 
reconocimiento” a partir de los correspondientes complejos monoméricos idénticos, y el tercero  
hetereroquiral (S,R) formado mediante un equilibrio de “no-auto reconocimiento” a partir de los dos 
complejos monoméricos enantiómeros. Prácticamente todo el complejo monomérico minoritario se 
transforma en el complejo dímero heteroquiral, termodinámicamente más estable, mientras que el 
exceso del complejo monomérico mayoritario forma el complejo dímero homoquiral, menos estable. 
Este último muestra mayor tendencia a disociarse en el monómero activo, por lo que es el responsable 
de la actividad catalítica, mientras que el enantiómero monomérico minoritario no participa en la 
reacción, puesto que está formando parte del dímero heteroquiral. 
Así pues, el efecto no lineal positivo puede explicarse mediante la participación de especies catalíticas 






Figura 5.2. Efecto no-linear en la reacción de Reformatsky de 2,2-dióxido benzoxatiazinas 
  





























1. Se ha diseñado un método enantioselectivo para llevar a cabo la reacción de aza-Reformatsky 
de aldiminas (1) y cetiminas (9) cíclicas de tipo 2,2 dióxido benzoxatiazina con iodoacetato de 
etilo (29) catalizada por un sistema formado por un ligando de tipo (S)-prolinol [(S)-bis(3,5-
bis(trifluorometil)fenil)(pirrolidin-2-il)metanol] y Me2Zn a 0 °C en MTBE.  
2. La reacción de aza-Reformatsky bajo las condiciones optimizadas se puede llevar a cabo con 
aldiminas cíclicas del tipo 2,2-dióxido benzoxatiazinas (1) con sustituyentes en diferentes 
posiciones del anillo aromático obteniéndose los correpondientes productos con buenas 
enantioselectividades (79-93%ee) y rendimientos elevados (70-98%).   
3. La reacción de aza-Reformatsky bajo las condiciones optimizadas se puede llevar a cabo con 
cetiminas cíclicas de tipo 2,2-dióxido benzoxatiazinas (9) con sustituyentes en diferentes 
posiciones del anillo aromático obteniéndose los correspondientes productos con excelentes 
enantioselectividades (96-99% ee) y rendimientos (87-98%). 
4. Las condiciones optimizadas también se pueden aplicar en la reacción con cetiminas cíclicas 
de 5 miembros de tipo N-sulfonil (33), obteniéndose los productos resultantes con elevados 
rendimientos (79-86%) y excesos enantiomericos (70-85%). 
5. Se han podido sintetizar γ-amino alcoholes (35-37), β-aminoácidos (38 y 39) y una β-lactama 
(40) mediante transformaciones sintéticas a partir de los compuestos 30a y 31a.  
6. La determinación de la configuración absoluta para los compuestos 30 se hizo mediante 
correlación química del compuesto 35. Para los compuestos 31 se determinó la configuración 
absoluta mediante difracción de Rayos X de monocristal del producto 31f.  En ambos casos la 
configuración absoluta resultante es (S). La configuración de los productos restantes se ha 
asignado admitiendo el mismo mecanismo de reacción para todos los sustratos. 
7. Se ha propuesto un posible mecanismo para la reacción de Reformatsky de 2,2-dióxido 
benzoxatiazinas con iodoacetato de etilo (29) catalizada por un complejo de Me2Zn-ligando 
de tipo diarilprolinol. 





5.5. EXPERIMENTAL SECTION 
5.5.1. General experimental methods 
Reactions were carried out under nitrogen round bottom flasks oven-dried overnight at 120 
°C. Dicloromethane, 1,2-dichloroethane and toluene were distilled from CaH2. THF was distilled from 
sodium benzophenone ketyl. Reactions were monitored by TLC analysis using Merck Silica Gel 60 F-
254 thin layer plates. Flash column chromatography was performed on Merck silica gel 60, 0.040-
0.063 mm. Melting points were determined in capillary tubes. NMR spectra were run at 300 MHz for 
1H and at 75 MHz for 13C NMR using residual non-deuterated solvent  as internal standard (CHCl3: δ 
7.26 and 77.0 ppm). Chemical shifts are given in ppm. The carbon type was determined by DEPT 
experiments. High resolution mass spectra (ESI) were recorded on a AB SCIEX Triple TOFTM 
spectrometer equipped with an electrospray source with a capillary voltage of 4.5 kV(ESI). Optical 
rotations were measured using sodium light (D line 589 nm). Chiral HPLC analyses were performed in 
a chromatograph equipped with a UV diode-array detector using chiral stationary columns from 
Daicel.  
5.5.2. Synthetic procedure and characterization data for compound 1l 
  Formic acid (20 mmol) was carefully added (dropwise) to chlorosulfonylisocyanate (20 mmol) 
at 0 °C. The mixture was stirred for 2 hours at room temperature to form 5. After 2 hours, the reaction 
was placed at 0 °C and diluted with DMA (15 mL). This solution was then added dropwise to a solution 
of salicylaldehyde 4l (10 mmol) in DMA (15 mL) at 0 °C. After the addition, the reaction was placed at 
room temperature and stirred for 18 h. Aftewards, the reaction was quenched with 100 mL ice cold 
water. The solution was then extracted with 3 x 50 mL dichloromethane, washed with 3 x 50 mL water 
and brine (50 mL). The organic layer was dried with MgSO4 and concentrated in vacuo. The residue 
was purified by flash chromatography obtaining product 1l.  
6,8-Dichlorobenzo[e][1,2,3]oxathiazine 2,2-dioxide (1l)32 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 8.62 (s, 1H), 7.79 (d, J = 2.4 Hz, 1H), 7.59 (d, J = 
2.4 Hz, 1H) ppm. 13C NMR (75 MHz, CDCl3) δ 165.9 (CH), 148.9 (C), 137.2 (CH), 131.6 (C), 
128.3 (CH), 125.2 (C), 116.79 (C) ppm. 
 
5.5.3. General synthetic procedure and characterization data for compounds 9 
Formic acid (20 mmol) was carefully added (dropwise) to chlorosulfonylisocyanate (20 mmol) 
at 0 °C. The mixture was stirred for 2 hours at room temperature to form 5. After 2 hours, the reaction 
was placed at 0 °C and diluted with DMA (15 mL). This solution was then added dropwise to a solution 
of 2-hidroxiacetofenona 8 (10 mmol) in DMA (15 mL) at 0 °C. After addition, the reaction was placed 
at room temperature and in the next hour, NaH (60% in oil, 24 mmol) was added in portions. 
Afterwards, the reaction was stirred for 18 h. After, the reaction was quenched with 100 mL ice cold 
water. The solution was then extracted with 3 x 50 mL dichloromethane, washed with 3 x 50 mL water 
and brine (50 mL). The organic layer was dried with MgSO4 and concentrated in vacuo. The residue 
was purified by flash chromatography obtaining product 9.  
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4-Methylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (9a)33 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.80 (dd, J = 7.9, 1.4 Hz, 1H), 7.72 (ddd, J = 8.3, 
7.5, 1.6 Hz, 1H), 7.43 – 7.35 (m, 1H), 7.32 – 7.28 (m, 1H), 2.73 (s, 3H) ppm. 13C NMR (75 
MHz, CDCl3) δ177.2 (C), 151.3 (C), 137.1 (CH), 128.4 (CH), 125.8 (CH), 119.1 (CH), 116.4 
(C), 23.7 (CH3) ppm. 
4,6-Dimethylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (9b)33 
Orange oil; 1H NMR (300 MHz, CDCl3) δ 7.58 – 7.55 (m, 1H), 7.54 – 7.48 (m, 1H), 7.18 (d, 
J = 8.4 Hz, 1H), 2.71 (s, 3H), 2.44 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 177.3 (C), 151.5 
(C), 137.8 (CH), 135.9 (C), 128.3 (CH), 118.8 (CH), 116.2 (C), 23.7 (CH3), 20.9 (CH3) ppm. 
 
6-Chloro-4-methylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (9c)33 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 2.4 Hz, 1H), 7.67 (dd, J = 8.8, 2.5 Hz, 
1H), 7.26 (d, J = 8.8 Hz, 1H), 2.72 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 176.1 (C), 151.8 
(C), 136.8 (CH), 131.3 (C), 128.0 (CH), 120.6 (CH), 117.3 (C), 23.7 (CH3) ppm. 
 
4,7-Dimethylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (9d)33 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.67 (d, J = 8.1 Hz, 1H), 7.19 (ddd, J = 8.1, 1.6, 
0.7 Hz, 1H), 7.08 (d, J = 0.6 Hz, 1H), 2.68 (s, 3H), 2.48 (s, 3H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 177.2 (C), 153.5 (C), 149.5 (C), 128.3 (CH), 126.8 (CH), 119.1 (CH), 114.1 (C), 
23.6 (CH3), 22.1 (CH3) ppm. 
7-Methoxy-4-methylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (9e) 
Clear oil; 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.9 Hz, 1H), 6.87 (dd, J = 8.9, 2.5 
Hz, 1H), 6.72 (d, J = 2.5 Hz, 1H), 3.92 (s, 3H), 2.65 (s, 3H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 176.5 (C), 166.5 (C), 155.9 (C), 130.1 (CH), 113.3 (CH), 109.9 (C), 102.9 (CH), 
56.3 (CH3), 23.6 (CH3) ppm. HRMS (ESI) m/z: 228.0328 [M + H]+, C9H10NO4S requires 
228.0325. 
6-Chloro-4,7-dimethylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (9f) 
Clear oil; 1H NMR (300 MHz, CDCl3) δ 7.74 (s, 1H), 7.18 (d, J = 0.6 Hz, 1H), 2.69 (s, 
3H), 2.50 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 176.1 (C), 151.6 (C), 147.1 (C), 
131.5 (C), 128.25 (CH), 121.0 (CH), 115.3 (C), 23.6 (CH3), 21.1 (CH3) ppm. HRMS (ESI) 
m/z: 245.9988 [M + H]+, C9H9ClNO3S requires 245.9986. 
 
4-Methylnaphtho[2,1-e][1,2,3]oxathiazine 2,2-dioxide (9g)34 
Orange oil; 1H NMR (300 MHz, CDCl3) δ 8.44 (ddt, J = 8.0, 1.5, 0.7 Hz, 1H), 7.92 (dd, 
J = 7.4, 1.2 Hz, 1H), 7.83 – 7.66 (m, 4H), 2.81 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3) 
δ 178.0 (C), 137.4 (C), 137.0 (C), 131.2 (CH), 128.2 (CH), 127.9 (CH), 125.3 (CH), 123.5 




4-Ethylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (9h)33 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.82 (dd, J = 8.0, 1.6 Hz, 1H), 7.70 (ddd, J = 8.3, 7.5, 
1.6 Hz, 1H), 7.39 (ddd, J = 7.9, 7.5, 1.2 Hz, 1H), 7.32 – 7.27 (m, 1H), 3.10 (q, J = 7.2 Hz, 2H), 
1.36 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 180.7 (C), 153.5 (C), 136.8 (CH), 
127.7 (CH), 125.8 (CH), 119.2 (CH), 116.1 (C), 29.3 (CH2), 9.6 (CH3) ppm. 
4-Phenethylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (9i) 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.75 (dd, J = 8.0, 1.5 Hz, 1H), 7.70 (ddd, J = 
8.3, 7.5, 1.6 Hz, 1H), 7.39 – 7.20 (m, 7H), 3.39 – 3.31 (m, 2H), 3.20 – 3.11 (m, 2H) 
ppm. 13C NMR (75 MHz, CDCl3) δ 179.1 (C), 153.6 (C), 139.7 (C), 136.9 (CH), 128.8 
(CH), 128.4 (CH), 127.8 (CH), 126.7 (CH), 125.8 (CH), 119.2 (CH), 116.2 (C), 37.6 
(CH2), 31.5 (CH2) ppm. HRMS (ESI) m/z: 288.0696 [M + H] +, C15H14NO3S requires 288.0689. 
5.5.4. General synthetic procedure and characterization data for compounds 33 
 To saccharin 32 (10.0 mmol), dissolved in THF (20 mL) at 0 °C under N2 atmosphere, 
alkylmagnesium bromide (23 mmol) was added slowly. The reaction was stirred at room temperature 
during 18 h. Afterwards, the reaction was poured carefully onto ice and the solution was acidified (2M 
HCl). The aqueous layer was then extracted with Et2O (3 x 50 mL) and the combined organic layers 
were washed with brine, dried (MgSO4) and concentrated in vacuo. The resulting solid was then 
purified by flash chromatography, obtaining product 33.23 
3-Methylbenzo[d]isothiazole 1,1-dioxide (33a)35 
Orange oil; 1H NMR (300 MHz, CDCl3) δ 7.94 – 7.90 (m, 1H), 7.80 – 7.72 (m, 1H), 7.71 – 
7.66 (m, 1H), 2.67 (s, 2H) ppm. 13C NMR (75 MHz, CDCl3) δ 173.1 (C), 139.6 (C), 133.9 
(CH), 133.6 (CH), 131.6 (C), 124.1 (CH), 122.4 (CH), 17.6 (CH3) ppm. 
3-Ethylbenzo[d]isothiazole 1,1-dioxide (33b)36 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.95 – 7.86 (m, 1H), 7.79 – 7.71 (m, 2H), 7.71 – 
7.66 (m, 1H), 3.02 (q, J = 7.2 Hz, 2H), 1.43 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) 
δ 177.1 (C), 139.8 (C), 133.9 (CH), 133.5 (CH), 131.2 (C), 123.7 (CH), 122.4 (CH), 24.8 (CH2), 
9.3 (CH3) ppm. 
5.5.5. General synthetic procedures and characterization data for compounds 
30, 31 and 34 
General procedure for the enantioselective Reformatsky reaction: In a two-neck 50 mL round 
bottom flask (one neck covered with a septum, the other neck with a drying finger, filled with CaCl2), 
purged with N2, the ligand L11 was added in solid by opening the septum. The ligand was dissolved 
with 3 mL of MTBE, followed by the addition of ethyl iodoacetate 29 (2 eq, 0.200 mmol). This 
dissolution was placed in an ice bath (0 °C) and stirred during 5 minutes at 0 °C. Me2Zn was added (7 
eq, 0.700 mmol), immediately followed by the addition of the substrate by opening the septum. The 
reaction was stirred at 0 °C until the reaction was complete (TLC). The reaction mixture was quenched 
with NH4Cl (10 mL), extracted with dichloromethane (3x15 mL), dried over MgSO4 and dried under 
reduced pressure. Purification by flash chromatography on silica gel afforded compound 30, 31 or 34. 
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General procedure for the non-enantioselective Reformatsky reaction: In a two-neck 50 mL 
round bottom flask (one neck covered with a septum, the other neck with a drying finger, filled with 
CaCl2), purged with N2 3 mL of MTBE was added, followed by the addition of ethyl iodoacetate 2 (2 eq, 
0.200 mmol). This dissolution was stirred during 5 minutes at rt. Me2Zn was added (7 eq, 0.700 mmol), 
immediately followed by the addition of the substrate 1, 4 or 6 in solid by opening the septum. The 
reaction was stirred at rt until the reaction was complete (TLC). The reaction mixture was quenched 
with NH4Cl (10 mL), extracted with dichloromethane (3x15 mL), dried over MgSO4 and dried under 
reduced pressure. Purification by flash chromatography on silica gel afforded compound 30, 31 or 34. 
Ethyl (S)-2-(2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30a) 
The enantiomeric excess (92%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 11.88 min, minor enantiomer 
tr = 15.15 min. 
Oil; []D
20 = -20.1 (c 1.0, CHCl3, 92% ee); 1H NMR (300 MHz, CDCl3) δ 7.39 – 7.27 (m, 
1H), 7.26 – 7.15 (m, 1H), 7.17 (d, J = 0.9 Hz, 1H), 7.09 – 6.98 (m, 1H), 5.92 (d, J = 9.1 Hz, 1H), 5.13 (dddd, 
J = 9.2, 6.8, 3.8, 1.0 Hz, 1H), 4.13 (qd, J = 7.2, 0.6 Hz, 2H), 3.31 (dd, J = 16.9, 6.7 Hz, 1H), 2.98 (dd, J = 
16.9, 3.8 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.8 (C), 151.4 (C), 129.9 
(CH), 125.6 (CH), 125.4 (CH), 120.7 (C), 119.1 (CH), 61.5 (CH2), 53.9 (CH), 37.1 (CH2), 14.0 (CH3) ppm. 
HRMS (ESI) m/z: 272.0587 [M + H]+, C11H14NO5S requires  272.0593. 
Ethyl (S)-2-(6-methyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30b) 
The enantiomeric excess (92%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 13.66 min, minor enantiomer 
tr = 16.89 min. 
Oil; []D
20 = -23.4 (c 1.0, CHCl3, 92% ee); 1H NMR (300 MHz, CDCl3) δ 7.15 – 7.08 (m, 
1H), 6.95 (dt, J = 1.7, 0.8 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 5.75 (s, 1H), 5.09 (dd, J = 
7.0, 3.7 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.29 (dd, J = 16.9, 7.0 Hz, 1H), 2.96 (dd, J = 16.8, 3.7 Hz, 1H), 
2.32 (d, J = 0.7 Hz, 3H), 1.21 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.8 (C), 149.3 (C), 
135.2 (C), 130.4 (CH), 125.9 (CH), 120.3 (C), 118.8 (CH), 61.5 (CH2), 53.9 (CH), 37.3 (CH2), 20.8 (CH3), 
14.0 (CH3) ppm. HRMS (ESI) m/z: 286.0744 [M + H]+, C12H16NO5S requires 286.0749. 
 Ethyl (S)-2-(6-(tert-butyl)-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30c) 
The enantiomeric excess (91%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 9.67 min, minor enantiomer 
tr = 11.08 min. 
Oil; []D
20 = -19.9 (c 1.0, CHCl3, 91% ee); 1H NMR (300 MHz, CDCl3) δ 7.34 (ddd, J = 
8.7, 2.4, 0.8 Hz, 1H), 7.14 (dd, J = 2.4, 1.0 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1H), 5.85 (d, J 
= 9.0 Hz, 1H), 5.13 (dddt, J = 8.8, 6.9, 3.9, 0.9 Hz, 1H), 4.13 (qd, J = 7.1, 0.7 Hz, 2H), 3.34 (dd, J = 16.7, 
6.9 Hz, 1H), 2.97 (dd, J = 16.7, 3.7 Hz, 1H), 1.29 (s, 9H), 1.19 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 170.9 (C), 149.2 (C), 148.5 (C), 126.9 (CH), 122.4 (CH), 119.8 (C), 118.5 (CH), 61.5 (CH2), 54.2 




Ethyl (S)-2-(6-methoxy-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30d) 
The enantiomeric excess (92%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 14.90 min, minor enantiomer 
tr = 18.84 min. 
Oil; []D
20 = -42.5 (c 1.0, CHCl3, 92% ee); 1H NMR (300 MHz, CDCl3) δ 6.97 (d, J = 9.0 
Hz, 1H), 6.85 (ddd, J = 9.0, 2.9, 0.7 Hz, 1H), 6.66 (dd, J = 2.8, 0.9 Hz, 1H), 5.83 (d, J = 
8.3 Hz, 1H), 5.08 (td, J = 7.7, 3.7 Hz, 1H), 4.15 (q, J = 7.1 Hz, 1H), 3.78 (s, 2H), 3.28 (dd, J = 16.9, 6.9 Hz, 
1H), 2.96 (dd, J = 16.9, 3.8 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.8 (C), 
156.7 (C), 145.1 (C), 121.6 (C), 119.9 (CH), 114.9 (CH), 110.9 (CH), 61.5 (CH2), 55.7 (CH3), 54.0 (CH), 
37.3 (CH2), 14.0 (CH3) ppm. HRMS (ESI) m/z: 302.0693 [M + H]+, C12H16NO6S requires 302.0698. 
Ethyl (S)-2-(6-bromo-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30e) 
The enantiomeric excess (85%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 9.10 min, minor enantiomer 
tr = 11.27 min.  
Oil; []D
20 = -44.6 (c 1.0, CHCl3, 85% ee); 1H NMR (300 MHz, CDCl3) δ 7.45 (ddd, J = 
8.8, 2.4, 0.8 Hz, 1H), 7.31 (dd, J = 2.3, 1.0 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 5.93 (s, 
1H), 5.10 (dd, J = 6.5, 3.8 Hz, 1H), 4.16 (qd, J = 7.2, 1.8 Hz, 2H), 3.29 (dd, J = 17.0, 6.5 Hz, 1H), 2.98 (dd, 
J = 17.0, 3.8 Hz, 1H), 1.23 (t, J = 7.2 Hz, 3H) ppm.13C NMR (75 MHz, CDCl3) δ 170.6 (C), 150.5 (C), 132.9 
(CH), 128.6 (CH), 122.7 (C), 120.8 (CH), 118.0 (C), 61.8 (CH2), 53.6 (CH), 36.8 (CH2), 14.0 (CH3) ppm. 
HRMS (ESI) m/z: 349.9692 [M + H]+, C11H13BrNO5S requires  349.9698. 
Ethyl (S)-2-(8-methyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30f) 
The enantiomeric excess (91%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 10.29 min, minor 
enantiomer tr = 14.16 min. 
Oil; []D
20 = -9.4 (c 1.0, CHCl3, 91% ee); 1H NMR (300 MHz, CDCl3) δ 7.18 (ddt, J 
= 7.4, 1.7, 0.8 Hz, 1H), 7.07 (t, J = 7.6 Hz, 1H), 6.99 (ddt, J = 7.7, 1.5, 0.7 Hz, 1H), 5.89 (d, J = 9.0 Hz, 1H), 
5.11 (ddd, J = 9.5, 6.7, 3.8 Hz, 1H), 4.14 (qd, J = 7.2, 0.7 Hz, 2H), 3.30 (dd, J = 16.9, 6.7 Hz, 1H), 2.97 (dd, 
J = 16.9, 3.8 Hz, 1H), 2.28 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.9 (C), 
149.9 (C), 131.3 (CH), 128.5 (C), 124.7 (CH), 123.0 (CH), 120.5 (C), 61.5 (CH2), 53.9 (CH), 37.2 (CH2), 
15.6 (CH3), 14.0 (CH3) ppm. HRMS (ESI) m/z: 286.0744 [M + H]+, C12H16NO5S requires 286.0749.  
Ethyl (S)-2-(5-methoxy-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30h) 
The enantiomeric excess (90%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 12.80 min, minor enantiomer 
tr = 16.47 min. 
Oil; []D
20 = -60.7 (c 1.0, CHCl3, 90% ee); 1H NMR (300 MHz, CDCl3) δ 7.28 (td, J = 8.4, 
0.7 Hz, 1H), 6.71 (dd, J = 8.3, 1.0 Hz, 1H), 6.65 (dd, J = 8.4, 1.0 Hz, 1H), 5.59 (d, J = 6.4 Hz, 1H), 5.20 
(ddd, J = 9.6, 6.5, 2.9 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 3.86 (s, 3H), 3.37 (dd, J = 16.9, 9.9 Hz, 1H), 2.99 
(dd, J = 16.9, 3.0 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 171.6 (C), 156.3 (C), 
151.8 (C), 129.9 (CH), 111.12 (CH), 109.6 (C), 107.0 (CH), 61.01 (CH2), 55.9 (CH3), 52.0 (CH), 36.8 (CH2), 
14.1 (CH3) ppm. HRMS (ESI) m/z: 302.0693 [M + H]+, C12H16NO6S requires 302.0698. 
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Ethyl (S)-2-(6,8-di-tert-butyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30i) 
The enantiomeric excess (88%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 6.99 min, minor 
enantiomer tr = 8.23 min. 
Oil; []D
20 = -22.9 (c 1.0, CHCl3, 88% ee); 1H NMR (300 MHz, CDCl3) δ 7.35 (dd, J 
= 2.3, 0.7 Hz, 1H), 6.99 (dd, J = 2.4, 0.9 Hz, 1H), 5.74 (d, J = 8.7 Hz, 1H), 5.09 
(dddt, J = 8.9, 7.3, 3.8, 0.8 Hz, 1H), 4.15 (qd, J = 7.1, 0.6 Hz, 2H), 3.31 (dd, J = 16.7, 7.3 Hz, 1H), 2.95 
(dd, J = 16.7, 3.9 Hz, 1H), 1.41 (s, 9H), 1.29 (s, 9H), 1.22 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) 
δ 171.0 (C), 148.3 (C), 147.5 (C), 139.4 (C), 124.5 (CH), 121.2 (C), 120.4 (C), 61.4 (CH2), 54.1 (CH), 38.0 
(CH2), 35.1 (C), 34.7 (C), 31.3 (CH3), 30.0 (CH3), 14.1 (CH3) ppm. HRMS (ESI) m/z: 384.1839 [M + H]+, 
C19H30NO5S requires  384.1845. 
Ethyl (S)-2-(3,3-dioxido-1,2-dihydronaphtho[1,2-e][1,2,3]oxathiazin-1-yl)acetate (30j) 
The enantiomeric excess (93%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 9.70 min, minor enantiomer 
tr = 12.79 min. 
Oil; []D
20 = -37.3 (c 1.0, CHCl3, 93% ee); 1H NMR (300 MHz, CDCl3) δ 7.96 – 7.80 (m, 
2H), 7.71 (dd, J = 8.5, 1.1 Hz, 1H), 7.62 (ddd, J = 8.5, 6.8, 1.5 Hz, 1H), 7.53 (ddd, J = 
8.1, 6.8, 1.3 Hz, 1H), 7.15 (d, J = 9.0 Hz, 1H), 5.77 (ddd, J = 10.9, 6.3, 2.4 Hz, 1H), 5.43 (d, J = 6.2 Hz, 1H), 
4.28 (qd, J = 7.2, 1.7 Hz, 2H), 3.66 (dd, J = 17.5, 10.9 Hz, 1H), 2.97 (dd, J = 17.5, 2.4 Hz, 1H), 1.32 (t, J = 
7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 171.1 (C), 149.1 (C), 131.2 (C), 131.1 (CH), 129.4 (CH), 
129.3 (C), 128.2 (CH), 125.9 (CH), 122.0 (CH), 118.4 (CH), 113.6 (C), 61.4 (CH2), 53.3 (CH), 38.0 (CH2), 
14.2 (CH3) ppm. HRMS (ESI) m/z: 322.0744 [M + H]+, C15H16NO5S requires 322.0749. 
Ethyl (S)-2-(6-nitro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30k) 
The enantiomeric excess (85%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 16.93 min, minor enantiomer 
tr = 30.37 min. 
Oil; []D
20 = -44.7 (c 1.0, CHCl3, 85% ee); 1H NMR (300 MHz, CDCl3) δ 8.24 (ddd, J = 
9.1, 2.6, 0.8 Hz, 1H), 8.13 (dd, J = 2.5, 1.1 Hz, 1H), 7.21 (d, J = 9.0 Hz, 1H), 6.14 (d, J 
= 7.1 Hz, 1H), 5.19 (s, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.41 (dd, J = 17.3, 5.9 Hz, 1H), 3.10 (dd, J = 17.4, 3.9 
Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.5 (C), 155.8 (C), 144.5 (C), 125.5 
(CH), 122.0 (C), 121.7 (CH), 120.2 (CH), 62.0 (CH2), 53.6 (CH), 36.3 (CH2), 14.0 (CH3) ppm. HRMS (ESI) 
m/z: 334.0706 [M + NH4]+, C11H16N3O7S requires 334.0735.  
Ethyl (S)-2-(6,8-dichloro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (30l) 
The enantiomeric excess (79%) was determined by chiral HPLC (Lux Amylose-1), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 5.57 min, minor 
enantiomer tr = 6.05 min. 
Oil; []D
20 = -42.6 (c 1.0, CHCl3, 79% ee); 1H NMR (300 MHz, CDCl3) δ 7.43 (dd, J = 
2.4, 0.7 Hz, 1H), 7.08 (dd, J = 2.4, 1.0 Hz, 1H), 5.89 (s, 0H), 5.10 (ddt, J = 6.0, 3.8, 
0.9 Hz, 1H), 4.23 – 3.99 (m, 2H), 3.29 (dd, J = 17.2, 6.3 Hz, 1H), 3.00 (dd, J = 17.2, 3.8 Hz, 1H), 1.24 (t, J 
= 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.5 (C), 146.3 (C), 130.5 (CH), 130.3 (C), 125.1 (C), 
144 
 
124.0 (CH), 123.7 (C), 61.9 (CH2), 53.8 (CH), 36.7 (CH2), 14.0 (CH3) ppm. HRMS (ESI) m/z: 339.9808 [M 
+ H]+, C11H12Cl2NO5S requires  339.9813. 
Ethyl (S)-2-(4-methyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (31a) 
The enantiomeric excess (99%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 12.93 min, minor enantiomer 
tr = 16.03 min. 
Oil; []D
20 = -22.0 (c 1.0, CHCl3, 99% ee); 1H NMR (300 MHz, CDCl3) δ 7.34 – 7.27 (m, 
2H), 7.20 (dd, J = 4.9, 0.9 Hz, 1H), 7.02 (dt, J = 8.2, 0.8 Hz, 1H), 6.53 (s, 1H), 4.03 (qd, J = 7.1, 1.9 Hz, 
2H), 3.10 (d, J = 15.7 Hz, 1H), 2.80 (d, J = 15.7 Hz, 1H), 1.81 (s, 3H), 1.06 (t, J = 7.1 Hz, 3H) ppm. 13C NMR 
(75 MHz, CDCl3) δ 170.5 (C), 150.1 (C), 129.8 (CH), 126.2 (CH), 125.5 (CH), 124.9 (C), 119.4 (CH), 61.4 
(CH2), 61.2 (C), 45.3 (CH2), 29.3 (CH3), 13.8 (CH3) ppm. HRMS (ESI) m/z: 286.0740 [M + H]+, C12H16NO5S 
requires 286.0744. 
Ethyl (S)-2-(4,6-dimethyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (31b) 
The enantiomeric excess (99%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 14.25 min, minor enantiomer 
tr = 18.31 min. 
Oil; []D
20 = -44.8 (c 1.0, CHCl3, 99% ee); 1H NMR (300 MHz, CDCl3) δ 7.13 – 7.04 (m, 
1H), 6.97 (d, J = 1.4 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 6.46 (s, 1H), 4.14 – 3.94 (m, 2H), 
3.09 (d, J = 15.7 Hz, 1H), 2.78 (d, J = 15.7 Hz, 1H), 2.33 (s, 3H), 1.79 (s, 3H), 1.07 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (75 MHz, CDCl3) δ 170.5 (C), 147.9 (C), 135.2 (C), 130.4 (CH), 126.3 (CH), 124.5 (C), 119.0 (CH), 
61.3 (CH2), 61.1 (C), 45.3 (CH2), 29.3 (CH3), 20.9 (CH3), 13.8 (CH3) ppm. HRMS (ESI) m/z: 300.0904 [M + 
H]+, C13H18NO5S requires 300.0900. 
Ethyl (S)-2-(6-chloro-4-methyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (31c) 
The enantiomeric excess (97%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 8.98 min, minor enantiomer 
tr = 11.23 min.  
Oil; []D
20 = -59.8 (c 1.0, CHCl3, 98% ee); 1H NMR (300 MHz, CDCl3) δ 7.27 (dd, J = 
8.8, 2.5 Hz, 1H), 7.18 (d, J = 2.4 Hz, 1H), 6.98 (d, J = 8.8 Hz, 1H), 6.54 (s, 1H), 4.18 – 
3.94 (m, 2H), 3.07 (d, J = 15.9 Hz, 1H), 2.81 (d, J = 15.9 Hz, 1H), 1.80 (s, 3H), 1.10 (t, 
J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.4 (C), 148.6 (C), 130.7 (C), 129.9 (CH), 126.6 (C), 
126.1 (CH), 120.8 (CH), 61.6 (CH2), 61.0 (C), 45.1 (CH2), 29.2 (CH3), 13.8 (CH3) ppm. HRMS (ESI) m/z: 
320.0358 [M + H]+, C12H15ClNO5S requires 320.0354 
Ethyl (S)-2-(4,7-dimethyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (31d) 
The enantiomeric excess (98%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 13.61 min, minor 
enantiomer tr = 17.71 min.  
Oil; []D
20 = -29.5 (c 1.0, CHCl3, 98% ee); 1H NMR (300 MHz, CDCl3) δ 7.07 (d, J = 
8.0 Hz, 1H), 7.00 (ddd, J = 8.0, 1.6, 0.6 Hz, 1H), 6.83 (d, J = 0.7 Hz, 1H), 6.49 (s, 1H), 4.04 (q, J = 7.1 Hz, 
2H), 3.07 (d, J = 15.7 Hz, 1H), 2.78 (d, J = 15.7 Hz, 1H), 2.32 (s, 3H), 1.78 (s, 3H), 1.08 (t, J = 7.1 Hz, 3H) 
ppm. 13C NMR (75 MHz, CDCl3) δ 170.6 (C), 149.8 (C), 140.3 (C), 126.4 (CH), 125.8 (CH), 121.8 (C), 119.5 
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(CH), 61.4 (CH2), 61.0 (C), 45.3 (CH2, 29.4 (CH3), 20.9 (CH3), 13.8 (CH3) ppm. HRMS (ESI) m/z: 300.0910 
[M + H]+, C13H18NO5S requires 300,0900. 
Ethyl (S)-2-(7-methoxy-4-methyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate 
(31e) 
The enantiomeric excess (98%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 14.81 min, minor 
enantiomer tr = 19.27 min.  
Oil; []D
20 = -34.5 (c 1.0, CHCl3, 98% ee); 1H NMR (300 MHz, CDCl3) δ 7.08 (d, J 
= 8.8 Hz, 1H), 6.75 (dd, J = 8.7, 2.6 Hz, 1H), 6.53 (d, J = 2.6 Hz, 1H), 6.51 (s, 1H), 4.04 (q, J = 7.1 Hz, 2H), 
3.79 (s, 3H), 3.04 (d, J = 15.6 Hz, 1H), 2.77 (d, J = 15.6 Hz, 1H), 1.77 (s, 3H), 1.09 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (75 MHz, CDCl3) δ 171.0 (C), 160.7 (C), 151.2 (C), 127.2 (CH), 117.0 (C), 113.0 (CH), 104.2 (CH), 
61.8 (CH2), 61.3 (C), 56.0 (CH3), 45.8 (CH2), 29.9 (CH3), 14.5 (CH3) ppm. HRMS (ESI) m/z: 316.0855 [M + 
H]+, C13H18NO6S requires 316.0849. 
Ethyl (S)-2-(6-chloro-4,7-dimethyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate 
(31f) 
The enantiomeric excess (96%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 10.41 min, minor 
enantiomer tr = 12.87 min. 
Oil; []D
20 = -58.2 (c 1.0, CHCl3, 96% ee); 1H NMR (300 MHz, CDCl3) δ 7.15 (s, 1H), 
6.91 (s, 1H), 6.50 (s, 1H), 4.26 – 3.90 (m, 2H), 3.05 (d, J = 15.9 Hz, 1H), 2.79 (d, J = 15.9 Hz, 1H), 2.34 (s, 
3H), 1.78 (s, 3H), 1.11 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.5 (C), 148.2 (C), 138.3 
(C), 130.9 (C), 126.2 (CH), 123.8 (C), 121.3 (CH), 61.6 (CH2), 60.8 (C), 45.1 (CH2), 29.3 (CH3), 19.8 (CH3), 
13.8 (CH3) ppm. HRMS (ESI) m/z: 334.0521 [M + H]+, C13H17ClNO5S requires 334.0511. 
Ethyl (S)-2-(4-methyl-2,2-dioxido-3,4-dihydronaphtho[2,1-e][1,2,3]oxathiazin-4-yl)acetate (31g) 
The enantiomeric excess (98%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 10.42 min, minor 
enantiomer tr = 14.49 min. 
Oil; []D
20 = -20.1 (c 1.0, CHCl3, 98% ee); 1H NMR (300 MHz, CDCl3) δ 8.22 – 8.17 
(m, 1H), 7.84 – 7.79 (m, 1H), 7.70 – 7.66 (m, 1H), 7.61 – 7.55 (m, 1H), 7.23 (d, J 
= 8.7 Hz, 1H), 6.70 (s, 1H), 3.99 (qd, J = 7.1, 1.4 Hz, 1H), 3.19 (d, J = 15.7 Hz, 2H), 2.87 (d, J = 15.7 Hz, 
1H), 1.88 (s, 3H), 1.00 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.6 (C), 145.3 (C), 133.8 
(C), 127.6 (CH), 127.4 (CH), 127.3 (CH), 125.2 (CH), 124.7 (C), 122.0 (CH), 121.4 (CH), 119.3 (C), 61.5 
(C), 61.4 (CH2), 45.0 (CH2), 28.9 (CH3), 13.8 (CH3) ppm. HRMS (ESI) m/z: 336.0893 [M + H]+, C16H18NO5S 
requires 336.0900. 
Ethyl (S)-2-(4-ethyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (31h) 
The enantiomeric excess (98%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 11.40 min, minor enantiomer 
tr = 13.99 min. 
Oil; []D
20 = -7.9 (c 1.0, CHCl3, 98% ee); 1H NMR (300 MHz, CDCl3) δ 7.30 (ddd, J = 8.2, 
6.4, 2.6 Hz, 1H), 7.24 – 7.12 (m, 2H), 7.05 – 7.00 (m, 1H), 6.40 (s, 1H), 4.03 (qd, J = 7.1, 1.9 Hz, 2H), 3.00 
(d, J = 15.7 Hz, 1H), 2.85 (d, J = 15.7 Hz, 1H), 2.40 (dq, J = 14.8, 7.4 Hz, 1H), 1.84 (dq, J = 14.5, 7.2 Hz, 
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1H), 1.06 (t, J = 7.2 Hz, 3H), 1.01 (t, J = 7.7 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 171.2 (C), 150.4 
(C), 129.7 (CH), 126.1 (CH), 125.4 (CH), 125.0 (C), 119.3 (CH), 64.2 (C), 61.4 (CH2), 42.1 (CH2), 33.6 (CH2), 
13.8 (CH3), 7.8 (CH3) ppm. HRMS (ESI) m/z: 300.0899 [M + H]+ , C13H18NO5S requires 300.0900. 
Ethyl (S)-2-(2,2-dioxido-4-phenethyl-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetate (31i) 
The enantiomeric excess (97%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 13.57 min, minor enantiomer 
tr = 22.65 min. 
Oil; []D
20 = -36.3 (c 1.0, CHCl3, 97% ee); 1H NMR (300 MHz, CDCl3) δ 7.37 – 7.23 (m, 
3H), 7.22 – 7.14 (m, 5H), 7.04 (dt, J = 8.1, 0.8 Hz, 1H), 6.58 (s, 1H), 4.11 – 3.94 (m, 
2H), 3.10 (d, J = 15.7 Hz, 1H), 3.03 – 2.85 (m, 2H), 2.72 – 2.60 (m, 2H), 2.14 – 2.00 
(m, 1H), 1.07 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 171.1 (C), 150.2 (C), 140.7 (C), 129.8 
(CH), 128.5 (CH), 128.4 (CH), 126.1 (CH), 126.0 (CH), 125.5 (CH), 124.7 (C), 119.4 (CH), 63.7 (C), 61.5 
(CH2), 42.9 (CH2), 42.5 (CH2), 29.8 (CH2), 13.8 (CH3) ppm. HRMS (ESI) m/z: 376.1214 [M + H]+, 
C19H22NO5S requires 376.1213. 
Ethyl (S)-2-(3-methyl-1,1-dioxido-2,3-dihydrobenzo[d]isothiazol-3-yl)acetate (34a) 
The enantiomeric excess (85%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 70:30, 1 mL/min, major enantiomer tr = 27.13 min, minor enantiomer 
tr = 50.07 min.  
Oil; []D
20 = -34.2 (c 1.0, CHCl3, 85% ee); 1H NMR (300 MHz, CDCl3) δ 7.77 (ddd, J = 
7.6, 1.2, 0.7 Hz, 1H), 7.64 (td, J = 7.5, 1.2 Hz, 1H), 7.54 (td, J = 7.5, 1.1 Hz, 1H), 7.42 – 7.37 (m, 1H), 7.26 
(s, 1H), 4.15 (q, J = 7.1 Hz, 2H), 2.87 (s, 2H), 1.70 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 170.22 (C), 143.08 (C), 135.06 (C), 133.31 (CH), 129.61 (CH), 122.80 (CH), 121.49 (CH), 61.36 
(CH2), 60.71 (C), 44.58 (CH2), 27.47 (CH3), 14.00 (CH3) ppm. HRMS (ESI) m/z: 270.0808 [M + H]+, 
C12H16NO4 requires 270.0795. 
Ethyl (S)-2-(3-ethyl-1,1-dioxido-2,3-dihydrobenzo[d]isothiazol-3-yl)acetate (34b) 
The enantiomeric excess (70%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 70:30, 1 mL/min, major enantiomer tr = 30.28 min, minor enantiomer 
tr = 57.56 min.  
Oil; []D
20 = -16.9 (c 1.0, CHCl3, 70% ee); 1H NMR (300 MHz, CDCl3) δ 7.79 (ddd, J = 
7.7, 1.2, 0.7 Hz, 1H), 7.68 – 7.61 (m, 1H), 7.55 (td, J = 7.6, 1.1 Hz, 1H), 7.37 – 7.31 (m, 1H), 5.86 (s, 1H), 
4.14 (q, J = 7.1 Hz, 2H), 2.94 – 2.79 (m, 2H), 2.13 – 1.83 (m, 2H), 1.19 (t, J = 7.1 Hz, 3H), 0.81 (t, J = 7.3 
Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.3 (C), 141.3 (C), 135.8 (C), 133.2 (CH), 129.7 (CH), 123.0 
(CH), 121.6 (CH), 64.5 (C), 61.4 (CH2), 44.0 (CH2), 32.5 (CH2), 14.0 (CH3), 8.1 (CH3) ppm. HRMS (ESI) m/z: 
284.0964 [M + H]+, C13H18NO4S requires 284.0951. 
5.5.6. Synthetic Procedures and characterization data for compounds 35-40 
tert-Butyl (S)-(3-hydroxy-1-(2-hydroxyphenyl)propyl)carbamate (35)29 and tert-butyl (S)-(1-(2-((tert-
butoxycarbonyl)oxy)phenyl)-3-hydroxypropyl)carbamate (36) 
To a solution of 30a (0.100 mmol) in THF (1 mL), LiAlH4 (1.0 M in THF, 3.3 equivalents, 0.33 
mmol) was added dropwise at rt over 4 min. The mixture was heated to 60 °C for 2.5 hours, allowed 
to cool down to rt, and then cooled with an ice bath. The reaction was quenched with EtOAc (1 mL), 
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followed by the addition of EtOH (1 mL) and H2O (1 mL). To the resulting turbid mixture Boc2O (1.2 
equivalents, 0.12 mmol) was added in one portion and the resulting mixture was stirred at rt 
overnight. The mixture was diluted with EtOAc (15 mL) and acidified with aq 2 M HCl until the aqueous 
layer became clear. The aqueous layer was then separated and extracted with EtOAc (2 x 15 mL). The 
combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. Purification of the 
residue by flash chromatography afforded compound 35 and 36. 
The enantiomeric excess (92%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 14.11 min, minor enantiomer 
tr = 19.13 min.  
Oil; []D
20 = -41.6 (c 1.0, CHCl3, 92% ee); 1H NMR  (300 MHz, CDCl3) δ 7.71 (s, 1H), 7.18 – 7.07 (m, 2H), 
6.85 (dd, J = 17.2, 7.8 Hz, 2H), 5.57 (s, 1H), 5.01 (dd, J = 14.5, 8.3 Hz, 1H), 3.79 – 3.60 (m, 2H), 2.87 (s, 
1H), 2.19 – 1.88 (m, 2H), 1.70 (s, 1H), 1.44 (s, 9H) ppm. 13C NMR (75.5 MHz, CDCl3) δ 157.1 (C), 154.3 
(C), 128.6 (CH), 127.9 (CH), 127.35 (C), 120.5 (CH), 116.8 (CH), 80.5 (C), 59.5 (CH2), 47.9 (CH), 37.6 
(CH2), 28.4 (CH3) ppm. HRMS (ESI) m/z: 268.1552 [M + H]+, C14H22NO4 requires 268.1543. 
 The enantiomeric excess (92%) was determined by chiral HPLC (Chiralpak ADH), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 9.45 min, minor 
enantiomer tr = 15.42 min.  
Oil; []D
20 = -52.8 (c 1.0, CHCl3, 92% ee); 1H NMR  (300 MHz, CDCl3) δ 7.36 – 7.27 
(m, 2H), 7.22 (td, J = 7.5, 1.5 Hz, 1H), 7.16 (dd, J = 7.9, 1.3 Hz, 1H), 5.17 (d, J = 8.5 Hz, 1H), 5.03 (d, J = 
2.9 Hz, 1H), 3.76 – 3.59 (m, 2H), 3.21 – 2.96 (m, 1H), 2.05 – 1.79 (m, 2H), 1.55 (s, 9H), 1.42 (s, 9H) ppm. 
13C NMR (75.5 MHz, CDCl3) δ 156.3 (C), 151.8 (C), 148.6 (C), 133.6 (C), 128.6 (CH), 128.1 (CH), 126.4 
(CH), 123.0 (CH), 84.0 (C), 79.9 (C), 59.0 (CH2), 47.9 (CH), 38.6 (CH2), 28.3 (CH3), 27.7 (CH3) ppm. HRMS 
(ESI) m/z: 368.2081 [M + H]+, C19H30NO6 requires 368.2068. 
(S)-4-(2-Hydroxyethyl)-4-methyl-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (37) 
To a solution of 31a (0.100 mmol, 28.5 mg) in THF (1 mL), LiAlH4 (1.0 M in THF, 1.1 equivalents, 
0.11 mmol) was added dropwise at 0 °C over 4 min. The reaction was stirred at 0 °C until completion 
(TLC). The mixture was diluted with EtOAc (10 mL) and acidified with aq 2 M HCl until the aqueous 
layer became clear. A saturated solution of Rochelle salt was added (5 mL) and the mixture was stirred 
for 2 hours. The aqueous layer was then separated and extracted with EtOAc (2 x 15 mL). The 
combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. Purification of the 
residue by flash chromatography afforded compound 37 (41% yield, 9.9 mg). 
The enantiomeric excess (99%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 11.81 min, minor enantiomer 
tr = 9.56 min.  
Oil; []D
20 = -16.6 (c 1.0, CHCl3, 92% ee); 1H NMR  (300 MHz, CDCl3) δ 7.30 (ddd, J = 
8.2, 7.3, 1.7 Hz, 1H), 7.20 (td, J = 7.6, 1.4 Hz, 1H), 7.09 (dd, J = 7.8, 1.7 Hz, 1H), 7.05 (dd, J = 8.1, 1.4 Hz, 
1H), 6.99 (s, 1H), 3.93 – 3.79 (m, 1H), 3.66 – 3.47 (m, 1H), 2.28 (ddd, J = 15.4, 10.9, 3.3 Hz, 1H), 2.11 
(ddd, J = 15.4, 4.0, 2.1 Hz, 1H), 1.56 (s, 3H) ppm. 13C NMR (75.5 MHz, CDCl3) δ 151.0 (C), 129.3 (CH), 
126.5 (CH), 125.6 (CH), 125.5 (C), 119.5 (CH), 63.8 (C), 59.9 (CH2), 42.9 (CH2), 30.2 (CH3) ppm HRMS 





(S)-2-(2,2-Dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetic acid (38)  
To a solution of 30a (0.15 mmol, 40.65 mg) in EtOH (1 mL) NaOH 1M (1 mL) wasw added. The 
dissolution was stirred at reflux temperature (73 °C) for 2 hours. The reaction was quenched with HCl 
2M (5 mL) and extracted with dichloromethane (3x15 mL), dried over MgSO4, filtered and 
concentrated in vacuo. Product 38 was obtained (91% yield, 33.2 mg). 
The enantiomeric excess (92%) was determined by chiral HPLC (Cellulose-3), 
hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 65.60 min, minor enantiomer 
tr = 70.15 min.  
Oil; []D
20 = -22.1 (c 1.0, CHCl3, 92% ee); 1H NMR  (300 MHz, CD3OD) δ 7.34 (t, J = 7.0 
Hz, 2H), 7.22 (td, J = 7.2, 1.2 Hz, 1H), 7.05 – 6.97 (m, 1H), 5.13 (dd, J = 9.1, 4.8 Hz, 1H), 4.90 (s, 2H), 
3.08 (qd, J = 16.4, 7.0 Hz, 2H) ppm. 13C NMR (75.5 MHz, CD3OD) δ 173.8 (C), 152.6 (C), 130.5 (CH), 
128.0 (CH), 126.3 (CH), 123.3 (C), 119.6 (C), 55.0 (CH), 40.3 (CH2) ppm.  HRMS (ESI) m/z: 242.0075 [M 
- H]-, C9H8NO5S requires 242.0123. 
(S)-2-(4-Methyl-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)acetic acid (39) 
To a solution of 31a (0.15 mmol, 42.8 mg)) in EtOH (1 mL) NaOH 1M (1 mL) was added. The 
dissolution was stirred at reflux temperature (73 °C) for 2 hours. The reaction was quenched with HCl 
2M (5 mL) and extracted with dichloromethane (3x15 mL), dried over MgSO4, filtered and 
concentrated in vacuo. Product 39 was obtained (99% yield, 38.2 mg). 
The enantiomeric excess (99%) was determined by chiral HPLC (Amylose-1), hexane-
iPrOH 90:10, 1 mL/min, major enantiomer tr = 6.55 min, minor enantiomer tr = 9.10 
min.  
Oil; []D
20 = -13.9 (c 1.0, CHCl3, 99% ee); 1H NMR  (300 MHz, CDCl3) δ 7.32 (ddd, J = 
8.2, 6.6, 2.4 Hz, 1H), 7.22 (tt, J = 7.5, 3.6 Hz, 2H), 7.06 – 7.00 (m, 1H), 3.22 (d, J = 16.3 Hz, 1H), 2.87 (d, 
J = 16.3 Hz, 1H), 1.82 (s, 3H) ppm. 13C NMR (75.5 MHz, CDCl3) δ 174.6 (C), 149.8 (C), 130.0 (CH), 125.9 
(CH), 125.9 (CH), 125.1 (C), 119.5 (CH), 60.7 (C), 44.6 (CH2), 29.2 (CH3) ppm. HRMS (ESI) m/z: 258.0443 
[M + H], C10H12NO5S requires 258.0431. 
(S)-9b-Methyl-1,9b-dihydro-2H-azeto[1,2-c]benzo[e][1,2,3]oxathiazin-2-one 4,4-dioxide (40) 
To a solution of 39 (0.10 mmol, 25.7 mg)) in dichloromethane N-methylmorpholine (1.1 eq, 
0.11 mmol) was added followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.1 eq, 0.11 
mmol). The reaction was stirred at rt for 2 hours. The mixture was quenched with HCl 1M (5 mL) and 
extracted with dichloromethane (3x15 mL), dried over MgSO4 and concentrated in vacuo. The 
resulting mixture was then purified by flash chromatography, obtaining compound 40 (72% yield, 17.2 
mg). 
The enantiomeric excess (98%) was determined by chiral HPLC (Amylose-1), hexane-
iPrOH 90:10, 1 mL/min, major enantiomer tr = 15.65 min, minor enantiomer tr = 12.28 
min.  
Oil; []D
20 = -75.6 (c 1.0, CHCl3, 98% ee); 1H NMR  (300 MHz, CDCl3) δ 7.41 (ddd, J = 8.2, 
5.5, 3.6 Hz, 1H), 7.37 – 7.30 (m, 2H), 7.16 – 7.10 (m, 1H), 3.59 (d, J = 16.4 Hz, 1H), 3.42 (d, J = 16.4 Hz, 
1H), 2.03 (s, 3H) ppm. 13C NMR (75.5 MHz, CDCl3) δ 162.2 (C), 149.4 (C), 130.6 (CH), 127.0 (CH), 126.6 
(CH), 125.3 (C), 120.0 (CH), 63.4 (C), 54.7 (CH2), 26.2 (CH3) ppm. HRMS (ESI) m/z: 257.0578 [M + NH4]+, 
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 With the results of the previous chapter in mind, in which we were able to perform the first 
example of an aza-Refromatsky reaction of cyclic imines (Chapter 5), we wanted to test the reaction 
conditions on different cyclic imines. For this reason we chose to study the aza-Reformatsky reaction 
of dibenzo[b,f][1,4]oxazepines, imines used before in this thesis (Chapter 4). 
6.2. OBJETIVOS 
El objetivo general de este capítulo es el desarrollo de un método catalítico y enantioselectivo 
que permita llevar a cabo la reacción de aza-Reformatsky de aldiminas cíclicas de tipo dibenzoxazepina 
con iodoacetato de etilo que transcurra con buenos rendimientos y excesos enantioméricos. 
 
 En el estudio de este proyecto se considerarán los siguientes aspectos: 
1. La influencia de la estructura de diversos ligandos quirales de tipo BINOL (L1-L3 y L6), (R)-VAPOL 
(L7), derivados de (S)-prolinol (L9-L12)  quinina (L13) y N-metilefedrina (L17) sobre el rendimiento y la 
enantioselectividad de la reacción. 
 
2. La influencia de la naturaleza del reactivo de dialquilzinc utilizado (Me2Zn y Et2Zn), el número de 
equivalentes de reactivo de dialquilzinc, disolvente, concentración y temperatura de reacción. 
3. Evaluación de diversas aldiminas cíclicas de tipo dibenzoxazepina 21 con diferente naturaleza 
electrónica y estérica. 
 
4. Evaluación de distintas transformaciones sintéticas de los productos obtenidos basadas en la 
reactividad del grupo éster sin pérdida de pureza óptica. 
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6.3. RESULTADOS Y DISCUSIÓN 
6.3.1. Optimización de las condiciones de la reacción 
El estudio de la reacción de aza-Reformatsky entre iodoacetato de etilo (29) con iminas cíclicas 
de tipo dibenzo[b,f][1,4]oxazepina 21 se inició con el proceso de optimización de las condiciones de la 
reacción. En primer lugar se inició el proceso de optimización ensayando un conjunto de ligandos [de 
tipo (R)-BINOL (L1, L2, L3 y L6), (R)-VAPOL (L7), derivados de (S)-prolinol (L9-L12), quinina (L13) y N-
metilefedrina (L14)],  en presencia de 7 equivalentes de Me2Zn empleando Et2O como disolvente a 
temperatura ambiente (Tabla 6.1), condiciones que se usaron también en la optimización de las 
condiciones de reacción del apartado anterior. 




Entrada Ligando t (min) R (%)b ee (%)c 
1 L1 30 62 0 
2 L2 30 68 0 
3 L3 30 70 5 
4 L6 30 44 3 
5 L7 30 52 10 
6 L9 30 57 34 
7 L10 30 42 46 
8 L11 30 71 39 
9 L12 30 36 43 
10 L13 30 45 -14 
11 L14 30 45 -31 
a 21a (0,100 mmol), 29 (0,200 mmol), 1,2 M Me2Zn en tolueno (0,700 mmol), L (0,020 mmol). b Rendimiento 
después de purificación por cromatografía de columna. c Exceso enantiomérico determinado mediante HPLC 
usando fases estacionarias quirales. 
 Los resultados de estas reacciones se puede encontrar en la tabla 6.1. Como se puede 
observar, en las reacciones con ligandos de tipo BINOL se obtiene el producto 41a con rendimientos 
moderados (44-70%) pero prácticamente como mezcla racémica (0-5% ee) (entradas 1-4). Un 
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resultado similar se pudo observar cuando se usó (R)-VAPOL como ligando (Tabla 6.1, entrada 5), 
obteniéndose el producto 41a con un rendimiento de un 52% y un exceso enantiomérico de 10%. Sin 
embargo cuando se utilizaron ligandos derivados de (S)-prolinol (L9-L12) se observó un aumento 
considerable en la enantioselectividad de la reacción. El uso del ligando L9 [(S)-difenil(pirrolidin-2-
il)metanol] dio lugar al producto final con un rendimiento del 57% y una enantioselectividad del 34% 
ee. Resultados similares se pudieron observar con el uso de ligandos sustituidos en los anillos 
aromáticos, derivados de L9 (L10-L12), con rendimientos entre 36% y 71% y enantioselectividades 
entre 39% y 46% ee. El mejor resultado se observó con el ligando L10 (Tabla 6.1, entrada 7) (42% de 
rendimiento y 46% ee). Con el objetivo de mejorar la enantioselectividad de la reacción, se ensayaron 
también la quinina (L13) y la N-metilefedrina (L14), pero el exceso enantiomérico obtenido era inferior 
al obtenido con los ligandos de tipo prolinol (Tabla 6.1, entradas 10 y 11). 
Una vez identificado el ligando L10 como el que proporcionaba el mejor resultado entre los 
ligandos examinados, continuamos el proceso de optimización ensayando la reacción con diferentes 
disolventes, número de equivalentes de iodoacetato de etilo (45), temperaturas, concentraciones y 
reactivos de dialquilzinc (Tabla 6.2). 
En primer lugar se estudió el efecto del disolvente en la reacción de aza-Reformatsky (Tabla 
6.2, entradas 2-10). Utilizando tolueno como disolvente se obtuvo el producto de reacción con un 
rendimiento (33%) y un exceso enantiomérico (37% ee) inferiores a los obtenidos con éter etílico 
(Tabla 6.2, entrada 2). Sin embargo la utilización de disolventes como diclorometano, metil terc-butil 
éter o isopropil éter (Tabla 6.2, entradas 3-5) dio lugar al producto de reaccion con rendimientos (44-
54%) y excesos enantiomericos (53-55% ee) superiores. La reacción en THF (Tabla 6.2, entrada 6) 
condujo a una mejora en el rendimiento (63%) de la reacción, pero no tanto en el exceso 
enantiomérico (49%). La reacción en dicloroetano (Tabla 6.2, entrada 7) dio lugar al producto de 
adición con un rendimiento (51%) y una enantioselectividad (56% ee) algo mejores. Cuando se hizo la 
reacción en acetonitrilo (Tabla 6.2, entrada 8), se observó un pequeño incremento en el rendimiento 
(53%), mientras que la reacción en cloroformo (Tabla 6.2, entrada 9) condujo al producto de adición 
con un rendimiento bajo (29%). En ambos casos, la enantioselectividad no mejoró (46 y 48% ee 
respectivamente). Finalmente, cuando se utilizó acetato de etilo como disolvente (Tabla 6.2, entrada 




Tabla 6.2. Reaccion de aza-Reformatsky enantioselectiva de la dibenzoxazepina 21a con iodoacetato de etilo 
(29). Evaluación de reactivos de dialquilzinc, número de equivalentes de reactivos de dialquilzinc, disolvente, 
número de equivalentes de iodoacetato de etilo (29), concentración  y temperatura de reacción.a 
 
 Disolvente T ( °C) t (min) R (%)b ee (%)c 
1 Et2O ta 30 42 46 
2 Tolueno ta 30 33 37 
3 CH2Cl2 ta 30 44 53 
4 MTBE ta 30 47 55 
5 iPr2O ta 30 54 53 
6 THF ta 30 63 49 
7 ClCH2CH2Cl ta 30 51 56 
8 CH3CN ta 30 53 48 
9 CHCl3 ta 30 29 46 
10 AcOEt ta 30 63 59 
11 AcOEt 0 30 22 90 
12d AcOEt 0 30 78 82 
13d AcOEt -10 180 46 90 
14d AcOEt -20 180 22 90 
15d, e AcOEt 0 30 75 68 
16d, f AcOEt 0 30 71 74 
17d, g AcOEt 0 30 97 86 
18d, h AcOEt 0 40 73 74 
19d, i AcOEt 0 60 92 83 
a 21a (0,100 mmol), 29 (0,200 mmol), 1,2 M Me2Zn en tolueno (0,700 mmol), L10 (0,020 mmol). b Rendimiento 
después de purificación por cromatografía de columna. c Exceso enantiomérico determinado mediante HPLC 
usando fases estacionarias quirales. d Se utilizaron 3 equivalentes de iodoacetato de etilo (29) (0,3 mmol) e Se 
utilizó 1M Et2Zn en hexano (0,70 mmol) f Se llevó a cabo la reacción en 1,5 mL de AcOEt g Se llevó a cabo la 
reacción en 6 mL de AcOEt h Se utilizaron 10 equivalentes de Me2Zn i Se utilizaron 5 equivalentes de Me2Zn.  
 Cuando se disminuyó la temperatura de la reacción a 0 °C (Tabla 6.2, entrada 11), se observó 
un incremento espectacular de la enantioselectividad hasta un 90% ee, pero desafortunadamente un 
rendimiento muy bajo de tan solo 22%. Al aumentar la cantidad de iodoacetato de etilo (29) hasta 3 
equivalentes (Tabla 6.2, entrada 12), mejoró el rendimiento de la reacción (78%), pero disminuyó la 
enantioselectividad (82% ee). Al disminuir la temperatura, a -10 °C y -20 °C (Tabla 6.2, entradas 13 y 
14), se mejoró la enantioselectividad (90% ee), pero afectó negativamente el rendimiento de la 
reacción (22-46%). 
 El uso de Et2Zn en lugar de Me2Zn disminuyó la enantioselectividad de la reacción (68% ee) 
(Tabla 6.2, entrada 15). 
 También se evaluó la concentración de reactivos en el medio de reacción. Un aumento en la 
concentración (o un descenso en el volumen) de reactivos condujo a un descenso en la 
enantioselectividad (74% ee), manteniéndose el rendimiento (71%) (Tabla 6.2, entrada 16). Sin 
embargo, cuando se llevó a cabo la reacción a una concentración más baja (mayor volumen de 
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disolvente), se pudo observar un aumento en el rendimiento de la reacción hasta un 97% y en la 
enantioselectividad (86% ee) (Tabla 6.2, entrada 17). 
 También se evaluó el efecto producido por la variación en el número de equivalentes de 
Me2Zn utilizados. Tanto un aumento como un diminución en el número de equivalentes produjo una 
disminución en el rendimiento (79-92%) y en la enantioselectividad (74-83% ee) (Tabla 6.2, entradas 
18 y 19).  
 En resumen, se obtiene el mejor resultado cuando la reacción entre la dibenzoxazepina 21a y 
el iodoacetato de etilo (29) se lleva a cabo en acetato de etilo como disolvente (6 mL) a 0 °C en 
presencia de 7 equivalentes de Me2Zn y 20 mol % del ligando L10.       
6.3.2. Alcance y limitaciones de la reacción 
6.3.2.1. Reacción entre iodoacetato de etilo y diferentes dibenzo[b,f][1,4]oxazepinas 
 Una vez optimizadas las condiciones de reacción, se procedió a estudiar el alcance y las 
limitaciones de la reacción. Para ello se evaluaron varias iminas de tipo dibenzo[b,f][1,4]oxazepina 
diferentemente sustituidas 21 (Esquema 6.1). 
En primer lugar, se evaluaron iminas de tipo dibenzo[b,f][1,4]oxazepinas sustituidas en posiciones 7 y 
8 (21b-21f). La presencia de un grupo electrón-donante (metilo), en la posición 7, condujo al producto 
41b con un rendimiento de 95% y un exceso enantiomérico de 79%. Sin embargo, la presencia del 
mismo grupo electrón-donante en la posición 8 dio lugar al β-amino ester 41c con un rendimiento de 
92% y exceso enantiomérico más elevado de 89%. Se pudo observar el mismo efecto cuando los 
sustituyentes son grupos electrón-atrayentes. Es decir la enantioselectividad es mayor cuando el 
sustituyente está situado en la posición 8. El producto 41d, con un átomo de cloro en la posición 7, se 
obtuvo con un rendimiento del 77% y un exceso enantiomérico de 79%, mientras que el producto 41e, 
con un átomo de cloro en la posición 8, se obtuvo con un rendimiento de 84% y un exceso 
enantiomérico más elevado (85%). Finalmente, cuando la reacción se llevó a cabo con el sustrato 24f, 
sustituido con un grupo metoxi en la posición 8, se obtuvo el correspondiente β-amino ester 41f con 
un rendimiento excelente (98%) y un exceso enantiomérico muy elevado (94%). 
 Posteriormente se ensayaron iminas mono-sustituidas en las posiciones 2 y 4. Un grupo metilo 
en la posición 4 condujo al producto 41g con un rendimiento del 88% y un exceso enantiomérico de 
88%. La presencia del mismo grupo en la posición 2 dio lugar al producto 41h con un rendimiento del 
91% y un exceso enantiomérico similar (87%). La reacción con la imina sustituida con un grupo cloro 
en la posición 6 dio como resultado el producto 41i con un rendimiento elevado (95%) y un exceso 
enantiomérico de 84%. La presencia de un grupo metoxi en la misma posición dio lugar al producto 
41j con un rendimiento del 90% y un exceso enantiomérico de 88%. Se puede observar que la 
presencia de grupos electrón-donantes o electrón-atrayentes en sustratos monosustituidos no tiene 
demasiada influencia a la enantioselectividad de la reacción.  
 También se evaluaron sustratos con varios sustituyentes bajo las condiciones optimizadas. La 
reacción con el sustrato 21k, sustituido con dos grupos metoxi en las posiciones 1 y 3, proporcionó el 
producto 41k con un rendimiento del 94% y un exceso enantiomérico del 79%. Se observa un descenso 
en la enantioselectividad, seguramente debido a un aumento en el impedimento estérico. Cuando se 
utilizó el sustrato trisustituido 21l, con dos grupos metilo en las posiciones 2 y 4 y un átomo de fluor 





Esquema 6.1. Reacción de aza-Reformatsky enantioselectiva de iminas cíclicas de tipo 
dibenzo[b,f][1,4]oxazepina 21 con iodoacetato de etilo (29). 21 (0,100 mmol), 29 (0,300 mmol), Ligando L10 
(0,020 mmol) y 1,2M Me2Zn en tolueno (0,700 mmol). Rendimiento después de purificación por cromatografía 
de columna. Exceso enantiomérico determinado mediante HPLC usando fases estacionarias quirales. a  Se 
utilizaron 10 mol % del ligando L10. 
 También han sido evaluados diferentes sustratos derivados del naftol. El sustrato 21m, 
derivado del 1-naftol, dio lugar al producto 41m con un rendimiento de 98% y un exceso 
enantiomérico elevado de (90%). El producto 41n, derivado del 2-naftol, se obtuvo con un 
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rendimiento (99%) y un exceso enantiomérico (91% ee) similares. Finalmente, el producto 41o, 
derivado del 2-naftol sustituido con un grupo bromo en la posición 6, se obtuvo con un rendimiento 
excelente (96%) y un exceso enantiomérico elevado (92%). Por tanto, los sustratos derivados del naftol 
dan resultados excelentes en la reacción de aza-Reformatsky. 
 Finalmente se ensayó la dibenzo[b,f][1,4]tiazepina bajo las condiciones optimizadas, 
obteniéndose el producto 42 con elevado rendimiento (95%) y un exceso enantiomérico de 89%, 
mostrando que también las dibenzotiazepinas son sustratos excelentes para la reacción de aza-
Reformatsky (Esquema 6.2).  
 
Esquema 6.2. Reacción de aza-Reformatsky enantioselectiva de la dibenzo[b,f][1,4]tiazepina 27 con iodoacetato 
de etilo (29). 27 (0,100 mmol), 29 (0,300 mmol), Ligando L10 (0,020 mmol) y 1,2 M Me2Zn en tolueno (0,700 
mmol). Rendimiento de después de purificación por cromatografía de columna. Excesos enantioméricos 
determinados mediante HPLC usando fases estacionarias quirales. 
6.3.2.2. Reacción de la dibenzo[b,f][1,4]oxazepina con diferentes reactivos de 
Reformatsky 
 Se decidió aplicar las condiciones optimizadas a la reacción de la dibenzo[b,f][1,4]oxazepina 
21a con los reactivos de Reformatsky generados a partir de 2-iodoacetonitrilo (43) y 2-iodo-1-
feniletan-1-ona (45).  
 Cuando se aplicaron las condiciones optimizadas a la reacción entre 2-iodoacetonitrilo (43) y 
dibenzo[b,f][1,4]oxazepina 21a, se obtuvo el producto 44 con buen rendimiento (73%), pero con un 
exceso enantiomérico bajo (50%) (Tabla 6.3, entrada 1). La disminución de la temperatura de reacción 
a 0 °C dio como resultado una disminución tanto en el rendimiento (61%) como en el exceso 
enantiomérico (44%) (Tabla 6.3, entrada 2).  A la vista de estos pobres resultados se decidió hacer una 
pequeña evaluación de ligandos (L11 y L12). El uso del ligando L11 proporcionó al producto con un 
buen rendimiento (72%), pero con un exceso enantiomérico bajo (9% ee) (Tabla 6.3, entrada 3), 
mientras que la utilización del ligando L12 dio lugar al producto 44 con un rendimiento moderado 
(67%) y un exceso enantiomérico de 50% (Tabla 6.3, entrada 4). Así pues, bajo las condiciones 
optimizadas, la reacción de aza-Reformatsky de la   dibenzo[b,f][1,4]oxazepina 21a con 2-




Tabla 6.3. Reacción de aza-Reformatsky enantioselectiva de la dibenzoxazepina 21a con 2-iodoacetonitrilo (43). 
Evaluación de ligandos.a 
 
 Ligando T ( °C) t (min) R (%)b ee (%)c 
1 L10 ta 45 73 50 
2 L10 0 40 61 44 
3 L11 ta 30 72 9 
4 L12 ta 30 67 50 
a 21a (0,100 mmol), 43 (0,300 mmol), Ligando L (0,020 mmol) y 1,2 M Me2Zn en tolueno (0,700 mmol). b 
Rendimiento después de purificación por cromatografía de columna. c Exceso enantiomérico determinado 
mediante HPLC usando fases estacionarias quirales. 
 Las condiciones optimizadas también fueron aplicadas a la reacción entre 2-iodo-1-feniletan-
1-ona  (45) y dibenzo[b,f][1,4]oxazepina 21a, dando lugar al producto 46 con un buen rendimiento 
(76%) pero una enantioselectividad baja (25% ee) (Tabla 6.4, entrada 1). También en este caso se llevó 
a cabo una pequeña evaluación de ligandos (L11 y L12) (Tabla 6.4, entrada 2 y 3). El ligando L11 dio 
lugar al producto de adición 46 con los mejores resultados (rendimiento de 65% y un exceso 
enantiomérico de 40%). Así pues, tampoco, la reacción de aza-Reformatsky con 2-iodo-1-feniletan-1-
ona dio resultados satisfactorios. La configuración absoluta del compuesto 46 se pudo determinar 
mediante correlación química del compuesto.1   
Tabla 6.4. Reacción de aza-Reformatsky enantioselectiva de la dibenzoxazepina 21a con 2-iodo-1-feniletan-1-
ona (45). Evaluación de ligandos.a 
 
 Ligando T ( °C) t (min) R (%)b ee (%)c 
1 L10 ta 120 76 25 
2 L11 ta 9 65 40 
4 L12 ta 105 45 28 
a 21a (0,100 mmol), 45 (0,300 mmol), Ligando L (0,020 mmol) y 1,2 M Me2Zn en tolueno (0,700+0,300 mmol). b 
Rendimiento después de purificación por cromatografía de columna. c Exceso enantiomérico determinado 




6.3.3. Transformaciones sintéticas  
Para demostrar la utilidad de los productos obtenidos, se realizaron varias transformaciones 
sintéticas de los productos obtenidos (Esquema 6.3). 
 
Esquema 6.3. Transformaciones sintéticas. a Rendimiento global de la reacción. 
La primera transformación que se realizó fue la saponificación del éster 41a con hidróxido 
sódico en etanol a 78 °C, obteniendo el β-aminoácido 47 con buen rendimiento (86%) y manteniendo 
el exceso enantiomérico. Esta transformación permite la síntesis de β-aminoácidos a partir de β-amino 
ésteres obtenidos anteriormente.  
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Una segunda transformación que se realizó fue la reducción del éster 41a con LiAlH4 a 0 °C, 
dando lugar al correspondiente 1,2-amino alcohol 48 con un buen rendimiento (86%) y conservando 
la pureza óptica. 
Una tercera transformación, consistió en una secuencia sintética de tres etapas, equivalente 
formalmente a una reacción de vinilación de la imina. En primer lugar, se llevó a cabo la reducción del 
éster 41a al correspondiente 1,2-amino alcohol 48. Una reacción posterior del alcohol obtenido con 
o-nitrofenilselenocianato (49) y tributilfosfina seguida por una oxidación con peróxido de hidrógeno, 
dio lugar al producto 50.2 El rendimiento global de la secuencia fue del 54% y se mantuvo el exceso 
enantiomérico (86% ee). 
Finalmente, a partir del producto 41o se pudo sintetizar el producto 52 sin pérdida de pureza 
óptica, mediante una reacción de acoplamiento cruzado con el ácido borónico 51  catalizada por 
paladio, con un rendimiento de 83%.3 Este resultado es interesante, ya que permite una gran variedad 
de funcionalizaciones debido al gran número de ácidos borónicos existentes en el mercado.  
6.3.4. Determinación de la configuración absoluta 
El compuesto 41o nos permitió obtener una muestra adecuada para el estudio por difracción 
de Rayos X de monocristal. La configuración absoluta del carbono esterogénico se estableció como (S) 
(parámetro de Flack: 0.004(4)) (Figura 6.1). La configuración de los productos restantes se ha asignado 













6.3.5. Propuesta mecanística para la reacción de aza-Reformatsky de 
dibenzoxazepinas 
 El mecanismo (esquema 6.4) que se propone se basa en el mecanismo presentado en el 
capítulo anterior (reacción de aza-Reformatsky de 2,2-dióxido benzoxatiazinas). En primer lugar se 
forma un complejo A entre el ligando y Me2Zn (en este caso con el ligando L10). Este complejo A está 
en equilibrio con un complejo B (dímero del complejo A) que no participa en la reacción. El complejo 
A se coordina con un zincato-metilacetato de etilo (formado en un paso previo, en la reacción del 
iodoacetato de etilo con Me2Zn y oxígeno), formando el complejo C. A este complejo C se coordina la 
imina 21, dando lugar a la formación del complejo D. En este complejo tiene lugar la reacción de aza-
Reformatsky mediante la transferencia del nucleófilo a la cara Si de la imina cíclica generando el 
producto E, a partir del cual se obtiene el β-amino éster 41, regenerando el monómero A y 
completando el ciclo catalítico. 
 
Esquema 6.4. Propuesta mecanística para la reacción de aza-Reformatsky de dibenzoxazepinas con iodoacetato 





1. Se ha diseñado un método enantioselectivo que permite la reacción de aza-Reformatsky de 
aldiminas cíclicas de tipo dibenzo[b,f][1,4]oxazepina (21) con iodoacetato de etilo (29) 
catalizada por un sistema formado por el ligando (S)-bis(3,5-dimetilfenil)(pirrolidin-2-
il)metanol y Me2Zn a 0 °C utilizando AcOEt como disolvente. 
2. La reacción de aza-Reformatsky bajo las condiciones optimizadas con aldiminas cíclicas admite 
sustituyentes en diferentes posiciones del anillo aromático obteniéndose buenos resultados, 
tanto de rendimiento (77-99%) como de enantioselectividad (79-94%).   
3. Se han podido sintetizar varios productos derivados de los β-aminoésteres resultantes de la 
reacción de aza-Reformatsky: un β-aminoácido (47), un 1,2-aminoalcohol (48), una vinilamina 
(50) y un producto de acoplamiento cruzado (52) mediante transformaciones sintéticas 
sencillas a partir de los compuestos 41a y 41o  
4. La determinación de la configuración absoluta para los compuestos 41 se ha podido llevar a 
cabo por difracción de Rayos X de monocristal del producto 41o. Se puede concluir que la 
configuración absoluta es (S). 
5. Se ha propuesto un mecanismo posible para la reacción de Reformatsky de 





6.5. EXPERIMENTAL SECTION 
6.5.1. General experimental methods 
Reactions were carried out under air in test tubes or round bottom flasks oven-dried overnight 
at 120 °C. Dicloromethane, 1,2-dichloroethane and toluene were distilled from CaH2. THF was distilled 
from sodium benzophenone ketyl. Reactions were monitored by TLC analysis using Merck Silica Gel 
60 F-254 thin layer plates. Flash column chromatography was performed on Merck silica gel 60, 0.040-
0.063 mm. Melting points were determined in capillary tubes. NMR spectra were run at 300 MHz for 
1H and at 75 MHz for 13C NMR using residual non-deuterated solvent  as internal standard (CHCl3:  
7.26 and 77.0 ppm). Chemical shifts are given in ppm. The carbon type was determined by DEPT 
experiments. High resolution mass spectra (ESI) were recorded on a AB SCIEX Triple TOFTM 
spectrometer equipped with an electrospray source with a capillary voltage of 4.5 kV(ESI). Optical 
rotations were measured using sodium light (D line 589 nm). Chiral HPLC analyses were performed in 
a chromatograph equipped with a UV diode-array detector using chiral stationary columns from 
Daicel.  
6.5.2. General synthetic procedures and characterization data for compounds 
41, 42, 44 and 46 
General procedure for the enantioselective Reformatsky reaction: A two-neck 50 mL round 
bottom flask (one neck covered with a septum, the other neck with a drying finger, filled with CaCl2), 
was flushed with nitrogen for 5 min. The ligand (S)-bis(3,5-dimethylphenyl)(pyrrolidin-2-yl)methanol 
(0.02/0.01 mmol) was added to the flask and dissolved in 5 mL of EtOAc. Ethyl iodoacetate (29) or 2-
iodoacetonitrilo (43) or 2-iodo-1-feniletan-1-ona (45) (0.3 mmol, 3 eq.) was added and the mixture 
was stirred at 0 °C. After 10 min dimethyl zinc solution (1.2 M in toluene) (7 mmol, 7 eq.) was added 
and immediately afterwards a dibenzo[b,f][1,4]oxazepine 21 or 27 (0.1 mmol, 1 eq.) dissolved in 1 mL 
EtOAc was added. The mixture was stirred for 60 min at 0 °C and quenched with 10 mL saturated 
aqueous NH4Cl solution. The mixture was extracted with DCM (3x20 mL), washed with brine (20 mL) 
and dried over MgSO4. The solvent was removed; the crude product was put on silica gel and purified 
by flash chromatography, obtaining the corresponding product. 
General procedure for the non-enantioselective Reformatsky reaction: A two-neck 50 mL 
round bottom flask (one neck covered with a septum, the other neck with a drying finger, filled with 
CaCl2), was flushed with nitrogen for 5 min. EtOAc was added to the flask (5 mL). Ethyl iodoacetate 
(29) or 2-iodoacetonitrilo (43) or 2-iodo-1-feniletan-1-ona (45) (0.2 mmol, 2 eq.) was added. After 5 
min of stirring the dimethyl zinc solution (1.2 M in toluene) (7 mmol, 7eq.) was added and immediately 
afterwards dibenzo[b,f][1,4]oxazepine 21 or 27 (0.1 mmol, 1 eq.) dissolved in 1 mL EtOAc. The mixture 
was stirred for 60 min at rt. After the reaction was stopped with 10 mL saturated aqueous NH4Cl, the 
mixture was extracted DCM (3x20 mL), washed with brine (20 mL) and dried over MgSO4.  
Ethyl (S)-2-(10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41a) 
Enantiomeric excess (91%) was determined by chiral HPLC (Chiralpak AD-H), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 16.7 min, minor enantiomer tr = 20.3 
min.  
Yellow oil; [α]D20 -59.2 (c 0.5, CHCl3, 86% ee); 1H NMR (300 MHz, CDCl3) δ 7.29 – 7.21 
(m, 1H), 7.18 – 7.12 (m, 2H), 7.11 – 7.00 (m, 2H), 6.85 (ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.67 (ddd, J = 7.9, 
7.3, 1.6 Hz, 1H), 6.56 (dd, J = 7.9, 1.6 Hz, 1H), 4.76 (dd, J = 10.0, 4.3 Hz, 1H), 4.47 (s, 1H), 4.13 (q, J = 7.1 
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Hz, 2H), 3.32 (dd, J = 16.6, 10.0 Hz, 1H), 2.86 (dd, J = 16.6, 4.3 Hz, 1H), 1.21 (t, J = 7.1 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 172.08 (C), 157.11 (C), 143.92 (C), 137.04 (C), 132.18 (C), 129.32 (CH), 127.81 (CH), 
124.63 (CH), 124.33 (CH), 121.75 (CH), 121.23 (CH), 119.22 (CH), 118.92 (CH), 60.68 (CH2), 54.71 (CH), 
40.11 (CH2), 14.14 (CH3). HRMS (ESI) m/z: 284,1281 [M + H]+, C17H18NO3 requires 284,1281. 
Ethyl (S)-2-(7-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41b) 
Enantiomeric excess (79%) was determined by chiral HPLC (Chiralpak AD-H), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 18.9 min, minor enantiomer tr = 21.8 
min.  
Yellow oil; [α]D20 = -10.2 (c 1.0, CHCl3, 79% ee); 1H NMR (300 MHz, CDCl3) δ 7.27 – 
7.19 (m, 1H), 7.16 – 7.10 (m, 2H), 7.07 – 7.00 (m, 1H), 6.91 (dd, J = 2.1, 0.8 Hz, 1H), 
6.70 – 6.64 (m, 1H), 6.49 (d, J = 8.0 Hz, 1H), 4.74 (dd, J = 10.0, 4.2 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.27 
(dd, J = 16.6, 10.0 Hz, 1H), 2.83 (dd, J = 16.6, 4.2 Hz, 1H), 2.21 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 172.1 (C), 157.0 (C), 144.1 (C), 134.2 (C), 132.0 (C), 129.3 (C), 129.2 (CH), 127.9 (CH), 
125.1 (CH), 124.1 (CH), 122.1 (CH), 121.2 (CH), 119.2 (CH), 60.7 (CH2), 54.9 (CH), 39.9 (CH2), 20.2 (CH3), 
14.1 (CH3). HRMS (ESI) m/z: 298.1437 [M + H]+, C18H20NO3 requires 298.1438. 
Ethyl (S)-2-(8-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41c) 
Enantiomeric excess (89%) was determined by chiral HPLC (Chiralpak AD-H), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 15.4 min, minor enantiomer tr = 17.0 
min.  
Yellow oil; [α]D20 = -38.3 (c 1.0, CHCl3, 89% ee); 1H NMR (300 MHz, CDCl3) δ 7.26 – 
7.19 (m, 1H), 7.13 (dt, J = 7.5, 1.4 Hz, 2H), 7.03 (td, J = 7.4, 1.4 Hz, 1H), 6.96 (d, J = 
8.1 Hz, 1H), 6.50 – 6.44 (m, 1H), 6.37 (dd, J = 2.0, 0.9 Hz, 1H), 4.74 (d, J = 9.6 Hz, 1H), 4.41 (s, 1H), 4.13 
(q, J = 7.1 Hz, 2H), 3.32 (dd, J = 16.6, 10.0 Hz, 1H), 2.91 – 2.79 (m, 1H), 2.16 (d, J = 0.7 Hz, 3H), 1.21 (t, 
J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 172.1 (C), 157.3 (C), 142.0 (C), 136.6 (C), 134.2 (C), 132.2 
(C), 129.3 (CH), 127.8 (CH), 124.2 (CH), 121.5 (CH), 121.2 (CH), 119.9 (CH), 119.3 (CH), 60.7 (CH2), 54.7 
(CH), 40.1 (CH2), 20.6 (CH3), 14.1 (CH3). HRMS (ESI) m/z: 298.1436 [M + H]+, C18H20NO3 requires 
298.1438. 
Ethyl (S)-2-(7-chloro-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41d)  
Enantimeric excess (79%) was determined by chiral HPLC (Chiralpak AD-H), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 16.4 min, minor enantiomer tr = 23.0 
min.  
Yellow oil; [α]D20 = -7.6 (c 0.33, CHCl3, 79% ee); 1H NMR (300 MHz, CDCl3) δ 7.32 – 
7.20 (m, 1H), 7.15 (d, J = 1.1 Hz, 1H), 7.13 (d, J = 1.9 Hz, 1H), 7.13 – 7.05 (m, 1H), 7.11 
– 7.03 (m, 1H), 6.81 (dd, J = 8.5, 2.4 Hz, 1H), 6.48 (d, J = 8.6 Hz, 1H), 4.74 (dd, J = 10.1, 4.1 Hz, 1H), 4.49 
(s, 1H), 4.13 (q, J = 7.3 Hz, 2H), 3.30 (dd, J = 16.7, 10.1 Hz, 1H), 2.83 (dd, J = 16.6, 4.1 Hz, 1H), 1.21 (t, J 
= 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 172.0 (C), 156.7 (C), 143.9 (C), 135.8 (C), 131.9 (C), 129.5 
(CH), 127.8 (CH), 124.7 (CH), 124.5 (CH), 123.0 (C), 121.8 (CH), 121.2 (CH), 119.5 (CH), 60.8 (CH2), 54.5 
(CH), 39.9 (CH2), 14.1 (CH3). HRMS (ESI) m/z: 218.0891 [M + H]+, C17H17ClNO3 requires 218.0891. 
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Ethyl (S)-2-(8-chloro-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41e)  
Enantiomeric excess (85%) was determined by chiral HPLC (Chiralpak AD-H), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 16.6 min, minor enantiomer tr = 19.4 
min.  
Yellow oil; [α]D20 = -44.1 (c 0.5, CHCl3, 85% ee); 1H NMR (300 MHz, CDCl3) δ 7.29 – 
7.22 (m, 1H), 7.15 (t, J = 1.9 Hz, 1H), 7.13 (dd, J = 2.6, 1.6 Hz, 1H), 7.11 – 7.03 (m, 
1H), 6.98 (d, J = 8.5 Hz, 1H), 6.59 (dd, J = 8.5, 2.4 Hz, 1H), 6.52 (d, J = 2.4 Hz, 1H), 4.74 (ddd, J = 9.8, 5.3, 
4.1 Hz, 1H), 4.54 (d, J = 5.4 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.33 (dd, J = 16.7, 10.1 Hz, 1H), 2.84 (dd, J 
= 16.6, 4.2 Hz, 1H), 1.22 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 171.9 (C), 156.9 (C), 142.3 (C), 
138.2 (C), 132.0 (C), 129.6 (CH), 129.5 (C), 127.8 (CH), 124.7 (CH), 122.9 (CH), 121.2 (CH), 118.6 (CH), 
117.9 (CH), 60.8 (CH2), 54.4 (CH), 40.1 (CH2), 14.1 (CH3). HRMS (ESI) m/z: 218.0885 [M + H]+, 
C17H17ClNO3 requires 218.0891. 
Ethyl (S)-2-(8-methoxy-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41f) 
Enantiomeric excess (94%) was determined by chiral HPLC (Chiralpak AD-H), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 28.5 min, minor enantiomer tr = 34.2 
min.  
Yellow oil; [α]D20 = -41.6 (c 1.0, CHCl3, 94% ee); 1H NMR (300 MHz, CDCl3) δ 7.27 – 
7.20 (m, 1H), 7.13 (dd, J = 7.8, 1.6 Hz, 1H), 7.08 – 7.01 (m, 1H), 6.99 (d, J = 8.7 Hz, 
1H), 6.21 (dd, J = 8.7, 2.9 Hz, 1H), 6.09 (d, J = 2.9 Hz, 1H), 4.76 (dd, J = 10.0, 4.2 Hz, 1H), 4.49 (s, 1H), 
4.22 – 4.07 (m, 2H), 3.68 (s, 2H), 3.35 (dd, J = 16.6, 10.0 Hz, 1H), 2.91 – 2.79 (m, 1H), 1.21 (t, J = 7.2 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 172.1 (C), 157.5 (C), 156.6 (C), 138.3 (C), 137.8 (C), 132.2 (C), 129.4 
(CH), 127.8 (CH), 124.4 (CH), 122.3 (CH), 121.1 (CH), 104.3 (CH), 103.6 (CH), 60.7 (CH2), 55.4 (CH3), 54.5 
(CH), 40.2 (CH2), 14.1 (CH3). HRMS (ESI) m/z: 314.1379 [M + H]+, C18H20NO4 requires 314.1387. 
Ethyl (S)-2-(4-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41g) 
Enantiomeric excess (88%) was determined by chiral HPLC (Chiralpak IC), 
hexane-iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 9.9 min, minor 
enantiomer tr = 8.2 min.  
Yellow oil; []D
20= -78.2 (c 1.0, CHCl3, 88% ee); 1H NMR (300 MHz, CDCl3) δ 7.12 
(dd, J = 2.6, 1.1 Hz, 1H), 7.11 – 7.08 (m, 1H), 7.00 – 6.96 (m, 1H), 6.97 – 6.91 (m, 1H), 6.84 (ddd, J = 8.0, 
7.2, 1.5 Hz, 1H), 6.65 (ddd, J = 8.0, 7.2, 1.6 Hz, 1H), 6.54 (dd, J = 7.9, 1.6 Hz, 1H), 4.76 (dd, J = 9.9, 4.3 
Hz, 1H), 4.13 (q, J = 7.2 Hz, 2H), 3.39 (dd, J = 16.5, 9.9 Hz, 1H), 2.88 (dd, J = 16.5, 4.3 Hz, 1H), 2.40 (s, 
3H), 1.21 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 172.2 (C), 155.4 (C), 143.1 (C), 137.5 (C), 132.5 
(C), 130.8 (CH), 130.6 (C), 125.2 (CH), 124.6 (CH), 124.2 (CH), 122.1 (CH), 118.7 (CH), 118.6 (CH), 60.6 
(CH2), 54.4 (CH), 40.0 (CH2), 16.3 (CH3), 14.1 (CH3). HRMS (ESI) m/z: 298.1432 [M + H]+, C18H20NO3 
requires 298.1438. 
Ethyl (S)-2-(2-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41h) 
Enantiomeric excess (87%) was determined by chiral HPLC (Chiralpak IC), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 10.6 min, minor enantiomer tr = 
12.6 min.  
Yellow oil; []D
20
 = -50.7 (c 1.0, CHCl3, 87% ee); 1H NMR (300 MHz, CDCl3) δ 7.08 – 
7.01 (m, 3H), 6.94 (s, 1H), 6.83 (ddd, J = 7.9, 7.2, 1.6 Hz, 1H), 6.66 (ddd, J = 7.9, 7.2, 
1.6 Hz, 1H), 6.55 (dd, J = 7.9, 1.6 Hz, 1H), 4.70 (dd, J = 10.1, 4.1 Hz, 1H), 4.45 (s, 1H), 4.13 (q, J = 6.9 Hz, 
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2H), 3.33 (dd, J = 16.6, 10.0 Hz, 1H), 2.84 (dd, J = 16.6, 4.1 Hz, 1H), 2.27 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.2 (C), 155.0 (C), 144.1 (C), 137.1 (C), 133.9 (C), 131.8 (C), 129.7 (CH), 
128.3 (CH), 124.5 (CH), 121.7 (CH), 120.9 (CH), 119.1 (CH), 118.9 (CH), 60.7 (CH2), 54.7 (CH), 40.1 (CH2), 
20.7 (CH3), 14.1 (CH3). HRMS (ESI) m/z: 298.1433 [M + H]+, C18H20NO3 requires 298.1438. 
Ethyl (S)-2-(2-chloro-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41i) 
Enantiomeric excess (84%) was determined by chiral HPLC (Chiralpak AD-H), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 14.3 min, minor enantiomer tr = 
24.7 min.  
Yellow oil; []D
20 = -32.2 (c 1.0, CHCl3, 84% ee); 1H NMR (300 MHz, CDCl3) δ 7.19 (dd, 
J = 8.5, 2.6 Hz, 1H), 7.13 (d, J = 2.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 1H), 7.05 (dd, J = 8.0, 
1.6 Hz, 1H), 6.86 (ddd, J = 7.9, 7.2, 1.5 Hz, 1H), 6.69 (ddd, J = 7.9, 7.2, 1.5 Hz, 1H), 6.56 (dd, J = 7.9, 1.6 
Hz, 1H), 4.72 (dd, J = 9.8, 4.3 Hz, 1H), 4.45 (s, 1H), 4.14 (qd, J = 7.1, 0.7 Hz, 2H), 3.27 (dd, J = 16.6, 9.8 
Hz, 1H), 2.84 (dd, J = 16.6, 4.3 Hz, 1H), 1.22 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 171.7 (C), 
155.6 (C), 143.7 (C), 136.7 (C), 133.7 (C), 129.1 (CH), 127.7 (CH), 124.9 (CH), 122.7 (CH), 121.7 (CH), 
119.6 (CH), 119.1 (CH), 60.8 (CH2), 54.3 (CH), 39.8 (CH2), 14.1 (CH3). HRMS (ESI) m/z: 318.0885 [M + 
H]+, C17H17ClNO3 requires 318.0892. 
Ethyl (S)-2-(2-methoxy-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41j) 
Enantiomeric excess (88%) was determined by chiral HPLC (Chiralpak IC), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 20.7 min, minor enantiomer tr = 
26.6 min.  
Beige oil, []D
20 = -34.7 (c 1.0, CHCl3, 88% ee); 1H NMR (300 MHz, CDCl3) δ 7.10 – 7.03 
(m, 2H), 6.83 (ddd, J = 7.9, 7.2, 1.6 Hz, 1H), 6.74 (dd, J = 8.7, 3.1 Hz, 1H), 6.70 – 6.61 
(m, 2H), 6.54 (dd, J = 8.0, 1.6 Hz, 1H), 4.71 (dd, J = 10.0, 4.1 Hz, 1H), 4.45 (s, 1H), 4.13 (qd, J = 7.1, 0.7 
Hz, 2H), 3.74 (s, 3H), 3.35 (dd, J = 16.6, 10.0 Hz, 1H), 2.86 (dd, J = 16.6, 4.2 Hz, 1H), 1.21 (t, J = 7.1 Hz, 
3H).13C NMR (75 MHz, CDCl3) δ 172.1 (C), 156.0 (C), 151.0 (C), 144.1 (C), 137.1 (C), 133.1 (C), 124.6 
(CH), 122.0 (CH), 121.6 (CH), 119.0 (CH), 118.8 (CH), 113.8 (CH), 113.1 (CH), 60.7 (CH2), 55.7 (CH3), 54.6 
(CH), 40.0 (CH2), 14.1 (CH3). HRMS (ESI) m/z: 314.1386  [M + H]+, C18H20NO4 requires 314.1387. 
Ethyl (S)-2-(1,3-dimethoxy-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41k) 
Enantiomeric excess (79%) was determined by chiral HPLC (Phenomenex Lux® 
5µm Amylose-1), hexane-iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 42.7 
min, minor enantiomer tr = 37.8 min.  
Beige oil; []D
20
 = -26.2 (c 1.0, CHCl3, 79% ee); 1H NMR (300 MHz, CDCl3) δ 7.05 
(dd, J = 8.0, 1.5 Hz, 1H), 6.85 (ddd, J = 7.9, 7.2, 1.6 Hz, 1H), 6.68 (ddd, J = 7.9, 7.2, 1.6 Hz, 1H), 6.56 (dd, 
J = 7.9, 1.6 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 6.20 (d, J = 2.4 Hz, 1H), 5.14 (dd, J = 10.6, 3.4 Hz, 1H), 4.53 
(s, 1H), 4.12 (q, J = 7.3 Hz, 2H), 3.77 (s, 3H), 3.77 (s, 3H), 3.23 (dd, J = 16.9, 10.7 Hz, 1H), 2.66 (dd, J = 
16.9, 3.4 Hz, 1H), 1.21 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 172.6 (C), 160.3 (C), 158.3 (C), 
156.7 (C), 144.3 (C), 137.5 (C), 124.7 (CH), 121.6 (CH), 119.3 (CH), 119.2 (CH), 113.0 (C), 97.8 (CH), 94.7 
(CH), 60.4 (CH2), 55.8 (CH3), 55.4 (CH3), 46.8 (CH), 39.8 (CH2), 14.2 (CH3). HRMS (ESI) m/z: 344.1500 [M 
+ H]+, C19H22NO5 requires 344.1493. 
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Ethyl (S)-2-(8-fluoro-2,4-dimethyl-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetate (41l) 
Enantiomeric excess (88 was determined by chiral HPLC (Phenomenex Lux® 
5µm Amylose-1), hexane-iPrOH 80:20, 1.0 mL/min, major enantiomer tr = 5.1 
min, minor enantiomer tr = 8.0 min.  
Yellow oil; []D
20 = -90.8 (c 1.0, CHCl3, 88% ee); 1H NMR (300 MHz, CDCl3) δ 7.01 
(dd, J = 8.7, 5.6 Hz, 1H), 6.93 (dt, J = 2.3, 0.8 Hz, 1H), 6.78 (d, J = 2.1 Hz, 1H), 6.28 
(ddd, J = 8.8, 7.8, 3.0 Hz, 1H), 6.21 (dd, J = 10.3, 2.9 Hz, 1H), 4.69 (dt, J = 9.4, 4.3 
Hz, 1H), 4.53 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.39 (dd, J = 16.6, 10.0 Hz, 1H), 2.84 (dd, J = 16.6, 4.1 Hz, 
1H), 2.34 (s, 3H), 2.23 (d, J = 0.7 Hz, 3H), 1.22 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 172.1 (C), 
159.7 (d, Jc-f = 240.1 Hz, CF), 153.3 (C), 139.3 (d, Jc-f = 2.6 Hz, C), 138.9 (d, Jc-f = 11.0 Hz, C), 133.9 (C), 
131.9 (C), 131.5 (CH), 130.1 (C), 125.7 (CH), 122.8 (d, Jc-f = 10.3 Hz, CH), 104.5 (d, Jc-f = 5.6 Hz, CH), 104.2 
(d, Jc-f = 9.2 Hz, CH), 60.7 (CH2), 54.1 (CH), 40.2 (CH2), 20.7 (CH3), 16.1 (CH3), 14.2 (CH3). 19F NMR (282 
MHz, CDCl3) δ -119.73. HRMS (ESI) m/z: 330.1499 [M + H]+, C19H20FNO3 requires 330.1500. 
Ethyl (S)-2-(7,8-dihydrobenzo[b]naphtho[2,1-f][1,4]oxazepin-7-yl)acetate (41m) 
Enantiomeric excess (90%) was determined by chiral HPLC (Chiralpak AD-H), 
hexane-iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 30.5 min, minor 
enantiomer tr = 36.5 min.  
Orange oil; []D
20 = -136.1 (c 1.0, CHCl3, 90% ee); 1H NMR (300 MHz, CDCl3) δ 
8.50 – 8.42 (m, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.59 – 7.55 (m, 1H), 7.55 – 7.52 (m, 1H), 7.48 (ddd, J = 8.1, 
6.8, 1.4 Hz, 1H), 7.31 (dd, J = 7.9, 1.5 Hz, 1H), 7.25 (d, J = 8.3 Hz, 1H), 6.87 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 
6.72 (ddd, J = 7.9, 7.2, 1.6 Hz, 1H), 4.89 (dd, J = 9.9, 4.2 Hz, 1H), 4.56 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 
3.41 (dd, J = 16.7, 10.0 Hz, 1H), 2.96 (dd, J = 16.7, 4.2 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 172.2 (C), 152.2 (C), 144.1 (C), 137.5 (C), 134.3 (C), 127.6 (CH), 127.4 (C), 126.9 (C), 126.5 (CH), 
126.4 (CH), 125.7 (CH), 124.8 (CH), 123.9 (CH), 122.1 (CH), 121.8 (CH), 119.4 (CH), 119.3 (CH), 60.7 
(CH2), 55.0 (CH), 40.3 (CH2), 14.2 (CH3). HRMS (ESI) m/z: 334.1447 [M + H]+, C21H20NO3 requires 
334.1438. 
Ethyl (S)-2-(12,13-dihydrobenzo[b]naphtho[1,2-f][1,4]oxazepin-13-yl)acetate (41n) 
Enantiomeric excess (91%) was determined by chiral HPLC (Chiralpak AD-H), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 18.3 min, minor enantiomer tr = 
44.2 min.  
Beige oil; []D
20= +125.9 (c 1.0, CHCl3, 91% ee); 1H NMR (300 MHz, CDCl3) δ 8.02 (d, 
J = 8.6 Hz, 1H), 7.81 (dd, J = 8.2, 1.4 Hz, 1H), 7.75 (d, J = 8.4 Hz, 2H), 7.53 (ddd, J = 
8.6, 6.8, 1.5 Hz, 1H), 7.41 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.14 
(dd, J = 7.9, 1.5 Hz, 1H), 6.88 (ddd, J = 7.8, 7.3, 1.5 Hz, 1H), 6.72 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 6.60 (dd, 
J = 7.8, 1.6 Hz, H), 5.57 (dd, J = 10.1, 3.8 Hz, 1H), 4.64 (s, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.49 (dd, J = 17.0, 
10.1 Hz, 1H), 2.89 (dd, J = 17.1, 3.9 Hz, 1H), 1.19 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 172.4 
(C), 154.8 (C), 144.2 (C), 137.2 (C), 130.9 (C), 130.6 (C), 129.8 (CH), 128.8 (CH), 127.0 (CH), 124.8 (C), 
124.7 (CH), 124.6 (CH), 122.2 (CH), 121.7 (CH), 121.5 (CH), 119.5 (CH), 119.0 (CH), 60.7 (CH2), 49.2 (CH), 






Ethyl (S)-2-(3-bromo-12,13-dihydrobenzo[b]naphtho[1,2-f][1,4]oxazepin-13-yl)acetate (41o) 
Enantiomeric excess (92%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose-1), hexane-iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 22.2 min, minor 
enantiomer tr = 43.1 min.  
White solid; Mp 80-82C; []D
20= +93.5 (c 1.0, CHCl3, 92% ee); 1H NMR (300 MHz, 
CDCl3) δ 7.95 (d, J = 2.1 Hz, 1H), 7.88 (d, J = 9.5 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.58 
(dd, J = 9.1, 2.1 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.13 (dd, J = 7.9, 1.5 Hz, 1H), 6.89 
(ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.73 (ddd, J = 7.9, 7.3, 1.7 Hz, 1H), 6.60 (dd, J = 7.9, 1.6 
Hz, 1H), 5.49 (dd, J = 10.0, 4.1 Hz, 1H), 4.61 (s, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.43 (dd, J = 17.1, 9.9 Hz, 
1H), 2.88 (dd, J = 17.1, 4.0 Hz, 1H), 1.18 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 172.2 (C), 154.9 
(C), 144.0 (C), 137.0 (C), 132.0 (C), 130.7 (CH), 130.2 (CH), 129.2 (C), 128.8 (CH), 125.2 (C), 124.8 (CH), 
124.1 (CH), 123.0 (CH), 121.5 (CH), 119.8 (CH), 119.1 (CH), 118.6 (C), 60.8 (CH2), 49.4 (CH), 40.1 (CH2), 
14.1 (CH3). HRMS (ESI) m/z: 412.0547 [M + H]+, C21H19BrNO3 requires 412.0543. 
Ethyl (S)-2- (10,11-dihydrodibenzo[b,f][1,4]thiazepin-11-yl)acetate (42) 
Enantiomeric excess (89%) was determined by chiral HPLC (Chiralpak AD-H), hexane-
iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 20.6 min, minor enantiomer tr = 
19.3 min.  
Clear oil; []D
20 = -34.8 (c=1, CHCl3, 89% ee); 1H NMR (300 MHz, CDCl3) δ 7.49 (dd, J 
= 7.2, 1.9 Hz, 1H), 7.27 – 7.16 (m, 3H), 7.13 (dd, J = 7.0, 2.2 Hz, 1H), 6.92 (ddd, J = 8.1, 
7.3, 1.6 Hz, 1H), 6.61 (ddd, J = 7.7, 7.3, 1.4 Hz, 1H), 6.45 (dd, J = 8.1, 1.3 Hz, 1H), 5.77 (dd, J = 10.0, 4.7 
Hz, 1H), 4.33 (s, 1H), 4.17 (qd, J = 7.2, 1.2 Hz, 2H), 3.21 (dd, J = 15.6, 9.9 Hz, 1H), 2.92 (dd, J = 15.6, 4.7 
Hz, 1H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 171.7 (C), 146.3 (C), 142.8 (C), 135.5 (C), 
131.9 (CH), 131.8 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 126.2 (CH), 119.2 (CH), 118.9 (CH), 117.9 
(C), 60.9 (CH2), 54.2 (CH), 39.9 (CH2), 14.2 (CH3). HRMS (ESI) m/z: 300.1054 [M + H]+, C17H18NO2S 
requires 300.1053. 
4-(10,11-Dihydrodibenzo[b,f][1,4]oxazepin-11-yl)but-2-ynenitrile (44)  
Enantiomeric excess (50%) was determined by chiral HPLC (Chiralpak AD-H), 
hexane-iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 22.7 min, minor 
enantiomer tr = 25.7 min.  
Yellow oil; [α]D20 -48.9 (c 0.5, CHCl3) (50% ee); 1H NMR (300 MHz, CDCl3) δ 7.30 
(ddd, J = 8.1, 7.1, 1.9 Hz, 1H), 7.21 – 7.14 (m, 2H), 7.11 (dd, J = 2.9, 1.4 Hz, 1H), 
7.08 (td, J = 3.6, 1.3 Hz, 1H), 6.90 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 6.72 (ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.63 
(dd, J = 7.9, 1.6 Hz, 1H), 4.57 – 4.41 (m, 2H), 3.38 (dd, J = 16.7, 9.1 Hz, 1H), 3.00 (dd, J = 16.8, 5.3 Hz, 
1H). 13C NMR (75 MHz, CDCl3) δ 157.0 (C), 143.6 (C), 135.9 (C), 130.4 (C), 130.3 (CH), 128.2 (CH), 125.2 
(CH), 124.9 (CH), 121.9 (CH), 121.6 (CH), 119.9 (CH), 118.9 (CH), 118.0 (C), 55.7 (CH), 25.8 (CH2). HRMS 
(ESI) m/z: 237.1014 [M + H]+, C15H13N2O requires 237.1022 
(S)-2-(10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)-1-phenylethan-1-one (46)1   
Enantiomeric excess (40%) was determined by chiral HPLC (Chiralpak AD-H), 
hexane-iPrOH 95:05, 1.0 mL/min, major enantiomer tr = 29.1 min, minor 
enantiomer tr = 30.7 min.  
Yellow oil; [α]D20 -29.5 (c 1.0, CHCl3) (40% ee); 1H NMR (300 MHz, CDCl3) δ 7.92 (t, 
J = 1.4 Hz, 1H), 7.90 (d, J = 1.5 Hz, 1H), 7.57 – 7.49 (m, 1H), 7.45 – 7.36 (m, 2H), 
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7.29 – 7.16 (m, 3H), 7.12 – 7.02 (m, 2H), 6.81 (ddd, J = 7.9, 7.2, 1.6 Hz, 1H), 6.65 (ddd, J = 8.0, 7.2, 1.6 
Hz, 1H), 6.53 (dd, J = 7.9, 1.6 Hz, 1H), 4.94 (dd, J = 9.7, 3.4 Hz, 1H), 4.61 (s, 1H), 4.13 (dd, J = 18.1, 9.7 
Hz, 1H), 3.51 – 3.38 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 199.1 (C), 157.1 (C), 143.7 (C), 137.1 (C), 136.6 
(C), 133.4 (CH), 132.6 (C), 129.3 (CH), 128.6 (CH), 128.3 (CH), 128.1 (CH), 124.7 (CH), 124.4 (CH), 121.7 
(CH), 121.3 (CH), 119.0 (CH), 119.0 (CH), 54.5 (CH), 44.2 (CH2). 
6.5.3. Synthetic procedures and characterization data for compounds 47, 48, 50 
and 52 
(S)-2-(10,11-Dihydrodibenzo[b,f][1,4]oxazepin-11-yl)acetic acid (47) 
To a solution of 41a (0.10 mmol) in EtOH (1 mL) aq. 1 M NaOH (1 mL) was added. The reaction 
mixture was stirred at reflux temperature (73 °C) for 2 hours. The reaction was quenched with HCl 2M 
(5 mL) and extracted with dichloromethane (3x15 mL), dried over MgSO4, filtered and concentrated 
in vacuo, obtaining product 47. 
Enantiomeric excess (86%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose-1), hexane-iPrOH 90:10, 1mL/min, major enantiomer tr = 13.6 min, minor 
enantiomer tr = 20.9 min. 
Brown oil; []D
20 = -34.1 (c 1.0, CHCl3, 86% ee); 1H NMR (300 MHz, CDCl3) δ 7.29 – 
7.23 (m, 1H), 7.20 – 7.03 (m, 4H), 6.90 (td, J = 7.6, 1.4 Hz, 1H), 6.81 – 6.74 (m, 1H), 
6.71 (d, J = 7.8 Hz, 1H), 4.82 (dd, J = 9.7, 3.8 Hz, 1H), 3.42 (dd, J = 17.0, 9.7 Hz, 1H), 2.96 (dd, J = 17.0, 
3.8 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 176.6 (C), 157.0 (C), 144.3 (C), 136.3 (C), 131.7 (C), 129.5 (CH), 
127.9 (CH), 124.8 (CH), 124.5 (CH), 121.8 (CH), 121.3 (CH), 119.9 (CH), 119.4 (CH), 54.5 (CH), 39.7 (CH2). 
HRMS (ESI) m/z: 256.0972 [M + H]+, C15H14NO3 requires 256.0968. 
 (S)-2-(10,11-Dihydrodibenzo[b,f][1,4]oxazepin-11-yl)ethan-1-ol (48) 
To a solution of 41a (0.10 mmol) in THF (1 mL), LiAlH4 (1.0 M in THF, 1.1 equivalents, 0.11 
mmol) was added dropwise at 0 °C over 4 min. The reaction was stirred at 0 °C until completion (TLC). 
The mixture was diluted with EtOAc (10 mL) and acidified with aq. 2 M HCl until the aqueous layer 
became clear. A saturated dissolution of Rochelle salt was added (5 mL) and the mixture was stirred 
for 2 hours. The aqueous layer was then separated and extracted with EtOAc (2 x 15 mL). The 
combined organic layers were dried (MgSO4), filtered, and concentrated in vacuum. The residue was 
purified by flash chromatography, obtaining product 48.[43] 
Enantiomeric excess (86%) was determined by chiral HPLC (Chiralpak IC), hexane-
iPrOH 90:10, 1mL/min, major enantiomer tr = 8.2 min, minor enantiomer tr = 19.7 
min. 
Orange oil; []D
20 = -6.0 (c 1.0, CHCl3, 86% ee); 1H NMR (300 MHz, CDCl3) δ 7.29 – 
7.21 (m, 1H), 7.17 (dt, J = 7.9, 1.6 Hz, 2H), 7.08 (ddd, J = 7.2, 4.0, 1.3 Hz, 2H), 6.86 
(ddd, J = 7.9, 7.3, 1.5 Hz, 1H), 6.68 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 6.59 (dd, J = 7.9, 1.6 Hz, 1H), 4.68 (dd, 
J = 9.2, 5.4 Hz, 1H), 3.90 (ddd, J = 11.2, 6.8, 4.5 Hz, 1H), 3.78 (ddd, J = 11.1, 6.8, 4.6 Hz, 1H), 2.41 (dddd, 
J = 13.8, 9.2, 7.1, 4.5 Hz, 1H), 2.24 (dddd, J = 13.7, 9.3, 7.0, 4.5 Hz, 1H).13C NMR (75 MHz, CDCl3) δ 157.3 
(C), 144.1 (C), 137.4 (C), 134,0 (C), 128.9 (CH), 127.0 (CH), 124.5 (CH), 124.4 (CH), 121.8 (CH), 121.1 
(CH), 119.2 (CH), 119.0 (CH), 60.7 (CH2), 54.8 (CH), 36.9 (CH2). HRMS (ESI) m/z: 242.1174 [M + H]+, 






 To a solution of 41a (0.10 mmol) in THF (1 mL), LiAlH4 (1.0 M in THF, 1.1 equivalents, 0.11 
mmol) was added dropwise at 0 °C over 4 min. The reaction was stirred at 0 °C until completion (TLC). 
The mixture was diluted with EtOAc (10 mL) and acidified with aq. 2 M HCl until the aqueous layer 
became clear. A saturated dissolution of Rochelle salt was added (5 mL) and the mixture was stirred 
for 2 hours. The aqueous layer was then separated and extracted with EtOAc (2 x 15 mL). The 
combined organic layers were dried (MgSO4), filtered, and concentrated in vacuum. The residue was 
purified by flash chromatography, obtaining product 48. 
To a solution of 48 in THF (1 mL), o-nitrophenylselenocyanate (48) (2.4 equivalents) and n-
Bu3P (2.5 equivalents) were added. The solution was stirred 4 hours at room temperature. The solvent 
was removed and the crude product was used for the next step. 
The crude product was dissolved in THF (1 mL) and was treated at 0 °C with 50% aqueous 
hydrogen peroxide (5 equivalents). The solution was, after addition of hydrogen peroxide, placed at 
room temperature for 2 hours. The solution was quenched with water and extracted with 
dichloromethane (3x15 mL). The organic layer was dried with MgSO4, filtered, and concentrated in 
vacuum. The residue was purified by flash chromatography, obtaining product 50. 
The enantiomeric excess (86%) was determined by chiral HPLC (Phenomenex Lux® 5µm 
Amylose 1), hexane-iPrOH 90:10, 1mL/min, major enantiomer tr = 8.64 min, minor 
enantiomer tr = 11.22 min. 
Orange oil; []D
20 = -5.9 (c 1.0, CHCl3, 86% ee); 1H NMR (300 MHz, CDCl3) δ 7.30 – 7.23 
(m, 2H), 7.18 (ddd, J = 7.9, 3.2, 1.6 Hz, 2H), 7.12 – 7.05 (m, 2H), 6.88 (ddd, J = 7.8, 7.4, 
1.5 Hz, 1H), 6.70 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 6.62 (dd, J = 7.9, 1.6 Hz, 1H), 6.32 (ddd, J = 17.1, 10.2, 
6.7 Hz, 1H), 5.37 (dt, J = 17.2, 1.3 Hz, 1H), 5.30 (dt, J = 10.3, 1.2 Hz, 1H), 5.14 (d, J = 6.8 Hz, 1H), 4.00 (s, 
1H). 13C NMR (75 MHz, CDCl3) δ 157.2 (C), 144.7 (C), 138.1 (CH), 137.6 (C), 132.8 (C), 129.1 (CH2), 127.5 
(CH), 124.5 (CH), 124.3 (CH), 121.8 (CH), 121.1 (CH), 119.5 (CH), 118.9 (CH), 116.6 (CH), 59.4 (CH). 
HRMS (ESI) m/z: 224.1063 [M + H]+, C15H14NO requires 224.1070. 
Ethyl (S)-2-(3-(4-methoxyphenyl)-12,13-dihydrobenzo[b]naphtho[1,2-f][1,4]oxazepin-13-yl)acetate 
(52) 
 To a solution of 41o (0.100 mmol) in DMF (2 mL), potassium phosphate n-hydrate (8 
equivalents) and p-methoxy-phenylboronic acid 51 (2 equivalents) were added. This solution was 
bubbled with N2 for 30 minutes and afterwards PdCl2(PPh)2 (10 mol %) was added and the reaction 
was placed at 100 °C for 4 hours. Afterwards, the reaction was quenched with a saturated aqueous 
ammonium chloride solution (10 mL) and the solution was extraced with dichloromethane (3x15 mL). 
The organic phase was then washed with water (2x15 mL), dried over MgSO4, filtered, and 
concentrated in vacuum. The residue was purified by flash chromatography, obtaining product 52. 
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The enantiomeric excess (90%) was determined by chiral HPLC (Phenomenex Lux® 
5µm Amylose 1), hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 26.27 min, 
minor enantiomer tr = 40.11 min. 
Brown oil; []D
20 = +57.0 (c 1.0, CHCl3, 90% ee); 1H NMR (300 MHz, CDCl3) δ 8.08 (d, 
J = 9.2 Hz, 1H), 7.97 (d, J = 2.0 Hz, 1H), 7.83 – 7.75 (m, 2H), 7.70 – 7.62 (m, 2H), 7.38 
(d, J = 8.8 Hz, 1H), 7.17 (dd, J = 7.9, 1.5 Hz, 1H), 7.06 – 6.98 (m, 2H), 6.91 (ddd, J = 
7.8, 7.3, 1.5 Hz, 1H), 6.76 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 6.63 (dd, J = 7.9, 1.6 Hz, 1H), 
5.60 (dd, J = 10.0, 3.7 Hz, 1H), 4.68 (s, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.87 (s, 3H), 3.51 
(dd, J = 17.1, 10.1 Hz, 1H), 2.94 (dd, J = 17.1, 3.9 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 172.4 (C), 159.3 (C), 154.6 (C), 144.2 (C), 137.2 (C), 136.9 (C), 133.0 (C), 131.3 
(C), 129.8 (CH), 129.4 (C), 128.2 (CH), 126.3 (CH), 125.8 (CH), 124.8 (C), 124.7 (CH), 122.8 (CH), 122.1 
(CH), 121.5 (CH), 119.5 (CH), 119.0 (CH), 114.4 (CH), 60.7 (CH2), 55.4 (CH), 49.4 (CH3), 40.2 (CH2), 14.1 
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